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Abstract 
 
Women have a higher incidence of various visceral and neuropathic chronic pain 
conditions. Most of the animal studies investigating pain mechanisms show oestrogen to be 
pronociceptive. However, similar studies in healthy humans are equivocal. The predisposition 
of chronic pain conditions in female patients with a history of stress emphasises the role of 
chronic stress in the pathogenesis of these conditions. Since glutamatergic system plays an 
import role in the transmission of pain-related information in the central nervous system 
(CNS), its impaired modulation may be a key phenomenon responsible for the pathogenesis 
of pain conditions and associated gender differences. The microbiota-gut-brain axis is shown 
to be capable of influencing the CNS function in health and various diseases, but as yet it is to 
be determined whether it has any role in the modulation of pain-related central nervous 
mechanisms. 
Extensive research is being carried out to understand the mechanisms through which 
sex hormones and chronic stress may influence the pain neurotransmission resulting in sex 
differences in pain. However, these mechanisms are not fully understood yet. As microbiota-
gut-brain axis has been shown to influence a number of CNS disorders, and there is emerging 
evidence of its role in pain modulation in preclinical studies, we specifically concentrated on 
gut microbiota and its associated mechanisms influencing pain sensitivity. Our objectives were 
to explore the interplay between sex, stress, glutamatergic system, gut microbiota, and their 
effect on pain responses. We performed experiments both in animals and healthy humans. 
We were able to demonstrate that in rats, synaptic glutamate metabolism in the spinal 
cord and anterior cingulate cortex of brain varied significantly depending upon the phase of 
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the oestrous cycle. Endogenous oestrogen exerted its effects through oestrogen receptor-α 
and was also shown to regulate glutamate receptor subunits expression. By utilising animal 
models of visceral hypersensitivity and stress (early-life stress & depression) in Wistar-Kyoto 
(WKY) and maternally separated rats, we could demonstrate that stress significantly altered 
pain responses through modifying the glutamatergic system and such effect was oestrous 
phase specific. In WKY rats, short-chain fatty acid producing gut microbiota abundance had a 
positive correlation with synaptic glutamate transporter function in a sex-specific manner. 
Finally, in healthy humans, we demonstrated a positive correlation between the abundance 
of butyrate producing bacteria in the bowel and pain sensitivity. Furthermore, hormonal 
contraceptive use was associated with increased lipopolysaccharide-binding protein levels. 
Taken together, our results show that oestrogen plays a vital role in glutamatergic 
neurotransmission and pain responses. Aberrant changes in the pain-related sensory 
mechanisms may develop by factors such as stress and altered gut microbiota. The emerging 
relationship between sex hormones, neuroendocrine system, and the gut microbiota in 
relation to pain modulation supports further investigations in large scale studies. Trials are 
needed to establish if interventions to correct gut microbiota imbalance can have analgesic 
effects. 
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1.1 Pain  
Pain is an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage (Treede, 2018). Depending on 
the cause, pain can be divided into two types: nociceptive and neuropathic pain (Spahr et al., 
2017). Table 1.1 (adapted from Dworkin et al.) details pain types and associated characteristics 
(Dworkin et al., 2003). Nociceptive pain occurs in response to mechanical, chemical or thermal 
stimulation and disappears when the stimulus is eliminated. It is a protective phenomenon 
which results in a number of processes including localisation of the painful stimulus and 
withdrawal, and the subsequent emotional, psychophysiological, and behavioural reactions. 
Neuropathic pain occurs due to abnormalities in the somatosensory system caused by 
imbalances between excitatory and inhibitory signalling, alterations in ion channels and 
changes in the central pain modulation (Colloca et al., 2017). Depending upon the body region 
involved, nociceptive pain can be further divided into two types: “somatic” and “visceral” 
(Cervero, 2009). While somatic pain is usually described as a “sharp,” “burning” or “prickling” 
sensation, it can be “dull” or “aching” when originating from the deep tissues. The stimuli for 
the somatic pain may originate from the skin, connective tissues, muscles, bones, and joints, 
and generally result in localised pain (Carver and Foley, 2003). Visceral pain, on the other 
hand, refers to pain that arises from stimuli to the internal organs or the tissues that support 
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Table 1.1. Types of pain, area of origin and related conditions and diseases are enlisted (Dworkin et al., 2003) 
Type Subtype Body area Related conditions and diseases 






Bones and cartilage 
Trauma / fractures 
Compartment syndrome 
Arthritis 
Bone cancer and metastasis 





Irritable Bowel Syndrome 




Noncardiac Chest pain 
Cardiac Angina 
Nonulcer dyspepsia 
Painful bladder syndrome 
Ureteric colic 
Cholelithiasis 




Complex regional pain syndrome 
Entrapment neuropathies (e.g., carpal 
tunnel syndrome) 
HIV sensory neuropathy 
Iatrogenic neuralgias (e.g., 
postmastectomy pain or postthoracotomy 
pain) 
Idiopathic sensory neuropathy 
Nerve compression or infiltration by 
tumour 
Nutritional deficiency-related neuropathies 
Painful diabetic neuropathy 
Phantom limb pain 
Postherpetic neuralgia 
Postradiation plexopathy 
Radiculopathy (cervical, thoracic, or 
lumbosacral) 
Toxic exposure-related neuropathies 
Tic douloureux (trigeminal neuralgia) 
Posttraumatic neuralgias 
 
 Central  Compressive myelopathy with spinal 
stenosis 
HIV myelopathy 
Multiple sclerosis–related pain 




Posttraumatic spinal cord injury pain 
Syringomyelia 
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1.1.1 Visceral Pain 
 The pain resulting from the stimulation of receptors in the internal body organs or 
associated tissue, e.g., heart, stomach, intestine, urinary bladder, is defined as visceral pain 
(Cervero and Laird, 1999; Sikandar and Dickenson, 2012). Hollow body organs, e.g., the urinary 
bladder, ureter, and gut show more visceral pain responses than the parenchymous viscera 
such as liver and pancreas (Giamberardino, 1999; Robinson and Gebhart, 2008). In 
parenchymous body organs, such as the liver, diseases affecting these are commonly not 
associated with pain, rather the symptoms arise from the altered organ functions (Robinson 
and Gebhart, 2008). The mechanical, chemical and ischaemic stimuli are the typical triggers 
known to induce visceral pain (Ness and Gebhart, 1988, 1990; Al-Chaer and Traub, 2002). 
Mechanical stimuli include spasm or distension of hollow viscus walls, for example, 
ureteric/biliary colic due to stones and intestinal obstruction pain (Giamberardino, 2013). 
Chemical stimuli include inflammation (Bercik et al., 2004), whereas ischaemic stimulus can 
result from the blockade of supplying artery, e.g., ischaemic cardiac pain, and mesenteric 
ischaemia (Stoney and Reilly, 1983; Sengupta, 2009; Walker, 2009). 
 Visceral pain is often felt at some distant cutaneous regions sharing the same 
dermatomal origin as the internal organ affected (Giamberardino and Vecchiet, 1995; Laird et 
al., 2001). The most common examples of this are a cardiac pain being referred to the left 
shoulder, or pain from the large bowel being referred to the umbilical region. 
1.1.2 Somatic Pain 
 Somatic pain can be “superficial somatic” or “deep somatic.” The superficial somatic 
pain originates from the skin and other superficial areas. Examples of injuries that induce 
superficial somatic pain include skin wounds and burns. Deep somatic pain is initiated by 
stimulation of nociceptors in ligaments, tendons, bones, blood vessels, fasciae, and muscles. 
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Examples of deep somatic pain include ligamentous sprains, bone fractures, and cancerous 
bone pains (Carver and Foley, 2003; Mantyh, 2014). 
 Somatic pain is a key component of the body’s normal defence mechanisms, 
protecting the body from the potentially hostile surrounding environment by initiating 
behavioural and reflex avoidance responses (Willer, 1977; Woolf, 2010). The absence of these 
responses in patients with peripheral neuropathies often results in tissue damage and even 
permanent deformities, as seen in diabetic feet (Allan et al., 2016). Congenital insensitivity to 
pain is a rare genetic condition characterised by inability to feel pain in response to any 
noxious stimulus (Schon et al., 2018). Patients suffering from this condition can easily develop 
significant trauma to their bodies such as skin cuts, burns, bone fractures and joint deformities 
(Zhang et al., 2016). Somatic pain is, therefore, a very important adaptive component of the 
nervous system, which should only be temporarily suppressed during surgical procedures and 
for pain relief procedures, e.g., nerve root injections for brachialgia or sciatica. Clinical pain 
also includes exaggerated pain response to noxious stimuli (hyperalgesia) (Lee et al., 2011) 
and pain produced by stimuli which generally would not elicit pain (allodynia) (Lolignier et al., 
2015). 
1.1.3 Pain Pathways 
1.1.3.1 Nociceptors 
 Nociceptors are the neuronal apparatus responsible for the detection of noxious 
stimuli. Some nociceptors are thinly myelinated A-fibres, but the majority are unmyelinated C 
fibres (Wooten et al., 2014). Somatic nociceptors can be classified as cutaneous, muscle and 
joint nociceptors depending upon their location in the body. Cutaneous nociceptors are 
mostly C-fibre mechano-heat (CMHs), A-fibre mechano-heat (AMHs) and high threshold 
mechanoreceptors (HTMs). The C fibres are also called polymodal nociceptors and can be 
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mechano-heat (C-MH), mechano-chemical (C-MC) or mechano-heat-chemical (C-MHC) 
(Campbell and Meyer, 1983; Martin et al., 1987; Dubin and Patapoutian, 2010; Wooten et al., 
2014). Table 1.2 (derived from Dubin, et al.) summarises fibre characteristics (Dubin and 
Patapoutian, 2010). 
 As their names indicate, AMHs and CMHs respond to noxious mechanical and heat 
stimuli, whereas HTMs respond only to intense noxious mechanical stimuli but not to heat 
stimuli. The sensory nerve endings in the skin are mostly associated with specialised 
structures, e.g., Merkel Cells, Ruffini endings and Pacinian corpuscles (Garcia-Mesa et al., 
2017). These structures play a role in the sensation of touch, pressure, and vibration. Lack of 
these unit on the viscera limits the visceral sensation to distension, inflammation and 
ischaemia only. Muscles have nociceptive afferent myelinated (group III) and unmyelinated 
(group IV) fibres with a relatively lower excitatory threshold (Abrahams, 1986; McCord and 
Kaufman, 2010). 
 The visceral afferent nociceptive information is carried out almost exclusively through 
thinly myelinated Aδ and unmyelinated C fibres (Sengupta and Gebhart, 1994; Robinson and 
Gebhart, 2008). Common forms of noxious cutaneous stimulation, such as pricking, cutting, 
do not generally elicit pain response when applied to body viscera. Moreover, different 
visceral organs may have specific nociceptors that respond to a particular stimulus. For 
example, the heart has unmyelinated fibres which are individually responsive to chemicals 
released by the ischaemic myocardium (Casati et al., 1979; Baker et al., 1980; Fu et al., 2010; 
Goodman-Keiser et al., 2010). In the gut, there are tension receptors located on the muscular 
wall which respond to distension, contraction, and constriction of the gut (Leek, 1977; Clarke 
and Davison, 1978; Lu et al., 2010; Humenick et al., 2015). 
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Table 1.2. Characteristics of unmyelinated C and myelinated A-fibres (Dubin and Patapoutian, 2010) 
Unmyelinated C-Fibre Myelinated A-Fibre 





A-mechano-heat, A-heat, A-mechanical 
 
Broadly distributed with less precise localisation Highly sensitive 
 
Group IV are small unmyelinated C fibres with 
conduction velocity <2.5 m/s and respond to strong 
pressure 
Group III are small myelinated A-fibres with 
conduction velocity 2.5-20 m/s and respond to 
pressure and pain 
 
1.1.3.2 Afferents Neurons 
 The primary nociceptive afferents innervating the viscera reach the central nervous 
system (CNS) mainly via sympathetic nerves, but some afferent fibres also project to CNS via 
parasympathetic nerves, including the pelvic nerve and the vagus nerve (Grundy, 2002; 
Almeida et al., 2004; Berthoud et al., 2004; Anand et al., 2007; Vermeulen et al., 2014). The 
vagus nerve innervates the gastrointestinal tract (GIT) from the oesophagus to the proximal 
third of the transverse colon. The remainder of the large bowel and rectum are supplied by 
pelvic nerves (Bennett and Stockley, 1975; Mei, 1983; Wingate, 1985; Vermeulen et al., 2014). 
Somatic afferent neurones enter the spinal cord at the corresponding spinal segments through 
the spinal nerves. The cell bodies of these first order neurons are located in the dorsal root 
ganglia of the spinal cord (Figure 1.1). These neurons then synapse with the second-order 
neurons in the dorsal horn and lateral grey matter of the spinal cord, where the pain signals 
travel further in the ascending sensory pathways (Armett et al., 1961; Scheibel and Scheibel, 
1968; Handwerker et al., 1975; Moreno-Lopez et al., 2013). 
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Figure 1.1. A schematic showing spinal cord cross section along with a spinal nerve. 
1.1.3.3 Ascending Sensory Pathways 
 The second-order neurons, with cell bodies lying in the dorsal horn, ascend mainly in 
the anterolateral system containing spino-thalamic and spino-reticular tracts. Other tracts 
include spino-mesencephalic, spino-tectal and spino-hypothalamic fibres (Purves et al., 
2001c). The visceral afferents terminate in laminae I, II, V–VII and X of the dorsal horn in the 
spinal cord (Purves et al., 2001a), as described in Figure 1.2. Laminae I and V form parts of the 
anterior and lateral spinothalamic tracts, whereas laminae VII and X constitute part of the 
dorsal column pathway (Rustioni et al., 1979; Bennett et al., 1983). 
 The two major tracts of the spinal cord known to transmit the visceral nociception are 
the spinothalamic tracts and the dorsal column. The nerve cells in the anterior and lateral 
spinothalamic tracts make synaptic connections in different locations along their pathway, 
e.g., within the mesencephalic reticular formation and the periaqueductal grey via spino-
reticular tract, in the tectum via spino-tectal tract, and in the intralaminar thalamus via 
spinothalamic tract (Jones et al., 2006; Sharma et al., 2009). Based on this knowledge, 
procedures such as anterior cordotomy and commissural myelotomy have been reported to 
be performed in the early 20th century to relieve visceral pain (Spiller and Martin, 1912). 
However, these techniques have been abandoned due to associated serious adverse events. 
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 The dorsal column of the spinal cord is generally known to be involved in the 
transmission of proprioception, vibration, and fine touch. However, its role in 
neurotransmission of visceral pain has also been established (Willis et al., 1999; Palecek, 
2004). A surgical lesion of the postsynaptic dorsal column has been shown to dramatically 
reduce the electrical responses of the ventral posterolateral nucleus (VPL) of the thalamus to 
colorectal distension in rats (Al-Chaer et al., 1996b, a). With the evolution of techniques in 
surgical lesions in dorsal columns, a recent, more accurate technique ‘punctate midline 
myelotomy’ has been described for intractable visceral cancer pain (Nauta et al., 2000). This 
procedure has been found to be very efficient and is associated with low morbidity and 
surgical mortality (Hong and Andren-Sandberg, 2007). 
 
Figure 1.2. A cross section of spinal cord showing laminae of Rexed in grey matter. The visceral afferents terminate 
in laminae I, II, V–VII and X of the dorsal horn in the spinal cord (C.D. Alberstone, 2009). 
 
1.1.3.4 Pain Processing in the Brain 
 The cell bodies of the third order neurons of nociception pathways are located in the 
ventral-posterior-lateral, the ventral-posterior-inferior and the intralaminar nuclei of the 
thalamus (Steeds, 2009). The fibres from ventral-posterior-lateral nucleus course through the 
posterior limb of the internal capsule and terminate in the primary somatosensory cortex (also 
known as postcentral gyrus) through the corona radiata. The primary somatosensory cortex 
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is located in the postcentral gyrus of the parietal lobe (Figure 1.3). The ventral-posterior-
inferior nucleus of the thalamus project mainly to secondary somatosensory cortex located 
on the superior aspect of the lateral fissure. The intralaminar nuclei project fibres to the 
striatum (caudate and putamen), primary and secondary somatosensory cortex, cingulate 
cortex, and prefrontal cortex (Eto et al., 2011; Fuchs et al., 2014; Seminowicz and Moayedi, 
2017). 
 
Figure 1.3. A schematic showing fibres carrying pain signals, travelling through the spinothalamic tracts 
to the postcentral gyrus of the brain cortex (Snell, 2010). 
 
 Clinical imaging studies such as electroencephalography (EEG), magnetic resonance 
imaging (MRI), and positron emission tomography have shown that nociception is not only 
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processed at the primary and secondary somatosensory cortices but also in the anterior 
cingulate cortex, insular cortex, and the supplementary motor cortex, thalamus and 
cerebellum (Apkarian et al., 2005). Figure 1.4 depicts these connections. In the context of 
nociception, these brain structures such as the primary and secondary somatosensory, the 
cingulate and the insular cortices are often referred to as "pain matrix", i.e., a network of 
cortical areas through which pain is generated from nociception (Melzack, 1999; Tracey and 
Mantyh, 2007). The somatosensory cortices process information about sensory features of 
pain such as location and duration (Kenshalo et al., 1988; Greenspan et al., 1999; Garland, 
2012). The anterior cingulate cortex (ACC) and anterior insular cortex are connected with the 
limbic cortex, which plays a role in the emotional aspect of pain (Bush et al., 2000). The ACC, 
which is thought to play a dominant role in cognitive and emotional processing, is also known 
to be involved in descending modulation of pain (Tracey and Mantyh, 2007). In posttraumatic 
stress disorder, there is decreased activation of ACC seen in functional imaging, which may 
indicate impairment of emotion regulation in this condition (Etkin and Wager, 2007). A similar 
effect of reduced activation of ACC is seen in depressed patients in response to emotional 
stimuli (Fitzgerald et al., 2008). Depressive disorders are often associated with chronic pain. 
Central neuronal plasticity may underlie these both conditions. A study showed that degree 
of depression was associated with the magnitude of activation of brain areas involved in the 
affective dimension of pain (Giesecke et al., 2005). Patients with lesions in ACC and insula 
show altered emotional responses to pain and based on this, surgical cingulotomy can be 
helpful in patients with cancer pain refractory to medical management (Viswanathan et al., 
2013; Agarwal et al., 2016). 
 Certain areas of the brain also play an important role in descending modulation of pain 
transmission which can either result in inhibition or facilitation (Ren and Dubner, 2002). These 
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brain regions include the frontal lobe, ACC, insula, amygdala, hypothalamus, PAG, nucleus 
cuneiformis, and rostral ventromedial medulla (RVM) (Ossipov et al., 2014). This pain 
modulatory system, which works through the attentional modulation of pain, regulates the 
nociceptive processing mainly at the dorsal horn and is mediated largely through the PAG and 
RVM (Reynolds, 1969; Yaksh and Rudy, 1978; Gebhart, 2004; D'Mello and Dickenson, 2008). 
PAG has been shown to have increased activity in people who were distracted compared to 
those who were attentive to pain stimulation (Tracey et al., 2002). The former group also had 
low pain score rating. During distraction, the cingulo-frontal cortex exerts influences on the 
PAG and posterior thalamus to gate the pain modulation (Valet et al., 2004). 
 
Figure 1.4. Afferent pain pathways to multiple brain regions. Nociceptive information from the thalamus 
is projected to the insula, anterior cingulate cortex (ACC), primary somatosensory cortex (S1) and secondary 
somatosensory cortex (S2), whereas information from the amygdala (AMY) is projected to the basal ganglia 
(BG). Information is also relayed into PAG, periaqueductal grey; PB, parabrachial nucleus; PFC, prefrontal 
cortex (Bushnell et al., 2013). 
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1.1.4 Neurotransmitter Signalling in the Pain Pathways 
 Some of the neurotransmitters and receptors involved in pain processing include; 
glutamatergic, GABAergic, opioid, nicotinic, cannabinoid, and glucocorticoid 
neurotransmitter-receptors systems (Otsuka and Yanagisawa, 1990; Argoff, 2011). Table 1.3 
(adapted from Steeds et al.) lists the neurotransmitters involved in the transmission of pain 
(Steeds, 2009). Among these, glutamate is the chief excitatory and gamma amino butyric acid 
(GABA) is a major inhibitory neurotransmitter involved in the pain processing. 
Table 1.3. List of neurotransmitters involved in pain neurotransmission (Steeds, 2009) 
Class Neurotransmitter Comments 
Amines Noradrenaline 
Serotonin 






Widespread in CNS, particularly along pain 
pathways. Inhibitory action on opioid receptors 
Non-opioid peptides Substance P Widespread especially in dorsal root ganglion (DRG) 
of C fibres. Associated with inflammation  
Gelanin Widespread. Involved with antinociception 
Cholecystokinin Present in DRG, dorsal horn, and spinal tracts. May 
be involved with visceral pain  
Excitatory amino acids Glutamate Act on N-methyl-D-aspartate (NMDA) and non-
NMDA receptors. Involved in development, memory, 
and neuronal plasticity  
Inhibitory amino acids GABA 
Glycine 
Regulate behaviour associated with non-noxious 
stimuli  
Others Cannabinoids Receptors in the brain and spinal cord and on 
primary afferent neurons. Involved in 
antinociception 
Nitric Oxide In sensory neurons and dorsal horn. Involved in 
peripheral and central sensitisation. Linked with 
NMDA activity  
 
1.1.4.1 Glutamatergic System 
 The study of the expression of various components of the glutamatergic system and 
functions of regulators of synaptic glutamate concentration is vital to explore multiple factors 
affecting nociception. The role of glutamatergic pathway in nociceptive processes has been 
associated with different types of pain such as neuropathic and visceral pain (Jensen and 
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Baron, 2003; Osikowicz et al., 2013; Zunhammer et al., 2016). Upregulation of glutamate 
clearance at synapses has been shown to attenuate the neuropathic pain and visceral pain 
(Gosselin et al., 2010; Chen et al., 2012; Moon et al., 2014; Nicholson et al., 2014b). Therefore, 
the drugs that can downregulate glutamatergic neurotransmission appear to be an attractive 
target for the future therapy of various pain syndromes. Glutamate is a major excitatory 
neurotransmitter in the CNS that participates in rapid signal transmission across the synapses. 
Glutamate receptors are found throughout the brain and spinal cord, both in neurons and glial 
cells. Glutamate concentration in the neuronal synapses is regulated by a number of 
mechanisms. Abnormal regulation of glutamate metabolism can lead to deleterious effects, 
for example; excessive concentration of extracellular glutamate can lead to postsynaptic 
excitotoxicity and cell death (Choi, 1994; Doble, 1996; Heath and Shaw, 2002). 
 Glutamine is the precursor of glutamate found in presynaptic neurons (Hamberger et 
al., 1979; Holten and Gundersen, 2008). Glutamate, once formed, is transported and stored 
in synaptic vesicles in the presynaptic neuron by vesicular glutamate transporters (VGLUTs). 
During signal transmission, glutamate is released into the synaptic cleft, which, in turn, causes 
activation of ionotropic glutamate receptors, also called N-methyl-D-aspartate (NMDA) 
receptors. Activation of these receptors results in neurotransmission across the synapse. The 
concentration and activity of glutamate are controlled by sodium-dependent excitatory amino 
acid transporters (EAATs), through which an influx of glutamate occurs into glial cell end feet 
wrapped around the synaptic cleft (Rothman et al., 2003). This movement is sodium-
dependent and involves an influx of sodium and glutamate, and efflux of potassium molecule 
(Zerangue and Kavanaugh, 1996; Rose et al., 2009). Inside glial cells, the glutamate is 
converted into glutamine and transported back in to the presynaptic neuron, where it is stored 
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again in synaptic vesicles in the form of glutamate by the action of glutaminase (Thanki et al., 
1983). Figure 1.5 summarises glutamate metabolism. 
 
Figure 1.5. Glutamatergic neurotransmission and glutamate metabolism across the synaptic cleft. Glutamate 
(Glu) is released into synapse by the presynaptic neuron. The Glu in the synapse is cleared by EAAT into the glial 
cell where it is converted into glutamine (Gln). Glutamine is transported into presynaptic neuron where after 
conversion into glutamate is stored in vesicular glutamate transporters (VGLUTs). 
 
1.1.4.1.1 Glutamate Transporters 
 
 To maintain a normal synaptic transmission and to avoid excitotoxicity, the regulation 
of glutamate metabolism is critical. EAATs regulate the concentration of glutamate in the 
synaptic clefts by rapidly transporting glutamate into the cells. Five EAA transporters have 
been identified; EAAT1 to EAAT5. L-glutamate/L-aspartate transporter (EAAT1), glutamate 
transporter-1 (EAAT2), and excitatory amino acid carrier-1 (EAAT3) were first identified in 
1992 (Kanai and Hediger, 1992; Pines et al., 1992; Storck et al., 1992). EAAT1 and EAAT2 are 
primarily found on glial cells, while EAAT3 is a neuronal membrane transporter (Eulenburg 
and Gomeza, 2010). EAAT4 and EAAT5 were later identified in the cerebellum and retina, 
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respectively (Fairman et al., 1995; Arriza et al., 1997). Primarily astrocytes, but also microglia 
and oligodendrocytes are involved in the regulation of extracellular glutamate (Olive, 2009). 
The majority of the EAA transporters in the glial cells are associated with synapses 
(Minelli et al., 2001) and therefore have a vital role in regularisation of neurotransmission and 
prevention of excitotoxicity. Interestingly, in certain pathophysiologic states, such as 
ischaemia, the high extracellular K+ may lead to reverse transport of glutamate out of glial cells 
into the extracellular space (Szatkowski et al., 1990; Rossi et al., 2000). This mechanism may 
have a causative role in brain cell death following ischaemic brain stroke (Grewer et al., 2008). 
Another morbid pathological condition associated with EAAT2 dysfunction is amyotrophic 
lateral sclerosis (Rosenblum and Trotti, 2017). In the spinal cord, EAAT1 and EAAT2 are the 
mediators of glutamate clearance at synapses, and their expression has an important role in 
visceral hypersensitivity1 (Tao et al., 2005; Yan et al., 2009; Bradesi, 2010). Moreover, 
transgenic mice overexpressing EAAT2 demonstrated twofold glutamate uptake across these 
transporters and a significant reduction in visceromotor response (VMR) to colorectal 
distension2 (Lin et al., 2009b). It has been shown in rats that intrathecal administration of 
spinal glutamate transporter antagonist results in increased sensitivity to colorectal distension 
(Gosselin et al., 2010). On the other hand, maternal separation (an animal model of early-life 
distress) leading to visceral hypersensitivity, resulted in a selective reduction in spinal EAAT1 
expression (Gosselin et al., 2010). Therefore, there is a need to study these transporters 
extensively to achieve specific therapeutic targets in pain syndromes. 
1. Visceral hypersensitivity is defined as a heightened sensation in response to a physiological stimulus 
to viscera.  
2. The abdominal musculature contractions in response to experimental colorectal distension is termed 
as visceromotor response. 
 
  19 
1.1.4.1.2 Glutamate Receptors 
 There are two main types of glutamate receptors- ionotropic and metabotropic (Kew 
and Kemp, 2005; Pleasure, 2008). As their names indicate, ionotropic receptors are voltage 
sensitive, whereas metabotropic receptors are ligand sensitive. Ionotropic receptors are fast 
acting, which upon activation leads to an immediate influx of sodium resulting in postsynaptic 
cell membrane depolarisation. Ionotropic receptors are named after their respective ligands 
as NMDA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainic acid as 
shown in Figure 1.5. 
 Metabotropic receptors are slow acting receptors and act via gene expression and 
protein synthesis via G-protein coupling effect (Niswender and Conn, 2010). The metabotropic 
receptors, summarised in table 1.4, are grouped into three categories (Kew and Kemp, 2005). 
Table 1.4. Glutamate receptors and their properties 
Receptors Protein Subunits Properties 
Inotropic Glutamate Receptors 
NMDAR NR1, NR2A, NR2B, NR2C, NR2D, NR3A, and NR3B Ca2+, Na+ 
AMPAR GluR1, GluR2, GluR3, and GluR4  
Na+, (Ca2+) 
Kainate Receptors GluR5, GluR6, GluR7, KA1, and KA2 
Metabotropic Receptors 
Group 1 mGluR1 and mGluR5  
Gq / G11  PLC 
Group 2 mGluR2 and mGluR3 
Group 3 mGluR4, mGluR6, mGluR7, and mGluR8 Gi / G0  AC 
Glutamate activates sodium and calcium dependent ionotropic receptors and stimulates metabotropic 
receptors coupled via G proteins (Gq, G11, Gi, G0) to activation of phospholipase C (PLC) and inhibition of 
adenylate cyclase (AC) activity (Kew and Kemp, 2005). 
 
Group I metabotropic receptors are located on postsynaptic neurons, group II on both 
presynaptic and postsynaptic neurons, and group III receptors are situated mainly on 
presynaptic neurons. The presynaptic location of group II and III indicate their inhibitory 
effects on glutamate transmission (Lesage and Steckler, 2010). Dysfunction of group II and III 
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have been shown to be implicated in nervous system disorders such as anxiety, fear, stress, 
schizophrenia, Alzheimer’s and Parkinson’s disease (Swanson et al., 2005). 
N-methyl-D-aspartate receptors (NMDARs) are expressed by all DRG neurons 
(Marvizon et al., 2002), and it has been shown that direct stimulation of peripheral afferent 
nerve terminal fields with NMDAR agonists causes pain responses in both human and animal 
models (Cairns et al., 2003; Cairns et al., 2006). Stimulation of NMDARs in peripheral nerves 
and central nerve endings in spinal cord results in the release of pronociceptive 
neuropeptides, such as substance P, calcitonin gene-related peptide, and brain-derived nerve 
growth factor (BDNF) (McRoberts et al., 2001; Zhao et al., 2006a). 
1.1.4.1.3 Measurement of Extracellular Glutamate 
 Extracellular glutamate can be measured by both in-vivo and ex-vivo techniques. Table 
1.5 summarises these techniques. 
A) In-vivo Measurement of Extracellular Glutamate 
i- Microdialysis 
 Microdialysis has been used to analyse the extracellular concentration of a number of 
electrolytes, neurotransmitters, hormones, and drugs from various regions of the brain and 
spinal cord (Chefer et al., 2009). Microdialysis probes are constructed utilising fused silica 
inlet, and outlet tubes joined together with a semi-permeable dialysis membrane with around 
2 mm active length (Baker et al., 2003). The in-vivo microdialysis probe is inserted into the 
target brain region after drilling small holes into the skull of animals using a stereotactic frame 
to identify the specific brain. There are various modifications, but for glutamate analysis, the 
most common approach is the no-net-flux method. In this method, after the insertion of the 
active probe into the desired tissue, increasingly concentrated exogenous glutamate solution 
is passed through the inlet probe at regular intervals. The final glutamate concentrations are 
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measured from the outlet probe. The point where there is no change in the concentration of 
both inlet and outlet solutions, i.e., no-net-flux, is inferred to the extracellular glutamate 
concentration of the tissue assessed (Jacobson et al., 1985; Lerma et al., 1986; Miele et al., 
1996; Galvan et al., 2003; Melendez et al., 2005; Miller et al., 2008; Berglind et al., 2009). 






Pain model Species, CNS region, 
awake/anaesthesia 
Reference 
Plantar incision Rat, dorsal horn, awake (Zahn et al., 2002) 
Pinching or saline injection 
in hind paw 
Rat, periaquiductal grey, 
awake 
(Rouge-Pont et al., 
1998; Silva et al., 
2000) 
Spinal capsaicin Rat, intrathecal, awake (Malmberg et al., 
1995) 
Phorbol ester into the 
dorsal horn 
Rat, intrathecal, awake (Palecek et al., 
1999) 
Mustard oil joint into 
temporo-mandibular joint 





Bereiter et al., 
2002) 
Formalin/capsaicin 
injection into hindpaw 
Mouse, spinal cord dorsal 
horn,  
(Watanabe et al., 
2012) 
Spinal cord injury Rat, the ventro-postero-
lateral nucleus of the 
thalamus, awake 
(Ghanbari et al., 
2014) 
Microsensors Tail pinch Rats, prefrontal cortex, 
awake 
(Rutherford et al., 
2007) 
Electrical stimulation of 
hind limb 
Rats, dorsal brainstem, 
anaesthetised  




Peripheral nerve injury Mice, anterior cingulate 
cortex 
(Xu et al., 2008; 
Cao et al., 2009b) 
Hindpaw injection of 
Complete Freund's 
adjuvant 
Rats, anterior cingulate 
cortex 




 Microsensors are prepared by coating 300-500 μM long carbon fibre electrodes with a 
hydrogel containing glutamate oxidase and peroxidase (Oldenziel and Westerink, 2005). 
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Microsensors utilise the principle of a one-step or two-step redox reaction (Qin et al., 2008). 
A one-step redox reaction involves the action of glutamate oxidase, coated onto the sensors, 
which produces H2O2 detected by electrodes. A more recent form of these microsensors 
utilises two-step redox reaction, where H2O2 produced is further reduced by a second enzyme 
peroxidase (Oldenziel et al., 2006). The resultant current generated by this reaction is 
calibrated to determine the concentration of extracellular glutamate, which can range from 
1-10 μM in normal brain tissue and can reach 100 μM upon activation (Baker et al., 2002). 
B) In-vitro Analysis of Extracellular Glutamate 
i- Electrophysiological Measurements in Brain Slices 
 Cavelier and Attwell originally described this method (Cavelier and Attwell, 2005), 
whereas some modifications have been published in the literature (Herman and Jahr, 2007; 
Meur et al., 2007). Briefly, brain slices are dissected in an oxygenated buffer solution 
containing sodium kynurenate (to block glutamate receptors), at 4°C and a pH of 7.4. 
  The cells are whole-cell voltage-clamped with a pipette solution containing QX-314 (to 
suppress voltage-gated sodium currents). The external solution, as for brain slicing but 
without sodium kynurenate, is superfused at 25°C. Tetrodotoxin, picrotoxin, strychnine, and 
glycine are used in the bathing fluid to block action potentials, block GABAA and glycine 
receptors, and to fully activate the glycine-binding site on NMDA receptors. The slices need to 
be pretreated with bafilomycin to deplete glutamate from synaptic vesicles, so slices are 
incubated in a solution (without sodium kynurenate) to which bafilomycin is added. Control 
slices are incubated for the same period in a solution containing sodium kynurenate. 
Excitatory postsynaptic tonic NMDA-receptor currents are evoked by placing a concentric 
stimulating electrode at a standard location, mediated by extracellular glutamate. Compared 
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to in-vivo techniques, these methods give extracellular glutamate concentrations to be very 
low, i.e., 23 to 89 nM (Cavelier and Attwell, 2005; Herman and Jahr, 2007). 
ii- Glutamate Uptake Assay by Radiolabelling 
 Glial glutamate uptake by glutamate transporter can be measured by radiolabelling 
the glutamate, a technique described by Frizzo et al. (Frizzo et al., 2002; Thomazi et al., 2004). 
During the procedure, animals are decapitated, their brains immediately removed and 
humidified with Hank’s balanced salt solution (HBSS), at pH 7.2. Brain tissue is dissected into 
Petri dishes with HBSS and slices (0.4 mm) obtained using a McIIwain tissue chopper. Slices 
are transferred to 24-well culture plates: one plate maintained at 35 °C and the other on the 
ice. The slices from the first plate are washed once with 1 mL of 35 °C HBSS and the second 
with 1 mL of 4 °C sodium-free HBSS for the analysis of non-specific uptake. Slices are pre-
incubated at 35 °C for 30 min, followed by the addition of Ci mL−1 L- [ 3H] glutamate, and 
100 M (final concentration) glutamate. Incubation is stopped after 3, 5 or 7 min for striatum, 
hippocampus, and cortex, respectively, with two ice-cold washes of l mL HBSS, immediately 
followed by the addition of 0.5N NaOH, which are then kept overnight. 
 To measure sodium-independent uptake, the same protocol described above is used, 
though with differences in the temperature and the medium used. Sodium-independent 
uptake is determined on ice (4 °C), using N-methyl-d-glucamine instead of sodium chloride. 
The results are subtracted from the total uptake to obtain the specific sodium-dependent 
uptake. The radioactivity is measured using a liquid scintillation counter. The final radioactivity 
is normalised to protein measured from the same tissue to get the total glutamate uptake. 
Since EAATs transport both glutamate and aspartate, either of these compounds can be used 
to assess the EAAT function (Ryan et al., 2009). 
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1.1.4.2 GABAergic System 
 γ-aminobutyric acid (GABA) is widely distributed throughout the CNS. GABA receptor 
agonists, as well as the inhibitors of its metabolism, have been shown to display 
antinociceptive activity (Sands et al., 2003; Jasmin et al., 2004; Hama and Borsook, 2005; Enna 
and McCarson, 2006). There are two distinct types of GABA receptors: ionotropic GABAA and 
metabotropic GABAB receptors. 
 GABAergic neurons, as well as GABAA and GABAB receptors, are located in the areas of 
the CNS related to the neurotransmission of pain signals. In the brain, the activation of GABAA 
receptors in the thalamus induces an antinociceptive response (Reyes-Vazquez et al., 1986; 
Umorin et al., 2016). Furthermore, there are GABAergic projections from the substantia nigra 
to the PAG and dorsal medullary raphe nucleus that regulate the behavioural and responses 
to pain (Kirouac et al., 2004; Omelchenko and Sesack, 2010; Dieb et al., 2016). There is data 
indicating that GABAA receptors are located on inhibitory neurons projecting from the rostral 
ventral medulla to the dorsal horn (Gilbert and Franklin, 2001; Kato et al., 2006). In the spinal 
cord, GABA receptors are present on the laminae I and II of the dorsal horn. Activation of 
presynaptic GABAB receptors on substance P or glutamate containing neurons tends to 
enhance the pain thresholds by inhibiting the release of these transmitters (Malcangio and 
Bowery, 1994). Thus, stimulation of GABAB receptors located presynaptically on the 
descending inhibitory serotonergic or noradrenergic terminals may lower the pain threshold 
by diminishing the release of transmitter from these cells (Yang et al., 2002). Likewise, direct 
GABAA or GABAB receptor-mediated inhibition of opioid-containing neurons tends to facilitate 
pain transmission by reducing the release of this endogenous analgesic (Mahmoudi and 
Zarrindast, 2002). 
  25 
1.2 Anatomical Sex Differences in Pain Pathways 
 Animal models have shown females to be more sensitive to visceral pain stimuli such 
as colorectal distension and urinary bladder distension (Holdcroft et al., 2000; Ness et al., 
2001; Ji et al., 2006; Ball et al., 2010; Ji et al., 2012). In contrast to this, some studies have 
shown no gender differences in visceral pain (Wang et al., 2009; Larauche et al., 2012). 
 Sex differences have been investigated in various aspects of pain, including 
physiological and pathophysiological characteristics, behaviours to pain and responses to 
different interventions (Fillingim et al., 2009; Bartley and Fillingim, 2013). The cause of most 
of these sex differences is multifactorial, but there are anatomical and molecular differences 
present in the CNS in both sexes, accountable for these differences in pain associated 
characteristics. 
1.2.1 Sex Difference Along Nociceptive Afferents Signalling 
 The lumbosacral spinal cord is an important area in the gut-related visceral pain and 
sciatica associated neuropathic pain pathways. Mills et al. have demonstrated that male rats 
have more DRG neurons as compared to females in the lumbar spine (Mills and Sengelaub, 
1993). They found that this distribution was testosterone dependent as no difference was 
found in day 18 female and male embryos, whereas this difference emerged at the age of 10 
days postnatal. This hypothesis of testosterone effect was endorsed by the finding that 
perinatal treatment with testosterone in females abolished this difference (Mills and 
Sengelaub, 1993). However, this difference is related to perineal musculature activity rather 
than visceral pain. 
 The hormonal modulation of DRGs was further suggested by the presence of 
oestrogen receptors in DRGs in 1994 for the first time (Sohrabji et al., 1994). It was also noted 
that cyclical changes in the expression of oestrogen receptors in DRGs occurred in the 
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different phases of the oestrous cycle in female rats. A few years later the distribution of both 
oestrogen receptor alpha (ERα) and oestrogen receptor beta (ERβ) in this region was 
described (Taleghany et al., 1999). The expression of mRNA of ERβ in almost all neurons in 
DRG, in both male and female rats was seen. In contrast, ERα mRNA along with ERα protein 
was mainly found in small-sized DRG neurons. These were found to be concentrated in DRGs 
in those levels related to visceral organs (lumbosacral spinal segments L6-S1) than those 
related to hind limbs (lumbar segments L4-L5). Moreover, DRG neurons were shown to be 
enriched with ERα mRNA at lumbar segments L1-L2 in males when compared to females. 
Later, it was established that approximately 17% of the L6-S1 DRG neurons contain ER-α, 23% 
contain ER-β and 5% express immunoreactivity for both subtypes of the ER suggesting that 
oestrogen may produce different effects in different neurons depending on their ER receptor 
expression (Papka and Storey-Workley, 2002). 
 It has yet to be established whether these gender differences in afferents have any 
role in visceral pain modulation. The electrophysiological studies of colonic afferents have 
shown no differences in responses to colorectal distension in intact and ovariectomised 
female rats, suggesting oestrogen may modulate visceral pain pathways distal to the primary 
afferents (Ji et al., 2011). 
1.2.2 Spinal Mechanisms Involved in Sex Differences 
1.2.2.1 Dorsal Horn Neurons 
 Different segments of the spinal cord may be involved in the transmission of visceral 
pain depending on its origin. For example, lumbosacral and thoracolumbar dorsal horn 
neurons have been shown to be involved in the transmission of the pain resulting from CRD 
(Ness and Gebhart, 1987, 1988). It has been shown that the activation of afferents to cervical 
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segments 1, 2, 6 & 7 led to inhibition of evoked responses to visceral stimulation of 
lumbosacral neurons (Qin et al., 1999). 
1.2.2.2 Glial Excitatory Amino Acid Transporters 
 To our knowledge, sex-specific comparisons of mRNA expression of these transporters 
have not been studied previously. Further studies are needed to elucidate the function of 
these transporters in males and females. This can be achieved by glutamate uptake assays on 
rat spinal cord slices and by comparing the results of males with females in various phases of 
the oestrous cycle. The factors affecting the glutamate transport, such as sex hormones, can 
also be elucidated with this technique. 
1.2.2.3 Glutamate Receptors 
 In the CNS, NMDARs activity is modulated by oestrogen. It has been shown that 
NMDARs showed more activity in DRGs in female rats as compared to males, and this effect 
was further potentiated in females by exogenous oestrogen (McRoberts et al., 2007). Double 
immunofluorescent labelling studies have shown co-localisation of oestrogen receptor alpha 
(ER-α) and NR1 (a subunit of NMDAR) in the dorsal horn of the lumbosacral cord, suggesting 
a direct modulation of glutamate receptor activity by oestrogen through ER-α (Tang et al., 
2008). Further studies to evaluate the expression of oestrogen receptors and glutamate 
receptors in the lumbosacral cord in females across their oestrous cycle may add more 
knowledge to effects of endogenous oestrogen on these receptors’ expression. 
1.2.2.4 Other Modulators 
 Toll-like receptors (TLRs) are a group of pathogen-recognition receptors activated by 
various bacterial and viral components. Their activation results in the transcription of 
inflammatory cytokines, such as interleukins and tumour necrosis factor α. In the gut, TLRs 
are among the key mediators of the host defence system, being responsible for maintenance 
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of mucosal and commensal homeostasis. Patients with irritable bowel syndrome show greater 
expression of TLR4 and TLR5 in their colonic mucosa and increased blood levels of TLR-agonist-
induced cytokines as compared to healthy individuals (Dinan et al., 2006; Liebregts et al., 
2007; Scully et al., 2010; Brint et al., 2011; McKernan et al., 2011). 
 From the family of TLRs, TLR4 has an important role in both somatic and visceral pain. 
Various animal models have shown increased lumbar spinal mRNA expression of TLR4 in 
peripheral nerve lesions (DeLeo et al., 2004; Raghavendra et al., 2004). TLR4-knockout mice 
have been shown to develop fewer pain responses and decreased expression of inflammatory 
cytokines (Tanga et al., 2004). Moreover, administration of TLR4 antagonist administration to 
mice has been demonstrated to relieve neuropathic pain (Bettoni et al., 2008). Our lab has 
demonstrated reduced visceral nociceptive responses in TLR4 deficient mice. It has also been 
demonstrated that selective antagonism of TLR4 resulted in reduced visceral hypersensitivity 
in wild- type mice and reversed visceral hypersensitivity in stressed mice (Tramullas et al., 
2014). 
 Although the role of TLRs in chronic pain has been increasingly emphasised, only a few 
studies have been carried out to see gender differences in their involvement. Sorge et al. have 
demonstrated a significant sex difference in the involvement of spinal TLR4 in the mediation 
of chronic pain through the administration of spinal intrathecal lipopolysaccharide (LPS-
agonist of TLR4), where allodynia in females was observed less as compared to males (Sorge 
et al., 2011). This difference was considered to be testosterone dependent. The TLR4 knockout 
female mice did not show a reduction in allodynia following lumbar nerve lesion as compared 
to males. These findings suggest pain processing at the level of the spinal cord in females is 
independent of the TLR4 pathway (Sorge et al., 2011; Stokes et al., 2013). 
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1.2.3 Role of Supraspinal Mechanisms in Sex Differences in Pain Signalling 
1.2.3.1 Brain-derived Neurotrophic Factor 
 BDNF is a growth factor regulating neuronal growth and differentiation. Its actions are 
mediated by a high-affinity receptor called tropomyosin receptor kinase B. BDNF and its 
receptor’s expression has been noted in all the key areas in pain pathways such as DRGs, spinal 
cord, thalamus, periaqueductal grey, hypothalamus, parabrachial nucleus, amygdala and 
brain cortex (Conner et al., 1997; Yan et al., 1997a; Yan et al., 1997b; Zhou et al., 2004; Salio 
et al., 2005; Bruns and Miller, 2007). The role of BDNF at these anatomical sites, as a pain 
modulator, has also been established (Merighi et al., 2008). 
 Li et al., have shown the effects of BDNF in males and females differentially. It 
facilitates the visceral pain in females but shows the opposite effect in male rats. After the 
intraperitoneal acetic acid (AA) injection (an animal model of visceral pain), females showed 
more pain behaviours than males. Ovariectomy attenuated this higher sensitivity to AA-
induced pain response in females. Pre-treatment with anti-BDNF antibody significantly 
exacerbated the pain response in males but attenuated it in females. While exogenous BDNF 
administration did not alter AA injection-induced pain response in females, BDNF pre-
treatment attenuated the pain response in males but exacerbated it in females with 
ovariectomy (Li et al., 2010). This effect can be partly explained by the findings of higher whole 
blood BDNF concentration in females (Trajkovska et al., 2007) and which displays a hormonal 
change-related rhythmic variation (Piccinni et al., 2008). The ability of oestrogen to regulate 
BDNF transcription and expression has also been demonstrated (Allen and McCarson, 2005). 
1.2.3.2 Spino-parabrachial-amygdala Pathway and Cortex 
 The parabrachial nucleus (PBn) in the brainstem has long been recognised as an 
important relay centre in visceral nociceptive sensory processing (Cechetto et al., 1985; 
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Bernard et al., 1994; Bester et al., 1997). Dorsal horn cell fibres project into the PBn, which in 
turn project in to the amygdala. This spino-parabrachial–amygdala pathway is thought to 
constitute an essential circuit for the affective-motivational component of visceral pain 
(Gauriau and Bernard, 2002). Murphy et al. found no sex differences in the anatomical 
organisation of spino-PBn neurons, but they discovered that noxious CRD activated spino-PBn 
neurons more in males compared to females. Moreover, morphine attenuated this activation 
significantly in males compared to females (Murphy et al., 2009). This suggests that spino-PBn 
pathway contributes to the sex difference in visceral pain by activating an opioidergic 
inhibitory circuit in males. Furthermore, the amygdala has been shown to be affected by the 
sex hormones (Myers et al., 2011). Oestrogen and progesterone implants, when placed in the 
amygdala in ovariectomised rats, resulted in heightened responses to CRD but not to 
mechanical pain, suggesting that an amygdala-dependent mechanism may have a role in the 
exacerbation of visceral symptomatology in females. Wang et al. measured functional 
activation of brains in male and female rats exposed to colorectal distension. They 
demonstrated greater changes in limbic (amygdala & hypothalamus) and paralimbic region 
(ventral striatum, nucleus accumbens, raphe) in females but greater cortical activation in male 
rats. In males, this was consistent with greater cortical inhibition of the limbic region (Wang 
et al., 2009). Increased activation of the prefrontal cortex and limbic/paralimbic changes in 
females suggest their role in affective responses during visceral pain. A clinical gender study 
utilising functional MRI of the brain during pain showed that women demonstrated greater 
activation in the cingulate cortex, insula, premotor cortex, and cerebellum and stronger 
deactivation in the caudate. In comparison, men showed increased activity in the 
supplementary motor area. In other words, during pain, women significantly activate brain 
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areas associated with the affective and motivation components of pain (Kano et al., 2013; 
Calvo-Perxas et al., 2016; Kisler et al., 2016). 
 In summary, there are anatomical and physiological gender differences present along 
the whole visceral pain pathways responsible for differential incidence and prevalence of 
visceral pain syndrome. However, most of the studies described above have not taken the 
phase of the oestrous/menstrual cycle into account when comparing females with males. As 
there is growing evidence of the role of sex hormones on various neurotransmission-related 
mechanisms, it is imperative to assess the factors modulating pain pathways in the context of 
the oestrous/menstrual cycle. 
1.3 Hormonal Modulation of Pain Depicted in Preclinical & Clinical Pain Models 
 Numerous preclinical and clinical studies have shown that gonadal hormonal 
variations can lead to altered pain responses. 
1.3.1 Effect of Sex Hormones on Pain in Preclinical Visceral Pain Models 
 During the oestrous cycle, systemic levels of oestrogen change in females depending 
upon the phase of the cycle. Oestrous cycle in female rats, which has been divided into four 
distinct phases (metestrus, diestrus, proestrus, and oestrus) lasts for four days on average. 
These phases can be identified by the relative populations of different vaginal epithelial cells 
under the microscope after vaginal smearing (Byers et al., 2012). The oestrogen level is highest 
during proestrus, and then it continues to decline in oestrus through to diestrus (Kalra and 
Kalra, 1974; Santmyire et al., 2010). 
 The role of gonadal hormones in visceral nociception has been investigated, with most 
studies indicating that oestrogen is pronociceptive (Ji et al., 2003; Lu et al., 2007; Ji et al., 2008; 
Tang et al., 2008; Fan et al., 2009a; Lu et al., 2009; Chaloner and Greenwood-Van Meerveld, 
2013), a few have concluded no effect (Robbins et al., 2010), and some of the earlier studies 
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demonstrating antinociceptive effects on visceral pain (Giamberardino et al., 1997; Bradshaw, 
1999; Bradshaw and Berkley, 2002). 
 Female rats have been shown to demonstrate higher visceromotor responses to 
colorectal distension in proestrus as compared to other phases (Ji et al., 2008; Peng et al., 
2008), although there are reports of no effect of the oestrous cycle on visceral pain (Cason et 
al., 2003). Furthermore, a study revealed more ureteral pain sensitivity in metestrus and 
diestrus (Giamberardino et al., 1997). These discrepancies may result from varying factors 
including strain differences, the accuracy of oestrous phase determination, study design, 
duration of pain stimulus and sample size. Ovariectomy of female rats resulted in decreased 
pain responses as compared to intact females, whereas replacement of oestrogen in these 
ovariectomised animals led to the restoration of increased visceromotor responses to 
colorectal distension (Ji et al., 2003; Tang et al., 2008). However, co-administration of 
progesterone blunted this effect of exogenous oestrogen in ovariectomised rats (Fan et al., 
2009a). Interestingly, direct activation of oestrogen receptor alpha (ER-α) had pronociceptive 
effects (Ji et al., 2011), whereas ER-β activation resulted in lower visceromotor responses to 
colorectal distension (Cao et al., 2012) suggesting that oestrogen exerts it pronociceptive 
effects via ER-α. 
 As there are a number of reports elucidating the effects of hormones on visceral pain 
responses, only a few reports are available in the literature detailing the direct implications of 
these sex hormones on neurotransmission in CNS. Further studies are needed to examine how 
pain modulatory systems such as the excitatory glutamatergic system are moderated by the 
effects of changing levels of gonadal hormones during the oestrous cycle, and how factors 
such as early-life stress and depression may impact on this hormonal modulation. 
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1.3.2 Hormonal Modulation of Pain in Clinical Studies 
 Women have cyclical variations of sex hormones across the menstrual cycle, which on 
average lasts around 28 days. The menstrual cycle can be divided into four phases depending 
upon the development of ovarian follicle and corpus luteum: early follicular (low-oestrogen, 
low progesterone), late follicular (high-oestrogen, low progesterone), early luteal (low-
oestrogen, low progesterone) and late luteal (low-oestrogen, intermediate progesterone). 
 Cephalic pain disorders, e.g., migrainous headaches and temporomandibular joint 
disorder, are worsened in early follicular and late luteal phases of the menstrual cycle when 
the blood levels of oestrogen are low (Johannes et al., 1995; Dzoljic et al., 2002; LeResche et 
al., 2003; Mattsson, 2003). A similar variation of non-cephalic pain disorders symptomatology 
has been reported, e.g., exacerbation of irritable bowel syndrome (IBS)-related abdominal 
pain and rheumatoid joint pain in early follicular phase (Latman, 1983; Houghton et al., 2002). 
Moreover, the chronic neck pain-related disability index was found to be low in the late 
follicular stage where the systemic levels of oestrogen were high (Balter et al., 2013). It is 
interesting to note that the disorders mentioned above are more prevalent in females, 
endogenous oestrogen seems to be antinociceptive in the studies mentioned above. In 
contrast, some reports in literature demonstrated no effect of menstrual cycle stage on pain 
sensitivity (Klatzkin et al., 2010; Banz et al., 2012; Balter et al., 2013). 
 Similar to observational experiments of menstrual cycle-related hormonal changes 
and their impact on pain sensitivity, the effect of exogenous ovarian hormones (hormone 
replacement therapy in menopausal women & hormonal contraception) on pain sensitivity 
has been assessed on healthy individuals and those with existing pain syndromes. Some 
reports have shown exogenous oestrogen to increase experimentally induced pain sensitivity, 
e.g., cold pressor pain and facial pain (Fillingim and Edwards, 2001; Bragdon et al., 2002; 
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Drobek et al., 2002; Kowalczyk et al., 2006). However, other studies have failed to 
demonstrate such differences (Dao et al., 1998; Isselee et al., 2001; Nekora-Azak et al., 2008). 
These inconsistencies may arise from different methodologies used in different studies, 
insufficient sample size and inaccuracy of determination of menstrual cycle stage. In a review 
of 13 experimental studies, only four confirmed the cycle stage with hormone assays 
(Sherman and LeResche, 2006). Another possible reason for such inconsistency may be a lack 
of consideration of newly emerging factors affecting neuronal mechanisms, such as birth 
delivery mode, gut microbiota and gut permeability, and early-life abuse. 
 We have summated relevant anatomical and physiological differences along the pain 
pathways in CNS, accountable for the gender differences in pain. Sex hormones seem to play 
a major role in the modulation of visceral pain as demonstrated by various preclinical and 
clinical studies. The clinical studies which fail to show the hormonal modulation do not 
necessarily point toward the inference of lack of such effect, as there is a possibility that the 
presence of two opposing factors may nullify each other’s effect. For example, the effect of 
low-oestrogen may have been revoked due to the presence of stress and depression, which 
co-occurs with chronic pain in subjects during the clinical experiments (Sheng et al., 2017). 
Studies of gender differences are paramount as these aim toward appropriate pain 
management across the groups. Further studies are needed targeting the excitatory 
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1.4 Role of Stress in Hormonal Modulation of Pain 
1.4.1 Hypothalamic-Pituitary-Adrenal (HPA) Axis and Stress 
 
 Acute stress activates HPA axis, sympathetic nervous system, and sympathoadrenal 
system (Ulrich-Lai and Herman, 2009). Corticotropin-releasing hormone (CRF), the chief 
regulator of the HPA axis, is synthesised and released from the periventricular nucleus (PVN) 
of the hypothalamus (Bonfiglio et al., 2011). Vasopressin is also synthesised in PVN (Ohbuchi 
et al., 2015). After release, CRF reaches anterior pituitary gland through hypophysial portal 
vessels and binds to CRF type 1 receptors (Hauger et al., 2006). Through cyclic adenosine 
monophosphate (cAMP) pathway, CRF induces the release of adrenocorticotropic hormone 
(ACTH) into the circulation (Lewis et al., 2016). Circulating ACTH binds to melanocortin type-2 
receptor in the adrenal cortex and stimulates glucocorticoid synthesis (Clark et al., 2016). 
Glucocorticoid receptors are widely distributed throughout the brain and peripheral tissues. 
The glucocorticoids, e.g., cortisol in humans and corticosterone in rodents regulate a number 
of physiological processes in the body including metabolism, cardiovascular, immune, and 
behavioural processes (Strelzyk et al., 2012). Cortisol is released in a diurnal pattern with 
systemic levels reaching a peak in the morning to facilitate arousal and steadily declining 
thereafter. Throughout the day, cortisol maintains blood glucose and suppresses nonvital 
organ systems to provide energy to an actively functioning brain and neuromuscular system 
(Edwards et al., 2001). Cortisol is also a potent anti-inflammatory hormone; it prevents 
inflammation and its associated widespread tissue damage (Yeager et al., 2011). 
 Activation of the HPA axis is a tightly controlled mechanism involving neuronal and 
endocrine systems. The endocrine regulation is maintained through negative feedback by 
circulating glucocorticoids via fast non-genomic and delayed genomic mechanisms. The 
neuronal regulation is maintained through a number of projections to PVN arising from the 
  36 
brainstem, lamina terminalis, hypothalamic nuclei, and limbic system (Ulrich-Lai and Herman, 
2009). Excessive and repetitive activation of HPA axis, as seen in chronic stress and depression, 
may attribute to the dysfunction of normal HPA axis (Hannibal and Bishop, 2014). 
 The repetitive, excessive activation of the HPA axis, as observed in chronic stress states 
can result in cortisol dysfunction (Stephens and Wand, 2012). Cortisol dysfunction can 
manifest as depletion of cortisol, insufficient free (unbound) cortisol, impaired cortisol 
secretion or CRH function, glucocorticoid receptor (GR) resistance or downregulation, or 
hypersensitivity of the negative feedback system (Hannibal and Bishop, 2014). In the presence 
of GR resistance, cortisol may enhance its affinity with mineralocorticoid receptors (MR) which 
may initiate pro-inflammatory effects (Sorrells et al., 2009). Furthermore, binding of cortisol 
of MR downregulates the negative feedback mechanism resulting in higher CRH levels (Fries 
et al., 2005). Higher CRH levels activate inflammatory cells, increase noradrenaline release, 
and upregulate glutamate and its receptors in the amygdala to condition a fear-based stress 
response (McEwen and Kalia, 2010). In humans, stress-induced inflammation has been 
associated with many pain disorders such as fibromyalgia, chronic pelvic pain, 
temporomandibular joint dysfunction, chronic low back pain, sciatica, and rheumatoid 
arthritis (Quartana et al., 2010; Tak and Rosmalen, 2010; Tak et al., 2011). 
Acute pain is likely to elicit cortisol secretion and is commonly associated with 
hypercortisolism. Repeated cortisol secretion following maladaptive responses to acute pain 
is likely to perpetuate hypocortisolism and chronic pain (Tennant, 2013). As cortisol is a potent 
anti-inflammatory hormone, its dysfunction can shift the balance toward a pro-inflammatory 
state. The resultant elevated levels of inflammatory cytokines may sensitise nociceptors, 
manifesting as an increase in pain sensitivity. HPA axis dysfunction is commonly implicated in 
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chronic pain disorders such as fibromyalgia, chronic pelvic pain and temporomandibular joint 
disorder (Eller-Smith et al., 2018). 
1.4.2 Sex Differences and Effect of Sex Hormones on HPA Axis 
 
 Animal studies have shown that glucocorticosteroid levels are higher in females 
compared to males (Heinsbroek et al., 1991; Yoshimura et al., 2003). However, similar studies 
in humans are inconsistent. Some studies founds men to have higher HPA activation responses 
to physiological stress (Seeman et al., 2001; Stroud et al., 2002; Traustadottir et al., 2003), 
while other found no such differences (Kirschbaum et al., 1992; Buske-Kirschbaum et al., 2003; 
Kudielka et al., 2004). Larger cortisol response to acute stress has been noted in women with 
major depression in some studies (Peeters et al., 2003), while other groups failed to observe 
such findings (Young et al., 2004). These inconsistencies can be partly because of the fact that 
most of these studies focus only on the acute stress in otherwise healthy individuals but from 
heterogenous populations. Moreover, the newly emerging factors such as gut microbiota and 
their related diseases, when considered, may change the inclusion criteria of participants and 
comparison groups completely. 
 In male rats, testosterone has been shown to inhibit stress-induced ACTH release, and 
peripherally, testosterone may interfere with cortisol metabolism in the liver and the adipose 
tissue (Viau and Meaney, 1996; Barat et al., 2007). In rodents, basal and stimulated ACTH and 
corticosterone levels tend to be greater in females than in males. Ovariectomy has been 
shown to attenuate the response of HPA axis in rodents, whereas oestrogen replacement has 
reversed this attenuation (Lesniewska et al., 1990b; Norman et al., 1992). Similarly, 
gonadectomy increased ACTH responses in male rats, which were reversed by testosterone 
replacement (Viau and Meaney, 1996). Animal studies suggest that locally activated androgen 
receptor may facilitate negative feedback regulation of glucocorticoid synthesis by 
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upregulating GRs in the pituitary gland (Miyamoto et al., 2007). Interestingly, it has been 
shown that although men had significantly higher ACTH and cortisol concentrations than 
women, the hormone response to CRH was conversely markedly higher in women than in men 
(Vicennati et al., 2006). Moreover, short-term oestrogen treatment seems to enhance HPA 
response to psychosocial stress in healthy men (Kirschbaum et al., 1996). 
 A number of animal experiments have suggested oestrogen to have a causative role in 
enhanced HPA responsiveness, which may be due in part to impairment of glucocorticoid 
negative feedback. As mentioned previously, female rats have higher peak diurnal plasma 
corticosterone as compared to males. Potential mechanisms of action include competition 
between ER-α and GR to regulate transcription at an AP-1 site and reduction of GR binding in 
the hippocampus, hypothalamus, and anterior pituitary (Weiser and Handa, 2009). Oestrogen 
may also modulate PVN neurosecretory function directly. For example, oestrogen 
supplementation has shown a greater induction of c-fos mRNA in PVN neurons in response to 
stress (Ochedalski et al., 2007). Other studies have elaborated oestrogen to regulate PVN 
neuropeptides and upregulated stress-induced CRH mRNA (Liu et al., 2012). Expression of ER-
β in preautonomic neurons in PVN makes it unlikely to influence the HPA modulation (Kudwa 
et al., 2014). Oestrogen seems to impair the glucocorticoid induced negative feedback on HPA 
axis via oestrogen receptor alpha in the hypothalamus (Weiser and Handa, 2009; Liu et al., 
2012). The predominance of chronic pain states, e.g., fibromyalgia, chronic fatigue syndrome, 
chronic pelvic pain, temporomandibular joint dysfunction, chronic low back pain in women 
and simultaneous higher incidence of chronic stress in these women, suggests an interplay 
between cortisol failure and oestrogen. This effect may not be apparent in a normally 
functioning HPA axis in healthy women. 
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1.5 Mechanism of Action of Oestrogen in Nociceptive Modulation 
1.5.1 General Actions  
 
 Oestrogen is one of the steroid hormones and is generated from cholesterol (Berg et 
al., 2002). Cholesterol is converted into pregnenolone which is a precursor of all the steroid 
hormones. The androstenedione and testosterone, derived from pregnenolone, are 
converted into estrone and oestradiol by aromatisation by the P450 aromatase 
monooxygenase enzyme (Becker, 2007). The secretion of oestrogens is modulated by the 
gonadotropin-releasing hormone (GnRH) secreted by the hypothalamus (Marques et al., 
2018). GnRH, in turn, induces the secretion of follicle stimulating hormone and luteinising 
hormone. These hormones act on the steroid producing cells, and oestrogens are generated 
(Ghayee and Auchus, 2007). The central nervous system has the ability to synthesise 
oestrogen from cholesterol due to the presence of all required enzymes within CNS (Hojo et 
al., 2008). Moreover, testosterone and androstenedione have the capability of freely entering 
the brain; therefore can provide a source of oestrogen synthesis in the brain (Banks, 2012). 
 Oestrogen receptors when in a free state, are usually located in the cell cytoplasm and 
are attached to heat-shock proteins (Fliss et al., 2000). Under the effect of oestrogen, the 
heat-shock proteins are dissociated from oestrogen receptors, and motor proteins such as 
dynein get attached to the oestrogen-oestrogen receptor complex, which allows the transport 
into the nucleus (Belmont, 2010). The oestrogen binds to specific sequences of DNA in the 
nucleus called oestrogen-response elements (ERE) leading to gene transcription, and the 
particular proteins are generated (Klinge, 2001). After transcription is complete, the oestrogen 
receptors attach back to heat-shock proteins and become inactive. Oestrogen receptors can 
also alter the activity of other transcription factors without binding to EREs and may affect the 
production of collagenase and insulin-like growth factors for example (Gunter et al., 2008). 
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Being a phosphoprotein, oestrogen receptors can also be activated by phosphorylation in the 
absence of oestrogen through the mitogen-activated protein kinase pathway (Lannigan, 
2003). 
 Oestrogens have the capability of acting rapidly via transcription-independent 
mechanisms (Vasudevan and Pfaff, 2008). These pathways are mediated by cell membrane-
bound oestrogen receptors. G-protein coupled receptor GPR30 may also be activated by 
oestrogens. Oestrogens can also affect several intracellular pathways including mitochondrial 
activated protein kinase pathway, protein kinase C pathway, calcium channel modulation, and 
activation of transcription factors. 
1.5.2 Rapid Dendritic Spine Formation 
 
 Oestrogen can induce rapid dendritic spine formation in the ACC. The formation of the 
dendritic spine, their number and morphology are very important in the cell to cell 
communication. Oestrogen can induce synaptic density which is linked with enhanced learned 
memory. Thus, oestrogen can rapidly and persistently potentiate NMDA transmission, 
increased pERK and pCREB in the hippocampus and rACC (Cao et al., 2009a), remodelling of 
dendritic spines (Shansky and Morrison, 2009), and pain-related aversion (Cao et al., 2009b). 
Functional MRI studies in humans have shown increased activation of ACC and cerebellum 
during low-oestrogen phases of menstrual cycle suggesting that the affective component of 
pain may be enhanced during the low-oestrogen phase in healthy women (Sundström 
Poromaa and Gingnell, 2014). 
1.5.3 Action Through Descending Inhibitory Pathways 
 
 The excitability of pain processing neurons is influenced by several descending 
pathways that reach the medulla oblongata and dorsal horn of the spinal cord. Examples 
  41 
include opioid, noradrenergic, and serotonergic systems, of which, the endogenous opioid is 
the most potent descending pain modulation pathway (Purves et al., 2001b). Endogenous 
opioids are manufactured in the CNS, pituitary region, and adrenal glands. Major examples of 
opioids include enkephalin and dynorphin. Enkephalins such as met-enkephalin and leu-
enkephalin are widely expressed in the brain and are concentrated in the superficial lamina of 
the spinal dorsal horn (Fukushima et al., 2011). The regional concentration of dynorphin is 
similar to that of enkephalins; it can be both pronociceptive and antinociceptive (Gintzler and 
Liu, 2012). The opioids act primarily via G-protein coupled opioid receptors inducing 
hyperpolarisation through potassium conductance and voltage-gated calcium channels. The 
three well described subtypes include δ, µ, and κ receptors; µ being the most potent (Traynor, 
2012). 
 The enkephalinergic neurons in lamina II exert an inhibitory effect on nociceptive 
signals (Todd, 2010). They are activated by ascending afferent fibres as well as descending 
fibres from pain modulating regions of the brain. Co-expression of ERα by most of the 
enkephalinergic neurons in the dorsal horn indicated a robust mechanistic role between two 
systems (Amandusson et al., 1996). 
 The opioid system plays a pivotal role in pregnancy-induced analgesia, which is 
primarily mediated through spinal dynorphin activity (Gupta et al., 2001). Spinal dynorphin 
and enkephalin pathways get activated simultaneously, but as pregnancy progresses, 
dynorphin remains concentrated in lumbar regions receiving pelvic inputs. Enkephalins, 
however, gradually increase in concentration throughout the spinal cord as pregnancy 
advances (Gupta and Gintzler, 2003). Exogenous oestrogen treatment in ovariectomised rats 
has shown increased expression of enkephalin gene and subsequent higher concentration of 
enkephalins in the CNS (Eckersell et al., 1998). 
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 Oestrogen can also modulate the expression and function of opioid receptors in brain 
regions along the pain pathways. For example, in the parabrachial nucleus, µ-opioid receptor 
expression fluctuates along the oestrous cycle being lowest in the proestrus phase (Murphy 
et al., 2009). A similar trend has been seen in periaqueductal grey (Loyd et al., 2008). In healthy 
women, Mu-opioid receptor activation in the brain in response to painful stimuli is oestrogen-
dependent (Lawson et al., 2010). Women in the low-oestrogen state have shown a lower 
capacity to activate the opioid system in comparison to men and in turn demonstrate higher 
pain responses (Smith et al., 2006). 
1.6 Gut Microbiota and Pain 
1.6.1 Gut Microbiota 
 The term human gut microbiota refers to all non-pathogenic commensal 
microorganisms residing in our digestive tract which are involved in vital bodily functions such 
as digestion, absorption of nutrients and modulation the immune system (Wu and Wu, 2012; 
Aziz et al., 2013; Purchiaroni et al., 2013; El Aidy et al., 2014; Moloney et al., 2016; Foster et 
al., 2017). The overall collection of the genome of gut microbiota is termed as gut microbiome 
(Qin et al., 2010). The gastrointestinal tract in the newborn infant is virtually sterile although 
some studies are highlighting the possibility of prenatal colonisation (Jimenez et al., 2008). 
Initial gastrointestinal microbiota is largely determined by delivery mode (Dominguez-Bello et 
al., 2010; Mueller et al., 2015) and this microbiota profile can remain in residence from 
months to years (Jakobsson et al., 2014) and has the capacity to influence health outcomes 
(Negele et al., 2004; Parfrey and Knight, 2012). The initial composition of gut microbiota in 
infants is similar to that of the mother and their surroundings (Mueller et al., 2015; Rodríguez 
et al., 2015), but it tends to change dramatically over the first two years of life (Palmer et al., 
2007). Following this dynamic period, it tends to develop a profile that will mostly habitate 
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the gut for life (Rodriguez et al., 2015). However, a number of factors in prenatal and early 
postnatal life can alter the microbiota composition and the adult life. These factors include 
maternal diet, use of drugs including antipsychotics, antiepileptics, and antibiotics, birth 
through caesarean section, formula feeding, and early-life stress (O'Mahony et al., 2014; Cong 
et al., 2015; Mueller et al., 2015; Codagnone et al., 2018). 
 In adults, the gut microbiota is mainly composed of phyla Firmicutes and 
Bacteroidetes, representing 79.4% and 16.9% of the microbiota respectively, followed by 
Actinobacteria (2.5%) and Proteobacteria (1%) (Tap et al., 2009; Arumugam et al., 2011). 
While gut microbiota tends to be relatively stable over time, it does change with age (O'Toole 
and Jeffery, 2015), disease (Larsen et al., 2010) and antibiotic usage (Jernberg et al., 2010; 
Modi et al., 2014; Mikkelsen et al., 2015). A shift in the microbiota has been observed toward 
a Bacteroidetes predominated population in older individuals compared to younger 
individuals (O'Toole and Jeffery, 2015). Metagenomic studies have further grouped the gut 
bacteria into three distinct enterotypes depending upon the composition. The enterotype-1 
is enriched with Bacteroides along with Parabacteroides. The enterotype-2 mainly comprises 
of Prevotella and Desulfovibrio, whereas, Ruminococcus is a major representative of 
enterotype-3 (Arumugam et al., 2011). This concept that each human being has a 
characteristic enterotype similar to blood grouping has become debatable due to recent 
reports of microbiota composition dependency on long-term diet preferences (Wu et al., 
2011; Claesson et al., 2012). 
 In the last few years, the utilisation of new techniques such as gene sequencing for the 
characterisation of gut microbiota in relation to health and disease has advanced our 
knowledge to a new level (Fraher et al., 2012). The composition of gut microbiota is found to 
be altered in various gut-related disorders, e.g. inflammatory bowel disease (Sartor and 
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Mazmanian, 2012; Matsuoka and Kanai, 2015), IBS (Distrutti et al., 2016; Moloney et al., 
2016), and colorectal cancer (Louis et al., 2014; Gagnière et al., 2016). Altered gut microbiota 
is also found to be implicated in certain psychiatric disorders including depression 
(Naseribafrouei et al., 2014; Lach et al., 2018), autism (Mayer et al., 2014a), and Alzheimer’s 
disease (Hill et al., 2014; Sarkar et al., 2018). Recent preclinical and clinical studies have shown 
an association of altered gut microbiota with a number of CNS disorders including Parkinson’s 
disease (Felice et al., 2016; Dinan and Cryan, 2017a), ischaemic stroke, amyotrophic lateral 
sclerosis (Fang, 2016) and multiple sclerosis (Winek et al., 2016; Sherwin et al., 2018). 
 The gut microbiota can be altered by oral administration of prebiotics, probiotics, 
antibiotics. A more advanced method of modulating gut bacteria involves faecal microbiota 
transplant (FMT). Prebiotics are defined as a selectively fermented ingredients that allow 
specific changes, both in the composition and/or activity in the gastrointestinal microflora that 
confer benefits upon host wellbeing and health (Gibson et al., 2004). The oligosaccharides, 
such as fructans, galactans, and lactulose are examples of prebiotics. The probiotics, on the 
other hand, are live microorganisms that, when administered in adequate amounts, confer a 
health benefit on the host (Sanders, 2008). The examples of probiotics include Lactobacillus 
Casei and Bifidobacterium Bifidum. 
1.6.2. Communication Between Gut Microbiota and Central Nervous System 
 Bidirectional communication between the brain and gut microbiota, and recognition 
that microbiota influences various signalling pathways in the brain have led to the concept of 
microbiota-gut-brain-axis (Cryan and Dinan, 2012; Forsythe et al., 2012; Montiel-Castro et al., 
2013a). Gut microbiota and the brain communicate through three distinct pathways, 1) 
neuronal (vagus nerve and enteric nervous system);2) endocrine (HPA axis), and 3) immune 
(bacterial metabolites, cytokines) systems (Cryan and Dinan, 2012; Montiel-Castro et al., 
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2013b; Dinan and Cryan, 2016). This relationship (as shown in Figure 1.6) is evident in 
psychologically stressful situations where increased cortisol levels can enhance cytokine 
secretion through inflammatory cells, but can also alter gut microbial composition (O'Mahony 
et al., 2011; Moloney et al., 2016) and gut barrier function (Vanuytsel et al., 2014). On the 
other hand, gut bacteria have the capability of producing cytokines and metabolites, and to 
modulate the normal immune status of the body, which may have direct implications for the 
development of many nervous system disorders. 
 The production and metabolism of certain neurotransmitters, short-chain fatty acids, 
and tryptophan by microbiota are associated with the modulation of some physiological 
functions of the brain such as behaviour and cognition (Cryan and Dinan, 2012; Dinan et al., 
2015; Jenkins et al., 2016). Among various bacterial products, lipopolysaccharide (LPS) has 
been emphasised to be associated with the development of some neurological disorders 
mentioned earlier. LPS is a constituent of the cell membrane of Gram-negative bacteria and is 
secreted to the surrounding environment as part of the normal physiological activity of these 
bacteria (Alexander and Rietschel, 2001). LPS has been found to increase the permeability of 
not only the gut mucosa (Anitha et al., 2012) but also the blood-brain barrier (Jangula and 
Murphy, 2013). There are studies of microglial activation in the brain by LPS (Qin et al., 2007). 
Therefore, LPS seems to have a pro-inflammatory effect on the brain through increased 
transport of bacterial products and direct activation of microglia. 
 Gut bacteria can also stimulate vagal nerve endings to its anxiogenic, anxiolytic, anti-
inflammatory and immunomodulatory effects on the brain depending on the nature of the 
stimulus (Bravo et al., 2011; Forsythe et al., 2012). The recognition of these communication 
pathways and associated implications has resulted in the increase in research exploring the 
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role of gut microbiota in the development and progression of neurological disorders (Mayer 
et al., 2014b). 
 
Figure 1.6. Populations of neurons, whose cell bodies either reside within (intrinsic) or outside (extrinsic) the 
GI wall. The gut microbiota are capable of impacting at both local and extraintestinal levels to influence visceral 
sensation. Factors affecting gut microbiota include stress, infection, antibiotics, and diet. These may induce an 
imbalance in the microbiota which can ultimately result in peripheral or central sensitisation. In turn, 
neuroplasticity contributes to abnormal sensation and results in the development of discomfort and pain. 
Reversal of the bacterial imbalance is possible through the consumption of prebiotics or probiotics and the 
introduction of healthy diet habits which have been associated with a reduction in visceral pain particularly 
related to the gut. 
Key: (1) extrinsic neurons-red: second- and third order neurons of the anterolateral tract; blue: autonomic 
nervous system neuron; grey: vagal afferent neuron; yellow: spinal afferent neuron and (2) intrinsic neurons-
green: secretomotor neuron; purple: intrinsic primary afferent; orange: motor neuron; pink: interneuron. GI, 
gastrointestinal; SCFA, short-chain fatty acid (O' Mahony et al., 2017). 
1.6.3 Role of Gut Microbiota in Pain 
1.6.3.1 Preclinical Studies on Microbiota and Pain 
 The presence of the gut microbiota is very important for the regulation of normal 
excitability of the myenteric complex in the enteric nervous system, as shown in a comparative 
study of germ-free and control mice (McVey Neufeld et al., 2013). Some preclinical studies 
have shown the links between disruption of normal gut microbiota (dysbiosis) with changes 
in the visceral pain perception. For example, Aguilera et al. demonstrated that an antibiotic-
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induced a colonic dysbiosis (increments in Bacteroides spp, Clostridium coccoides and 
Lactobacillus spp and reduction in Bifidobacterium spp) in mice was associated with increased 
levels of secretory-IgA, and TLR 4 and 7. This resulted in attenuation in visceral pain-related 
responses to intraperitoneal AA or intracolonic capsaicin (Aguilera et al., 2015). Similarly, 
early-life stress-induced dysbiosis resulted in increased visceral pain responses in the stressed 
group of adult rats (O'Mahony et al., 2009; O'Mahony et al., 2014; Luczynski et al., 2017). 
 The administration of probiotics in animals has shown to attenuate the visceral pain 
responses. For example, administration of probiotic Lactobacillus rhamnosus reduced the 
visceromotor response to colorectal distension in adult rats who had neonatal inflammation-
induced visceral hypersensitivity (Kannampalli et al., 2014). Similarly, the administration of 
probiotic Bifidobacterium infantis reduced CRD-induced pain behaviours in both adult 
Sprague-Dawley and Wistar-Kyoto rat strains (McKernan et al., 2010). In another set of 
experiments, the increased visceral hypersensitivity, secondary to antibiotic-induced 
dysbiosis, normalised following the administration of Lactobacillus paracasei to these animals 
(Verdú et al., 2006). Miquel et al. were able to demonstrate the antinociceptive effects of 
Faecalibacterium prausnitzii in IBS like models in rodents (Miquel et al., 2016). These studies 
have shown the association between the visceral hypersensitivity and the gut microbiota 
composition. However, more extensive research is required in this field to explore the 
causative mechanisms responsible for this relationship. 
1.6.3.2 Clinical Studies on Microbiota and Pain 
 IBS is a classic example of a functional gastrointestinal disorder associated with visceral 
pain in humans. Patients typically develop recurring abdominal pains related to the bowel 
movements and altered bowel habits without the presence of an identified underlying organic 
disease (Schmulson and Drossman, 2017). Although the aetiology of IBS is multifactorial, the 
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changes in the gut microbiota have been increasingly observed in both adult and paediatric 
patients. 
 In a study evaluating the relative abundance of microbiota in infants with or without 
colic, Proteobacteria were significantly increased in infants with colic when compared to 
control infants (de Weerth et al., 2013b). In contrast, Bifidobacteria and Lactobacilli were 
significantly reduced in infants with colic shown in the same study. In another study on 
preterm babies, the administration of probiotic Lactobacillus rhamnosus alleviated the colic 
symptoms (Partty et al., 2013). Furthermore, the use of Lactobacillus rhamnosus moderately 
increases treatment success in children with abdominal pain-related functional 
gastrointestinal disorders, particularly IBS (Horvath et al., 2011). 
 Adult IBS patients, with predominate diarrhoea, have been shown to have significant 
populations of Enterobacteriaceae, and lower levels of Fecalibacterium genera compared to 
healthy individuals (Carroll et al., 2012). IBS patients demonstrate an abnormal IL-10/IL-12 
ratio, indicative of a pro-inflammatory state. This ratio may be normalised with probiotic B. 
infantis resulting in a reduction in the abdominal pain and discomfort (O'Mahony et al., 2005). 
Probiotic Lacbacillus acidophilus induces colonic mu-opioid receptor expression and 
downstream signalling suggesting a possible mechanism by which probiotics may modulate 
pain sensation in humans (Ringel-Kulka et al., 2014). The gut microbiota or probiotics may act 
directly through bacterial metabolites on the pain receptors in the gut wall, or indirectly by 
influencing intestinal epithelial barrier, the mucosal and systemic immune mechanisms 
(Theodorou et al., 2014). The observed increased thickness of the somatosensory cortex in 
female IBS patients may suggest an underlying interplay of the microbiota-gut-brain axis and 
the sex hormones (Jiang et al., 2013). 
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 The studies mentioned above suggest a plausible link between the gut microbial 
composition and symptomatology of visceral pain. However, a lot of research is needed to 
study further the bidirectional interplay between the gut and the brain in relation to pain. The 
influence of other factors affecting visceral pain, such as stress, dietary factors, sex hormones 
needs to be studied extensively in the future preclinical and clinical research. Table 1.6 
(modified from (O' Mahony et al., 2017)) enlists the preclinical and clinical studies signifying 
the role of gut microbiota in pain modulation. The possible mechanisms by which gut 
microbiota may influence the nociceptive neurotransmission directly include regulation of 
neurotransmitter synthesis in CNS (Desbonnet et al., 2010; Lyte, 2013, 2014; Dinan and Cryan, 
2017c), alterations in various receptors such as adrenergic receptor, cholecystokinin B 
receptor, opioid and cannabinoid receptors (Rousseaux et al., 2007; O'Mahony et al., 2014), 
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Table 1.6. List of preclinical and clinical studies elucidating role of gut microbiota on pain disorders (O' Mahony 
et al., 2017) 
Preclinical and clinical studies of pain disorders and gut microbiota 





Oxaliplatin-induced mechanical hyperalgesia was reduced in 
germ-free mice and in mice pretreated with antibiotics. 
Restoring the microbiota of germ-free mice abrogated this 
protection 
(Shen et al., 2017) 
 Antibiotic cocktail in 
adulthood 
A reduction in visceral pain to acetic acid and intracolonic 
capsaicin 
(Aguilera et al., 
2015) 
Antibiotic cocktail in 
adulthood 
Increased visceral pain to colorectal distension in mice; 
reversed by L. paracasei 
(Verdú et al., 2006) 
Antibiotic 
vancomycin and 
cocktail in early-life 
Increased visceral pain seen during colorectal distension in rats (O'Mahony et al., 
2014) 
Maternal separation Early-life stress leads to a reduced diversity of faecal 
microbiota in rats 
Administration of Faecalibacterium prausnitzii reduces pain 
following maternal separation 
(O'Mahony et al., 
2009; Miquel et al., 
2016) 
Wistar-Kyoto Administration of Bifidobacterium infantis reduced pain to 
colorectal distension in rats 




induced visceral pain 
Administration of the probiotic Lactobacillus GG reduced the 
pain response to the inflammatory stimulus 
(Kannampalli et al., 
2014) 
   
Gastric distension–
induced visceral pain 
Administration of Lactobacillus reuteri reduced jejunal spinal 




Irritable bowel syndrome 
Microbiota changes 
from control 
GI infection leads to persistent IBS symptoms (Thabane et al., 
2007) 
Patients with IBS show a reduced bacterial diversity as well as 
changes to the Firmicutes to 
Bacteroidetes ratio 
(Jeffery et al., 
2012) 
Increased numbers of Dorea, Ruminococcus, and Clostridium 
spp; decreased numbers of 
Bifidobacterium and Faecalibacterium spp; a correlation is 
seen between the changes in the 
above microbial groups and IBS symptom scores 
(Rajilic-Stojanovic 
et al., 2011; 
Jalanka-Tuovinen 
et al., 2014) 
IBS was associated with an enrichment in bacteria related to 
Ruminococcus which correlates 
with symptoms 
(Malinen et al., 
2010; Rajilic-
Stojanovic et al., 
2011; Carroll et al., 
2012) 
Diarrhoea-predominant IBS patients have significantly higher 
levels of Enterobacteriaceae and 
lower levels of Fecalibacterium genera. This is associated with 
higher beta-diversity 
(Ringel-Kulka et al., 
2016) 
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IBS patients show significantly higher numbers of Veillonella 
and Lactobacillus 
(Pimentel et al., 




Antibiotic rifaximin reduces pain 
Probiotics can reduce abdominal pain in IBS. More specifically, 
Bifidobacterium infantis-treated patients experienced a 
reduction in for abdominal pain 
(O'Mahony et al., 
2005; Hungin et 
al., 2013; Gulden 
et al., 2015; Curro 
et al., 2017) 
Paediatric irritable bowel syndrome 
Microbiota changes 
from control 
Ruminococcus-like microbe was associated with IBS symptoms 
in this paediatric 
population. Visceral pain also correlated with an increased 
bacterial taxa from the genus Alistipes 




Prebiotics and synbiotics effective in paediatric IBS 
A mixture of Bifidobacterium infantis M-63, breve M-16V and 
longum BB536 improved 
abdominal pain in children 
(Saulnier et al., 
2011) 




L. acidophilus was seen to reduce functional abdominal pain in 
adults 
(Ringel-Kulka et al., 
2014) 
Colonic diverticulosis Depletion of Clostridium cluster IV. Clostridium cluster IX, 
Fusobacterium, and Lactobacillaceae 
were reduced in symptomatic vs asymptomatic patients with 
colonic diverticulosis 
(Barnes and Yeh, 
2015) 
Infantile colic  
Increased pathogenic bacteria and reduced Lactobacilli, 




(Savino et al., 




Prebiotic (PDX/GOS) and probiotics (L. actobacillus reuteri and 
L. rhamnosus) reduced colics 
(Savino et al., 
2011; Partty et al., 
2013) 
 
Interstitial cystitis Reduced gut levels of E. sinensis, C. aerofaciens, F. prausnitzii, 
O. splanchnicus, and L. longoviformis are seen in patients with 
interstitial cystitis 
(Braundmeier-




A positive correlation seen between knee osteoarthritic pain 
scores and abundance of streptococcus species 
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1.7 Experimental Models of Pain 
1.7.1 Animal Models of Pain 
 Literature is populated with several validated experimental pain models utilising 
animals. These pain models are designed considering pain stimulus type and resulting pain 
behaviours. Similarly, some models are developed that mimic pain resulting from some 
pathological conditions. Table 1.7 lists various animal models of pain utilised in the preclinical 
studies (Gregory et al., 2013). 
Table 1.7. Animal models of pain 



















Tail flick test (Dewey et al., 1970) 
Hot-plate test (Woolfe and Macdonald, 
1944) 




Paw withdrawal with 
Von-frey filament 
 
(Dixon, 1980; Sluka, 
1997; Tverskoy et al., 
1998) 
Pressure application (Randall and Selitto, 
1957; Sufka, 1994; 
Schafers et al., 2003; 
Luis-Delgado et al., 2006; 








Paw elevation/licking (injection of 
formaldehyde, capsaicin, mustard 
oil) 
(Dubuisson and Dennis, 






Thermal escape test (Mauderli et al., 2000) 
Conditioned place avoidance (Johansen et al., 2001) 
Place Escape avoidance paradigm (LaBuda and Fuchs, 
2000; Moqrich et al., 
2005) 




Capsaicin injection (Tominaga et al., 1998; 
Sluka, 2002) 
Carrageenan injection (Radhakrishnan et al., 
2003; Radhakrishnan et 
al., 2004; Pratt et al., 
2013) 
Complete Freund’s adjuvant (Ren et al., 1992; 






Cortical/thalamic injection of the 
excitotoxic agent 
(Oliveras and Montagne-
Clavel, 1994, 1996; 
LaBuda et al., 2000) 
Spinal cord injury (Vierck et al., 1971; Levitt 
and Heybach, 1981; 
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Neuropathic 
pain 
Yezierski and Park, 1993; 
Yezierski et al., 1998) 
Peripheral nerve injury 
Ligating/transacting/injecting a 
peripheral nerve 
(Kim and Chung, 1992; 
Ringkamp et al., 1999; 





Xenograft injection of cancer cell 
Orofacial region 
Metastasis induced bone pain 
(Wacnik et al., 2005; 
Nagamine et al., 2006; 
Cata et al., 2008; Hidaka 




Rheumatoid arthritis-injection of 
collage type-II antibodies 
Osteoarthritis-ligamentous injury 
(Christianson et al., 
2010; Longo et al., 2012; 
Vincent et al., 2012; 
Sluka et al., 2013) 
Muscle Pain 
models 
Myositis- injecting irritants (Hoheisel and Mense, 
1989; Hoheisel et al., 
1993; Radhakrishnan et 




Hindpaw/calf surgical incision (Brennan et al., 1996; 




injection of acetic acid 
(Reichert et al., 2001; Lin 
et al., 2009b; Li et al., 
2010) 
Colorectal distension (Ness and Gebhart, 1987; 
Lin et al., 2009b; 
Larauche et al., 2012; 
O'Mahony et al., 2012) 
Cystitis-bladder injury with 
irritants 
(Lanteri-Minet et al., 
1995; Bon et al., 1998; 
Malykhina et al., 2013; 
Stemler et al., 2013) 
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1.7.2 Human Models of Experimental Pain 
 Human pain models help to evaluate the mechanism of action and effect of analgesics 
and bridge the gap between basic studies and clinical therapeutics. Table 1.8 enlists various 
types of human models of experimental pain (extracted from a review by Olesen et al. (Olesen 
et al., 2012)). 
Table 1.8. Experimental human models of pain 
Area 
Assessed 




Touch (Curatolo et al., 2000; Bars et al., 2001) 
Pinprick (Curatolo et al., 2000; Bars et al., 2001) 
Pressure (Curatolo et al., 2000; Kinser et al., 2009) 
Electrical Neurophysiological electrical 
stimulation 




Cold (Fowler et al., 1988) 
Contact heat (Roberts et al., 2008) 







Capsaicin (Scanlon et al., 2006) 
Nerve growth factor (Rukwied et al., 2010) 
Glutamate (Gazerani et al., 2006) 
Burns injury with ultraviolet 
radiation 
(Bishop et al., 2009) 
Freeze Lesion (Kilo et al., 1994) 
Mustard Oil (Koltzenburg et al., 1992) 
Menthol (Binder et al., 2011) 
Acid Phosphate Buffer (Steen et al., 1995) 
Sodium Lauryl Sulfate (Petersen et al., 2010) 






Muscle Pressure Algometry (Polianskis et al., 2001; Graven-Nielsen 
and Arendt-Nielsen, 2003) 
Mechanical pressure on bone 
(tibia, mastoid process etc.) 
(Andresen et al., 2011; Finocchietti et al., 
2012) 
Electrical Needle electrodes (Schulte et al., 2003) 




Ischaemic stimulation with a 
tourniquet 
(Graven-Nielsen and Arendt-Nielsen, 
2003) 
Exercise induced muscle pain (Graven-Nielsen, 2006) 
Chemically induced 
hyperalgesia 
(Graven-Nielsen and Arendt-Nielsen, 
2003; Mork et al., 2003) 
Viscera Mechanical Bowel distension with a barostat (van der Schaar et al., 1999; Staahl et al., 
2006; Arendt-Nielsen et al., 2009; Olesen 
et al., 2010a) 
Electrical Depolarisation of afferents by 
electrical current 
(Drewes et al., 2003; Brock et al., 2009) 
Temperature  Luminal heat stimulation (Staahl et al., 2006; Arendt-Nielsen et al., 
2009; Olesen et al., 2010a) 
Evoking 
Hyperalgesia 
Chemicals such as acid, 
capsaicin, and glycerol 
(Drewes et al., 2003; Brock et al., 2009; 
Olesen et al., 2009; Olesen et al., 2010b) 
Examples of mechanical, electrical, and thermal pain and evoked hyperalgesia applied to somatic and visceral 
areas are listed (Olesen et al., 2012).  
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1.8 Aims of the Thesis 
 We designed our experiments to evaluate the sex differences in glutamatergic 
signalling. We explored specific factors affecting glutamatergic system and pain, such as 
cyclical sex hormone variation in females, early-life stress, gut microbiota and exogenous 
oestrogen. 
Aim 1: Is the Spinal Glutamatergic System Modulated by Sex Hormones? 
 Most pain-related studies investigating sex differences in animals have not 
investigated the effects of physiological variations of sex hormones. We aimed to look at the 
function of synaptic glutamate regulators under different hormonal, physiological states in 
animals (Chapter 2). We investigated mechanisms responsible for the effects of hormones on 
glutamate metabolism. We carried out ex-vivo studies on rat spinal cord to achieve our goals. 
Our hypothesis was that oestrogen will have an inhibitory action on glutamate transporters. 
Aim 2: Is the Hormonal Modulation of the Glutamatergic System Affected by Stress? 
 Early-life stress is a known risk factor for visceral hypersensitivity in adult life. We 
assessed the glutamatergic turnover in animal models of early-life stress and visceral 
hypersensitivity with an aim to establish the interplay between stress, hormones and the 
neurotransmission in pain states (Chapter 3 & 4). We performed colorectal distension in rats 
exposed to early-life stress and animal models of visceral hypersensitivity and studied 
glutamatergic system in both the spinal cord and the brain. We hypothesised that animal 
stress models will show a comparatively high visceral pain sensitivity, and it will be associated 
with glutamate transporter function inhibition. 
Aim 3: Is There a Role of Gut Microbiota on Glutamatergic Signalling and Pain Sensitivity? 
 The role of the microbiota-gut-brain axis in CNS disorders has an emerging recognition. 
We aimed to establish if gut microbiota had any role in glutamatergic signalling and pain 
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sensitivity. We correlated synaptic glutamate transporter function with the relative 
abundance of gut microbiota in WKY rats (Chapter 4). We assessed pain sensitivity in humans 
and correlated it with their gut microbiota (Chapter 5). Our hypothesis was that the 
abundance of short-chain fatty acid producing gut bacteria will be more in the subjects 
demonstrating higher pain thresholds.   
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2.1 Abstract 
Background: Females are more likely to experience visceral pain than males, yet mechanisms 
underlying this sex bias are not fully elucidated. Moreover, pain sensitivity can change 
throughout the menstrual cycle. Alterations in the glutamatergic system have been implicated 
in several pain disorders; however, whether these are sex-dependent is unclear. Thus, we 
aimed to investigate sex differences in the spinal cord glutamate uptake and how it varies 
across the oestrous cycle. Methods: The activity of the glutamate transporters, excitatory 
amino acid transporters (EAATs) was assessed using an ex-vivo aspartate radioactive uptake 
assay in the lumbosacral spinal cord in Sprague-Dawley male and female rats. The gene 
expression of EAATs, glutamate receptor subunits NR1 and NR2B and the oestrogen receptors 
ERα & ERβ in the spinal cord were also analysed. Results: EAAT activity was lower in females, 
particularly during the oestrus phase, and this was the only cycle stage that was responsive to 
the pharmacological effects of the EAATs activator riluzole. Interestingly, EAAT1 mRNA 
expression was lower in high-oestrogen and high-ERα states compared to diestrus in females. 
Conclusion: We conclude that the spinal EAAT activity in females is different to that in males, 
and varies across the oestrous cycle. Furthermore, the expression levels of oestrogen 
receptors also showed a cycle-dependent pattern that may affect EAATs function and 
expression.  
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2.2 Introduction 
 In general, women are more sensitive to pain than men, and some painful disorders 
such as IBS (Chang and Heitkemper, 2002; Mogil and Bailey, 2010), chronic pelvic pain (Scialli, 
1999), temporomandibular disorder (Cairns, 2010), fibromyalgia (Yunus, 2002), biliary colic 
(Palsson and Sandblom, 2015), esophagitis (Krarup et al., 2013), and rheumatoid arthritis 
(Brennan and Silman, 1995) are more prevalent in women. Similar associations have been 
reported in rodents, where female rats showed exaggerated visceromotor responses to 
colorectal distension (Holdcroft et al., 2000; Ji et al., 2006; Ji et al., 2012; Winston et al., 2014; 
Guo et al., 2015) as well as other types of pain (Mogil and Bailey, 2010). On the other hand, 
there are some reports of increased visceral and somatic hypersensitivity in male rats exposed 
to early-life stress as compared to female rats (Prusator and Greenwood-Van Meerveld, 2015). 
Significant gender differences in incidence, symptomatology, and therapeutic outcome in 
various pain disorders indicate the necessity for gender-tailored treatment approaches. 
However, to achieve this, it is necessary to have a comprehensive understanding of the 
molecular mechanisms responsible for these pain-related gender differences. 
 IBS is the most common functional gastrointestinal disorder with symptoms of altered 
bowel habit and visceral hypersensitivity (Kennedy et al., 2014; Hyland et al., 2015). The 
majority of women with IBS who seek health care are of reproductive age. Population surveys 
have reported that the prevalence of IBS declines after the age of 40 years (Hungin, 2003); 
suggesting a role of female sex hormones in the aetiology of IBS. Studies on gender differences 
in visceral pain are increasingly being carried out, yet few of these have evaluated the impact 
of menstrual cycle on pain perception (Stening, 2007; Heitkemper and Chang, 2009a). 
Moreover, there is a paucity of information on the potential mechanisms underlying sex 
differences in visceral pain. Of these, plasma levels of cytokines have been shown to vary 
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depending on the cycle stage (O'Brien et al., 2007). Furthermore, there is growing evidence of 
the involvement of gonadal hormones (e.g. oestrogen) in visceral and somatic pain sensitivity; 
however, conflicting results have been reported. Some studies have shown ovarian hormones 
(e.g. oestrogen) to be antinociceptive (Bradshaw, 1999; Sanoja, 2005; Heitkemper and Chang, 
2009a), whereas others indicate that these hormones may be pronociceptive (Ji et al., 2003; 
Lu et al., 2009; Chaloner and Greenwood-Van Meerveld, 2013). Noteworthy, visceromotor 
response to colorectal distension was shown to be higher in proestrus (high-oestrogen state) 
than in metestrus/diestrus (low-oestrogen states) (Ji et al., 2008; Peng et al., 2008). A need, 
therefore, arises to assess the underlying mechanisms that are implicated in visceral pain with 
regard to the changing levels of gonadal hormones across the female cycle. 
 During pain signal transmission, glutamate is released into the synaptic cleft, which, in 
turn, causes activation of NMDA receptors and hence neurotransmission across the synapse 
occurs. The synaptic concentration and resultant activity of glutamate are controlled by EAATs 
which transport glutamate from the synaptic cleft into the glial cells. In the spinal cord, EAAT1 
and EAAT2 are the most efficient mediators of glutamate clearance at synaptic cleft (Danbolt, 
2001; Holmseth et al., 2012), and their gene expression has an important role in visceral 
sensitivity (Lin et al., 2009b; Gosselin et al., 2010). It has been shown that intrathecal 
administration of a glutamate transporter antagonist results in increased sensitivity to 
colorectal distension in rats (Gosselin et al., 2010). It has also been demonstrated that 
transgenic mice overexpressing EAAT2 demonstrated a twofold increase in the glutamate 
uptake across these transporters and a significant reduction in the visceromotor response to 
colorectal distension (Lin et al., 2009b). Furthermore, maternally separated rats have shown 
an increase in visceral sensitivity associated with a selective reduction in spinal EAAT1 
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expression (Gosselin et al., 2010). However, most of the preclinical studies assessing the role 
of EAATs in pain have been carried out in male animals. 
 Oestrogen levels fluctuate during the phases of the menstrual cycle (humans) and 
oestrous cycle (rodents) (Marcondes et al., 2001; Stricker et al., 2006) and were shown to alter 
the activity of glutamate receptors (Tang et al., 2008). Moreover, NMDARs showed higher 
activity in DRGs in female rats as compared to males, and this effect was further potentiated 
in females by exogenous oestrogen (McRoberts et al., 2007). Co-localisation of oestrogen 
receptor alpha (ER-α) and NR1 (a subunit of NMDAR) in the dorsal horn of the lumbosacral 
spinal cord suggests a direct modulation of glutamate receptor activity by oestrogen through 
ER-α (Tang et al., 2008). Furthermore, it has been shown that the threshold for visceral pain 
is lower in high-oestrogen proestrus phase (Ji et al., 2008). 
 Thus, we aimed to investigate if the activity of spinal glutamate transporters/or 
efficiency of glutamate reuptake differs between sexes, across the oestrous cycle and in 
response to the EAATs activator riluzole. We further sought to determine if subunits of the 
NMDA and oestrogen receptors are differentially expressed in males and females, as well as 
throughout different phases of the oestrous cycle. 
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2.3 Materials and Methods 
 
2.3.1 Animals 
 Adult male and female Sprague-Dawley rats weighing 250–300 g (Harlan, UK) were 
housed in a local animal facility with food (2018 Teklad Global 18% Protein Rodent, Envigo) 
and water ad libitum, on a 12:12-hour dark–light cycle (lights on at 7:00 AM) with the 
temperature at 20°C ± 1°C. Animals were group housed by 4 to 5 per cage in plastic cages with 
sawdust bedding, shredded paper, and a cardboard roll. They were allowed to habituate in 
the new environment for a week before the commencement of experiments. Female rats 
underwent vaginal smearing on the day of each experiment to assess their oestrous cycle 
phase (Byers et al., 2012). One cohort of 10 males and 30 female rats was used for the 
aspartate uptake studies. Another cohort of 10 males and 29 females was used for gene 
expression analysis of glutamate receptors subunit and oestrogen receptors in the spinal cord. 
All experiments were in full accordance with the European Community Council Directive 
(2010/63/EU) and approved by Animal Experimentation Ethics Committee of University 
College Cork. 
2.3.2 Vaginal Smearing 
 
Females were vaginally lavaged with saline, and cells were immediately viewed under 
the microscope at round 08:00 am on the day of the experiment. The stage of oestrous cycle 
was determined as previously described (Ji et al., 2008). Briefly, the metestrus was 
characterised by the appearance of small leukocytes mixed with round nucleated epithelial 
cells, whereas, diestrus smear had fewer leukocytes along with cornified epithelial cells. The 
smears from proestrus rats had a predominance of round nucleated cells of uniform size, with 
a complete absence of leukocytes. Finally, in oestrus, nonnucleated cornified epithelial cells 
were predominant. Since metestrus only lasts for a short period (5–6 h) and the plasma 
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oestrogen concentration in metestrus does not differ largely from that in diestrus, data from 
these two groups of rats were pooled. Animals were lavaged immediately before euthanasia, 
to determine oestrous stage accurately for all tissue collected. 
2.3.3 Aspartate Uptake 
 Aspartate uptake on brain slices has been previously described (Thomazi et al., 2004); 
here we optimised this technique to be used on spinal cord slices. 
2.3.4 Reagents 
 Aspartic Acid, D- [2,3-3H] (specific gravity 12.9 Ci/mmol) was purchased from Perkin-
Elmer, USA. RIPA buffer and Peirce BCA protein assay kit were purchased from Fisher Scientific 
Ireland. (3S)-3-[[3-[[4-(Trifluoromethyl) benzoyl] amino] phenyl] methoxy]-L-aspartic acid 
(TFB-TBOA), 2-amino-6-trifluoromethoxybenzothiazole (Riluzole) and 17-β-estradiol-3-
benzoate were purchased from Tocris UK. All other reagents were purchased from Sigma-
Aldrich. HBSS was prepared in-house containing (in mM): 137 NaCl; 0.63 Na2HPO4; 4.17 
NaHCO3; 5.36 KCl; 0.44 KH2PO4; 1.26 CaCl2; 0.41 MgSO4; 0.49 MgCl2 and 1.11 glucose, pH 7.2. 
In sodium-free HBSS, NaCl was replaced by 137 mM N-methyl-D-glucamine. 
2.3.5 Spinal Cord Slice Preparation 
 Animals were euthanised by decapitation immediately after vaginal smearing. The 
spinal cord was removed by hydraulic pressure into HBSS filled Petri dishes, and 0.4 mm thick 
slices were obtained from the lumbosacral region using a McIIwain tissue chopper. These 
slices were separated by fine dissection under a microscope and transferred into either (1ml) 
sodium-containing HBSS (labelled as Na+) or (1ml) sodium-free HBSS (labelled as Na-) on 24 
well cell culture plates. Na+ plates were maintained at 35 °C and Na- on the ice. The slices from 
Na+ plates were washed once with 1 mL of 35 °C sodium-containing HBSS and Na- plate with 
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1 mL of 4 °C sodium-free HBSS to assess sodium-dependent and independent uptake 
respectively. 
2.3.6 Total Uptake 
Spinal cord slices were pre-incubated at 35 °C and on ice in Na+ and Na- HBSS 
respectively for 30 min. Then a solution containing 1µL 0.66 μCi/mL aspartic acid D- [2,3-3H], 
15 µL of cold 100 μM D-Aspartate and 84 µL H2O was added. After 3 minutes of incubation, 
slices were washed twice with 1 mL of the corresponding ice-cold HBSS. Samples were then 
transferred into 1.5 mL tubes containing volume RIPA buffer and then were mechanically 
homogenised with pestles. To improve the efficiency of lysis, tissue homogenate was 
incubated for further 15 minutes at 4 °C. Tissue lysate was cleared by centrifugation at 14000g 
for 10 min at 4 °C and used for the radioactivity analysis. Radioactivity was measured using a 
Perkin-Elmer scintillation counter. Data obtained from Na- samples were subtracted from 
those of the Na+ samples to specifically estimate sodium-dependent uptake mediated by EAAT 
1 & 2 transporters. Uptake procedure was performed in triplicate. Protein was measured using 
Peirce BCA protein assay kit. Aspartate uptake in each slice was presented as scintillation per 
minute (CPM) per mg of protein. 
2.3.7 Effect of Compounds on Aspartate Uptake 
 To assess the influence of various drugs on spinal cord aspartate uptake, slices of the 
spinal cord were pre-incubated with these drugs for 30 minutes before addition of tritium 
labelled aspartate. Drug concentrations used were as follows: TFB-TBOA 200 ηM in 0.00008% 
DMSO (Jiang et al., 2012), Riluzole 10 μM in 0.0025% DMSO (Gosselin et al., 2010) and 17-β-
estradiol-3-benzoate 100 ηM in 0.000025% DMSO (a dose-response experiment was 
performed, data not shown). DMSO was used as a vehicle control. 
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2.3.8 Quantitative Real-time PCR (RT-qPCR) 
 Lumbosacral spinal cord samples were collected from a separate cohort of female and 
male animals (n=39). Samples were snap frozen and stored at −80°C until the analysis. Total 
RNA was isolated using a mirVana miRNA isolation kit (Life Technologies). RNA concentration 
was quantified using the NanoDrop spectrophotometer. 10 ng/mL of RNA was reverse 
transcribed to cDNA using the Applied Biosystems High Capacity cDNA kit (Applied Biosystems, 
Warrington, UK). RT-qPCR was carried out using TaqMan probes designed by Applied 
Biosystems on the ABI7300 Real-Time PCR machine (Applied Biosystems, Warrington, UK) 
according to the manufacturer’s protocol. The following primers were used: Rn00665089_m1 
for EAAT1, Rn00691548_m1 for EAAT2, Rn01436038_m1 for NR1, Rn00680474_m1 for NR2B, 
Rn01640372_m1 for ESR1, Rn00562610_m1 for ESR2, Rn01485494_m1 for β-Actin as an 
endogenous control. 
 RT-qPCR was carried out experimental samples were run in triplicate with 1µL cDNA 
per reaction. Cycle threshold (Ct) values were calculated; averaged Ct values of each triplicate 
were used in further analysis. The Ct value for the target gene in each sample was normalised 
to its endogenous control Ct value and transformed to relative gene expression value using 
2−ΔΔCt equation (Livak and Schmittgen, 2001). The gene expression levels in female groups 
were presented as a fold change vs the male group. 
2.3.9 Statistical Analysis 
 All data was normally distributed according to Gaussian distribution analysis. An 
unpaired two-tailed student’s t-test, a one-way ANOVA or two-way ANOVA with Tukey’s post-
hoc analysis was utilised. Values of P < 0.05 were considered statistically significant. 
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2.4 Results 
2.4.1 Oestrogen and TFB-TBOA Reduce Spinal Cord Aspartate Uptake in Male Rats 
 To validate the aspartate uptake technique and ensure we are able to detect 
alterations to the EAATs activity in the spinal cord, spinal cord slices were pre-incubated with 
TFB-TBOA which is a high-affinity selective blocker of the glial glutamate transporters EAAT1 
and EAAT2. There are various analogues available, but we chose TFB-TBOA because of its high 
potency, high selectivity for EAATs and is not neurotoxic (Bozzo and Chatton, 2010). 
Administration of TFB-TBOA significantly reduced the aspartate uptake, thus validating the 
technique (p < 0.01, Figure 2.1A). 
 We next sought to determine the effect of female gonadal hormone oestrogen on the 
aspartate uptake in spinal cord tissue in males. We wanted to explore if exogenous oestrogen 
was directly able to modify the function of EAATs. When spinal cord slices from male rats were 
pre-incubated with female sex hormone oestrogen (17-β-estradiol-3-benzoate), aspartate 
uptake was significantly reduced (p < 0.01, F(2, 27) = 7.14, Figure 2.1B). The vehicle, DMSO, did 
not affect the aspartate uptake. 
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Figure 2.1. Effect of TBOA and oestrogen on EAAT function in male rat spinal cord. (A) EAAT blocker TFB-TBOA 
decreased aspartate reuptake in spinal cord slices obtained from male rats, thus proving the validity of the 
technique applied, n=4, ** p < 0.01. (B) 17-β-estradiol-3-benzoate decreased the uptake of aspartate in male 
rats. Vehicle solution of 0.000025% DMSO did not have an effect on aspartate uptake. Data are presented as 
mean ± standard error of the mean (SEM), n=10, **p < 0.01 vs. control and vehicle. 
 
2.4.2 Reduced Aspartate Uptake in Females Relates to Oestrous Cycle Stage 
 Based on the findings that oestrogen had a significant effect on aspartate uptake in 
male rats, we investigated EAATs function across the female oestrous cycle which is 
characterised by different oestrogen systemic levels. Here we show that oestrous cycle had a 
significant effect on the spinal aspartate uptake (p < 0.0001, F (3,24)=10.91, Figure 2.2). Post-
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hoc analysis showed that males and diestrus females did not have any differences in aspartate 
uptake. However, EAATs activity was significantly lower in high-oestrogen states, i.e., 
proestrus and oestrus females as compared to both diestrus female rats and males (p < 0.05 
and p < 0.0001 respectively). 
 
Figure 2.2. Aspartate uptake in the spinal cord of males and females across oestrous cycle. In oestrus and 
proestrus states, the aspartate uptake is significantly low compared to diestrus females and male rats. Values 
represent mean ± SEM, n=6-8. *p < 0.05 vs proestrus, ***p < 0.001 vs. oestrus. 
 
2.4.3 Pharmacological Enhancement of EAATs Reverses the Inhibitory Effect of 
Endogenous Oestrogen on Aspartate Uptake 
 Here we assessed the effect of riluzole on spinal EAATs function across different stages 
of oestrous cycle in female rats. A two-way ANOVA revealed a significant interaction between 
oestrous phase and riluzole treatment (p < 0.0001, F (2,34)=17.63, Figure 2.3). Post-hoc analysis 
showed that it significantly enhanced the EAATs function in oestrus phase only, thus possibly 
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reversing the inhibitory effect of endogenous oestrogen (p < 0.0001). Notably, riluzole had no 
effect on aspartate uptake in diestrus and proestrus phases of the oestrous cycle. 
 
Figure 2.3. Effect of riluzole on aspartate uptake in the spinal cord across the oestrous cycle. Riluzole 
significantly enhanced the aspartate uptake in oestrus phase, but no effect was seen in other stages of oestrous 
cycle. Values represent mean ± SEM, n=7, ***p < 0.0001 vs. oestrus group. 
 
2.4.4 Diestrus Female Rats Have Increased mRNA Expression of EAAT1 in 
Lumbosacral Spinal Cord 
 The EAAT1 mRNA expression levels showed significant variation across the oestrous 
cycle (one-way ANOVA, p < 0.05, F (3,29) =4.3). Post-hoc analysis revealed increased expression 
of EAAT1 in diestrus as compared to proestrus females (p < 0.05, Figure. 2.4A). There was no 
significant difference in the expression of EAAT2 across the groups (Figure. 2.4B) 
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2.4.5 NMDA-Receptor Subunit-1 Gene Expression Is Reduced in Proestrus 
 We compared the expression of glutamate receptor (NMDAR) subunits 1 and 2b genes 
in the spinal cord of males and females in the different phases of the oestrous cycle. 
Expression of subunit-1 was significantly lower in proestrus compared to diestrus and oestrus 
females (post-hoc analysis, p < 0.05, and p < 0.001 respectively) t (one-way ANOVA showed p 
< 0.01, F (3, 35) = 5.4, Figure 2.4C). Expression of the NMDAR 2b subunit was not different across 
all groups (Figure 2.4D). 
2.4.6 Expression of ERα and ERβ change throughout the oestrous cycle 
 As aspartate uptake appeared to be lower in high-oestrogen states, we evaluated 
differential expression of oestrogen receptor genes, ERα, and ERβ, across the same phases. A 
one-way ANOVA showed a significant effect of oestrous cycle on ERα (p < 0.0001, F (3,35) = 
13.67, Figure 2.4E). Post-hoc comparisons showed significantly higher expression of ERα in 
oestrus females as compared to males, diestrus and proestrus females (p < 0.0001). 
 Expression of ERβ also varied significantly across oestrous cycle (one-way ANOVA, p < 
0.01, F (3,35) = 5, Figure 2.4F). However, its expression was higher in diestrus as compared to 
proestrus (post-hoc analysis, p < 0.001). 
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Figure 2.4. mRNA expression of EAAT1 & 2, NR1, NR2B, and oestrogen receptors in males and females. (A) 
EAAT1 gene mRNA expression in the spinal cord is higher in the diestrus phase. * p < 0.05 vs. diestrus (B) mRNA 
expression of EAAT2 gene does not change across the oestrous cycle (C) mRNA expression of the NMDA-receptor 
subunit-1 gene was changed across the oestrous cycle. *p < 0.05, **p < 0.01 vs proestrus. (D) mRNA expression 
of NMDA-receptor subunit-2B gene in the spinal cord of male and female rats was not different between sexes 
or changed during the oestrous cycle. (E) mRNA expression of ERα gene in the spinal cord was different between 
the sexes and between stages of the oestrous cycle. ****p < 0.00001, ***p < 0.0001 vs oestrus. (F) mRNA 
expression of ERβ gene was different in stages of the oestrous cycle. **p < 0.01 (diestrus vs. proestrus). Values 
represent mean ±SEM, n=9-10. 
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2.5 Discussion 
 In this study, we have demonstrated that EAAT activity in the lumbosacral spinal cord 
differs between male and female rats. The activity of these transporters is decreased in spinal 
cord slices from male rats when exogenous oestrogen is applied. Moreover, uptake via EAATs 
varies across the oestrous cycle in female rats gradually decreasing from the diestrus to the 
oestrus phase. This indicates that the gonadal hormone oestrogen is capable of influencing 
the activity of these transporters and can be artificially manipulated. This provides insights 
into sex differences in visceral pain as the lumbosacral level of the spinal cord receives sensory 
signals from the gastrointestinal tract. Alterations in the expression of these transporters in 
this part of the spinal cord have been previously associated with visceral pain in an animal 
model of IBS (Gosselin et al., 2010), a disorder that is more prevalent in females. Hence, we 
proposed to assess in healthy rats if a difference in the activity of these transporters existed 
between the sexes that may help explain differences in pain that are contributed to by gonadal 
hormones. 
Interestingly, we observed an increase in the RNA expression levels of the EAAT1 
transporter in the diestrus phase compared to males and the other phases. This may indicate 
that a compensatory higher expression of the transporter is possible in low-oestrogen states 
that allow maintenance of same EAAT activity as male rats, while in proestrus this expression 
is decreased and may be associated with the exaggerated decrease in activity compared to 
male rats and the diestrus phase. The functional consequences of this may be seen as higher 
synaptic glutamate levels during high-oestrogen states and result in increased pain signalling. 
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No difference was noted between males and females or between the different stages 
with regard to the expression of EAAT2 mRNA, indicating that the sex and cyclical difference 
seen in the uptake of aspartate were related to the expression of EAAT1 solely. 
Here we also demonstrate that riluzole, which enhances EAAT function increases 
uptake of aspartate during the oestrus phase in female rats only. This indicates that EAAT1 
function in female rats may only be susceptible to manipulation during this stage of the cycle. 
As riluzole has been shown to have a therapeutic effect in chronic pain states (Gosselin et al., 
2010; Nicholson et al., 2014a), our study highlights the need to take fluctuating female 
hormones into account in pain management with riluzole or other EAAT enhancers. Our 
results correlate with other preclinical in-vivo studies, which have shown that ovariectomy in 
rats (resulting in oestrogen deficiency) significantly decreased the magnitude of visceromotor 
response to colorectal distension, and this effect was reversed by administration of oestrogen 
to these animals (Ji et al., 2003). 
In the spinal cord, EAAT1 constitutes 40% of all high- affinity EAATs, and it is abundantly 
present in lumbar dorsal horn (Queen et al., 2007). In physiological conditions, EAATs remove 
glutamate from the synaptic cleft by co-transporting glutamate and sodium into adjacent glial 
cells. The inefficient function of EAATs can lead to high extracellular glutamate concentration 
causing neuronal damage (Kanai et al., 2013). In the spinal cord, glutamate transporters have 
been shown to be downregulated following chronic sciatic nerve injury (Sung et al., 2003; Yan 
et al., 2009; Ramos et al., 2010). Drugs inhibiting EAATs such as TBOA have shown the 
pronociceptive effect by increasing synaptic glutamate and hence neuronal excitability (Liaw 
et al., 2005). 
Interestingly in pathological chronic pain states, these compounds have shown 
opposite i.e. antinociceptive effect (Minami et al., 2001; Yang et al., 2015). Tao et al. have 
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proposed various possible causes of this phenomena including sustained higher extracellular 
glutamate leading to neurotoxicity; glutamate conversion to inhibitory molecule gamma 
amino butyric acid (GABA); presynaptic glutamate trans- porter blockade leading to depletion 
of presynaptic gluta- mate and postsynaptic glutamate receptor desensitisation (Tao et al., 
2005). The exogenous oestrogen decreased the EAATs activity in the male spinal cord at 
100nM concentration in our study. This concentration of oestrogen is higher than the 
physiological one but was used to allow the penetration into the spinal cord tissue in our ex-
vivo experiments. In females, the proestrus phase exhibited less active EAAT state most likely 
under the effect of high endogenous oestrogen. This effect proved to be sustainable and 
persisted in oestrus phase where oestrogen usually decreases its circulatory levels. Mitrovic 
et al. demonstrated that the exogenous progesterone showed no effect on glial glutamate 
uptake in male rats, alone or in combination with oestrogen (Mitrovic et al., 1999). In our 
study, the glutamate uptake was high in metestrus and diestrus, implying that progesterone 
does not reduce the uptake in this case. 
Remarkably, the oestrogen receptor ERα gene expression was upregulated in the 
oestrus phase suggesting an enhanced hormone signalling. Furthermore, studies have shown 
that selective activation of spinal ERα mimics the pronociceptive effects of 17b-estradiol on 
visceral sensitivity (Ji et al., 2011). Oestrogen generates its effects via the nuclear receptors: 
oestrogen receptors alpha (ERα) and beta (ERβ), which upon their activation instigate 
transcriptional changes for target genes modulating cellular function (Dechering et al., 2000). 
Oestrogen also has non-genomic effects through cellular membrane oestrogen receptors by 
initiating activation of intracellular signalling pathways depending upon their location e.g. 
mitogen-activated protein kinase/extracellular signal-regulated kinases (MAPK/ERK) in the 
spinal cord (Bjornstrom and Sjoberg, 2005). Oestrogen potentially exerts its nociceptive 
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effects on visceral pain pathways through ERα leading to activation of ERK pathway (Ji et al., 
2011). Our study showed increased expression of spinal ERα mRNA in the oestrus phase which 
may be linked to the decreasing levels of oestrogen. We also noted an increase in ERβ in the 
diestrus phase which is related to decreased oestrogen and visceral pain. Moreover, ERβ 
ligands have an antinociceptive effect in rats during colorectal distension (Cao et al., 2012). 
Future work is needed to focus on whether this is causally related to the changes in gluta- 
mate transporter per se and downstream pain states. This may include the use of selective 
ERα and ERβ inhibitors while assessing the glutamate uptake. 
Interestingly, oestrogen has been shown to upregulate NMDA receptors (NDMARs), 
which are heterotetramers composed of two N1 and two N2 or three subunits. NMDA-
receptor activity is subject to changes in receptor abundance, distribution, phosphorylation 
status, and subunit composition and may be altered by ischaemia, inflammation, ageing, or 
sex hormones (Tang et al., 2008; Ji et al., 2015). Oestrogen also increases receptor 
phosphorylation of the NR1 subunit contributing to an increase in NMDA-receptor activity in 
a model of visceral pain (Tang et al., 2008). This may result in a negative feedback mechanism 
and thus decreased expression of the NR1 subunit mRNA, which is possibly the case in our 
data as there was a selective reduction of NR1 mRNA in proestrus. This effect was not present 
in oestrus phase of the oestrous cycle most likely due to the decreasing concentration of 
systemic oestrogen levels in the oestrus phase. We noted no change in the NR2B subunit 
between the sexes or between cycle stages. This conflicts with other studies possibly due to 
our use of healthy rats and Ji et al., using a model of inflammatory visceral pain (Ji et al., 2012). 
One possible pathway summarising the overall action involves NMDA-receptor 
activation – Ca2+ influx – protein kinase A (PKA) activation – ERK phosphorylation and 
subsequent synaptic plasticity (Thomas and Huganir, 2004). A few studies have also shown 
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modulation of synaptic glutamate transporters in the brain by oestrogen, although both 
enhancement (Keller et al., 1997; Liang et al., 2002) and inhibition (Sato et al., 2003) of 
glutamate uptake have been reported. 
These findings suggest high-affinity glutamate transporters as potential therapeutic 
targets for chronic pain states that tend to fluctuate over the female cycle. Pharmacological 
strategies to upregulate EAAT function e.g. riluzole; ceftriaxone and valproate can potentially 
alleviate pain in certain chronic pain conditions. However, a human trial failed to show the 
efficacy of riluzole in chronic neuropathic pain (Galer et al., 2000). Interestingly there have 
been some reports of its efficacy in visceral pain states such as IBS (Mishra et al., 2014). Our 
data would suggest that care is needed as to when its efficacy may be most potent across the 
menstrual cycle in females. 
2.6 Conclusions 
 
Here we show that the spinal glutamate transporter activity is oestrogen state-
dependent which can potentially affect the efficiency of excitatory glutamate 
neurotransmission. Oestrogen potentially exerts its effects through ERα which may lead to 
altered expression of EAATs and glutamate receptor subunits. While more research is needed 
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3.1 Abstract 
Background: Early-life stress (ELS) is a recognised risk factor for chronic pain disorders, and 
females appear to be more sensitive to the negative effects of stress. Moreover, oestrous 
cycle-related fluctuations in oestrogen levels have been linked with alternating pain 
sensitivity. Aberrant central circuitry involving both the ACC and the lumbosacral spinal cord 
has also been implicated in the modulation of visceral pain in clinical and preclinical studies. 
Here we further investigate changes in visceral pain sensitivity and central glutamatergic 
systems in rats with respect to oestrous cycle and ELS. 
Methods: We investigated visceral sensitivity in adult female Sprague-Dawley rats, which had 
undergone maternal separation (MS) in early-life or remained non-separated (NS), by 
performing colorectal distension (CRD). We also assessed excitatory amino acid uptake 
through EAATs in the lumbosacral spinal cord and ACC. 
Results: NS animals in proestrus and oestrus exhibited reduced EAAT uptake and decreased 
threshold to CRD. Moreover, total pain behaviours were increased in these stages. MS rats 
exhibited lower pain thresholds and higher total pain behaviours to CRD across all stages of 
the oestrous cycle. Interestingly, cortical EAAT function in MS rats was inhibited in the low-
oestrogen state- an effect completely opposite to that seen in NS rats. 
Conclusion: This data confirms that oestrous cycle and ELS are significant factors in visceral 
sensitivity and fluctuations in EAAT function may be a perpetuating factor mediating central 
sensitisation. 
Keywords: Visceral pain, colorectal distension, ELS, excitatory amino acid transporter, 
glutamatergic system, aspartate uptake.   
  79 
3.2 Introduction 
 Chronic pain syndromes such as IBS, fibromyalgia, migraine and interstitial cystitis 
display a striking female preponderance with females presenting at the clinic up to 10 times 
more often than their male counterparts (Unruh, 1996; Mogil, 2012). Moreover, females 
report more intense pain, of longer duration and more frequently. With these high prevalence 
rates, a growing body of evidence suggests that gonadal hormones play a significant role in 
pain processing (Iacovides et al., 2015). In line with this, recent evidence suggests the possible 
interaction of gonadal hormones with the brain-gut axis and downstream pain processing 
(Heitkemper and Jarrett, 2001; Ji et al., 2003; Myers et al., 2011). Indeed, gonadal hormone 
binding sites are widely distributed in areas of the CNS involved in pain processing. Sex 
steroids also have receptors located throughout the entire intestine, with both oestrogen and 
progesterone exhibiting direct effects on visceral organs (Arendt-Nielsen et al., 2004). 
Furthermore, oestrogen has been implicated in the possible modulation of visceral pain 
perception (Ji et al., 2003; Chaloner and Greenwood-Van Meerveld, 2013). However, both 
clinical studies and animal models have revealed conflicting evidence on the role of the female 
hormonal cycle on pain perception (Fillingim and Ness, 2000; Heitkemper and Chang, 2009b). 
Numerous studies in the rat have shown a decreased threshold and greater sensitivity in the 
proestrus phase, however, others have reported no difference between oestrous stages 
(Sapsed-Byrne et al., 1996; Ji et al., 2003, 2006; Ji et al., 2008). These discrepancies may be 
due in part to strain differences and the inaccuracy of oestrous cycle determination. 
 Oestrogen receptors have also been shown to interact with other key 
neurotransmitter systems such as the glutamatergic system, which itself is critical to pain 
processing mechanisms (Zhang et al., 2012). In particular, the process of central sensitisation, 
implicates a critical role of excessive glutamatergic signalling leading to the development of 
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plasticity, thus maintaining the chronic pain state (David-Pereira et al., 2015; Falnikar et al., 
2015). The glial EAATs, in particular, EAAT 1 and EAAT 2 are crucial in the maintenance of 
homeostasis within the glutamatergic synapse. However, their expression has been shown to 
be altered in chronic pain models (Gosselin et al., 2010; Moloney et al., 2015a). Intrathecal 
administration of EAAT blockers in naïve animals results in spontaneous somatic pain, as well 
as hyperalgesia and allodynia, implying that a continuous spinal glutamate uptake has a key 
basal antinociceptive action (Aanonsen and Wilcox, 1987; Brambilla et al., 1996; Kontinen and 
Meert, 2002). Moreover, EAAT 2 has also been shown to play a vital role in numerous models 
of visceral pain (Bradesi et al., 2011) with an increased expression showing antinociceptive 
effects (Lin et al., 2009a). Moreover, pharmacological activation of these transporters has also 
demonstrated therapeutic potential (Gosselin et al., 2010). 
 Many chronic pain disorders are also included in categories of stress-induced disorders 
as a significant proportion of patients attribute the onset and exacerbation of their symptoms 
to an early-life stressful period or chronic stress throughout life. Indeed, it is now becoming 
more evident that females appear more sensitive to the negative effects of stress (Bangasser 
et al., 2013). ELS during childhood is related to increased risk to develop depression, anxiety 
and chronic pain in adulthood (Raphael and Widom, 2011; Burke et al., 2017). Maternal 
separation in the early days of life in animals is a widely used model of ELS and has been used 
to elucidate the underlying mechanisms of depression as well as chronic pain disorders 
(O'Mahony et al., 2009; O'Mahony et al., 2011; Moloney et al., 2015b). The model is based on 
the evidence that adverse environmental alterations during early-life can cause long-lasting 
effects into adulthood, e.g., increased visceral pain sensitivity (O'Mahony et al., 2011). In the 
present study, we aimed to assess whether maternal separation and the oestrous cycle alter 
visceral sensitivity and if changes in phenotype were associated with changes in excitatory 
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amino acid transport via glial uptake in the lumbosacral spinal cord and the ACC, two critical 
regions within the CNS, known to play a role in visceral pain processing (Lieberman and 
Eisenberger, 2015; Moloney et al., 2015b). 
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3.3 Material and Methods 
3.3.1 Animals 
 Adult male and female Sprague-Dawley rats (250-300g) (Harlan, UK) were used as 
breeding partners to generate offspring in this study. Upon arrival, animals were housed 
according to sex, four to five animals per cage in plastic cages and were maintained in a 
temperature-controlled room (20±1 °C) with a 12-hour light/dark cycle (7:00 am to 7:00 pm). 
The animals were allowed one week to acclimatise to the animal facility in University College 
Cork after arrival. Breeding pairs were housed together until confirmation of pregnancy. 
Females were then group housed throughout gestation until gestation day 19 after which time 
they were housed singly and allowed to give birth. Two cohorts of animals were used in the 
current study; (1) the first cohort was used for behavioural analysis of visceral sensitivity. (2) 
The second cohort was used for naïve sample collection to assess EAAT function. Group sizes 
were 9-10 animals and was based on previous experiments. All experiments were conducted 
in accordance with the European Directive 2010/63/EU and approved by Animal 
Experimentation Ethics Committee of University College of Cork. 
3.3.2 Maternal Separation 
 Maternal Separation was performed from postnatal day 2 (PND 2) to PND 12 inclusive 
as previously described (Neumann et al., 2005; O'Mahony et al., 2009). Briefly, litters were 
randomly assigned to either the NS group or the maternally separated (MS) group. NS animals 
were left undisturbed except for routine husbandry practices. MS pups were separated daily 
from their mothers in a separate room and placed in a clean cage with fresh bedding, placed 
on top of heated pads (30°C–33°C), for 3 hours from 9:00 am until 12:00 pm after which time 
animals were placed back in their mother’s home cage. Following the separation period 
(PND2-12) animals were left undisturbed except for weekly cage cleaning. Offspring were 
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weaned and sexed at PND 21. Animals were allowed to mature to adulthood (8 weeks), and 
all female animals were used for the remainder of the study. 
3.3.3 Vaginal Smears 
 Females were vaginally lavaged daily with saline for at least two consecutive oestrous 
cycles, and cells were immediately viewed under a microscope prior to behavioural 
assessment. Those rats that were regularly cycling were used in this study. The stage of 
oestrous cycle was determined as previously described (Ji et al., 2008). Since metestrus only 
lasts for a short period (5-6 hours) and the plasma oestrogen concentration in metestrus do 
not differ from that in diestrus, data from these two groups of rats were pooled. For cohort 1, 
the behavioural study, animals were lavaged immediately before balloon insertion into the 
colorectum, to assess oestrous stage during visceral pain measurement. For cohort 2, tissue 
collection only, the animals underwent vaginal smears for cycle phase estimation immediately 
before decapitated for tissue collection. Toward the end of each study there was occasions 
where the lavaged rats were not in the correct phase (we aimed for 9-10 per group), and then 
we waited a day or two until we lavaged again to check the stage and if it fit into the groups 
that required more numbers. 
3.3.4 Colorectal Distension 
 CRD was performed as previously described (O'Mahony et al., 2010; O'Mahony et al., 
2012). Briefly, animals were fasted overnight and anaesthetised with isoflurane (3-5% in 
oxygen) followed by insertion of a 6 cm latex balloon into the colorectal cavity, 1 cm from the 
anus. The animals were allowed to recover for 10 minutes before CRD commenced (9:00 am 
to 12:00 pm), in unrestrained freely moving animals. The paradigm used was an ascending 
phasic distension from 0 mmHg to 80 mmHg over 8 minutes. The parameters of interest were 
(1) the threshold pressure (mmHg) that evokes the first visually identifiable visceral pain 
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behaviour and (2) the total number of pain behaviours over the distension period. Postures 
defined as visceral pain behaviours were abdominal retractions and/or abdominal withdrawal 
reflex. The experimental groups were randomised, and behavioural testing was performed by 
an experimenter blinded to treatment groups to eliminate any bias. All animals underwent 
CRD only once. 
3.3.5 Sample Preparation for Aspartate Transport Assay 
 The animals were euthanised by decapitation immediately after vaginal smearing. 
Their spinal cords were removed by hydraulic pressure into HBSS filled Petri dishes, and 0.4 
mm thick slices were obtained from lumbosacral spinal cord using a McIIwain tissue chopper. 
Similarly, brain tissue was removed from the skull and sectioned using a vibratome to obtain 
ACC sections. These slices were separated by fine dissection under a microscope and 
transferred to 24-well culture plates filled with both sodium-containing HBSS (labelled as Na+) 
and sodium-free HBSS (labelled as Na-) separately. The Na+ plate was maintained at 35 °C and 
Na- on the ice. The slices from Na+ plate were washed once with 1 mL of 35 °C HBSS and Na- 
plate with 1 mL of 4 °C sodium-free HBSS to assess sodium-dependent and independent 
uptake respectively. 
3.3.6 Aspartate Transport Assay 
 Since EAATs show high-affinity to both glutamate and aspartate, we used aspartate. 
This protocol has been previously described in brain slices (Thomazi et al., 2004); we optimised 
this technique to be used on spinal cord slices for the first time. Aspartic Acid, D-[2, 3-3H] 
(specific activity 12.9 Ci/mmol) was purchased from Perkin-Elmer, USA. RIPA buffer and Pierce 
BCA protein assay kit were purchased from Fisher Scientific Ireland. All other reagents were 
purchased from Sigma-Aldrich. HBSS was prepared containing (in mM): 137 NaCl; 0.63 
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Na2HPO4; 4.17 NaHCO3; 5.36 KCl; 0.44 KH2PO4; 1.26 CaCl2; 0.41 MgSO4; 0.49 MgCl2 and 1.11 
glucose, in pH 7.2. In sodium-free HBSS, NaCl was replaced by 137 mM N-methyl-D-glucamine. 
 Spinal cord and ACC slices were pre-incubated at 35 °C and ice in Na+ and Na- HBSS 
respectively for 30 min. Then a solution containing 1µL 0.66 μCi/mL aspartic acid D- [2,3-3H], 
15 µL of cold 100 μM D-Aspartate and 84 µL H2O was added. After 3 and 7 minutes of 
incubation of spinal cord and ACC respectively, the slices were washed twice with 1 ml of 
corresponding ice-cold HBSS. Tissue was transferred into 1.5 ml tubes containing RIPA buffer 
and was mechanically dissociated with pestles. This mixture was homogenised for 15 minutes 
at 4 °C and residue was removed. Radioactivity was measured in terms of counts per minute 
(CPM) using a liquid scintillation counter and results for Na- samples were subtracted from 
those of Na+ samples to achieve sodium-dependent uptake-hallmark of EAAT 1 & 2 function. 
Uptake procedure was performed in triplicate. Protein was measured using Peirce BCA protein 
assay kit. Final scintillation result for each slice was divided by respective protein value to 
achieve aspartate uptake in terms of CPM/mg-indicative of spinal and cortical EAAT’s function. 
3.3.7 Statistical Analysis 
 All data was normally distributed according to Gaussian distribution analysis. Data are 
expressed as mean ± SEM. Two-Way-ANOVA and Tukey post-hoc test were used in all cases. 
P < 0.05 were considered statistically significant. The sample size (n=9/10) was based on 
previous studies showing that it was sufficient to observe statistically significant results. 
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3.4 Results 
3.4.1 Early-life Stress and Oestrous Cycle-dependent Variations in Visceral 
Sensitivity 
 A two-way ANOVA analysis of threshold sensitivity revealed a significant effect of 
stress (F (1, 50) = 11.42, p < 0.01), oestrous cycle (F (2, 50) = 6.847, p < 0.01) and an interaction 
effect of stress x oestrous cycle (F (2, 50) = 5.561, p < 0.01, Figure 3.1A, n=9/10 per group). 
Overall MS rats displayed a lower threshold compared to NS rats. Post-hoc analysis revealed 
significant differences between groups with NS animals in both the proestrus (p < 0.0001) and 
oestrus (p < 0.01) phases exhibiting decreased threshold values compared to NS 
metestrus/diestrus animals. In addition, a difference was noted between MS rats and NS rats 
in metestrus/diestrus (p < 0.0001). There were no between-group differences observed in MS 
animals. 
 A two-way ANOVA analysis of total pain behaviours also revealed a significant effect 
of stress (F (1, 50) = 8.657, p < 0.01) and a significant effect of oestrous cycle (F (2, 50) = 3.571, p < 
0.05) but no interaction effect of oestrous cycle x stress (F (2, 50) = 1.305, p > 0.05, Figure 3.1B, 
n=9/10 per group). Overall MS rats showed a higher number of pain behaviours, with post-
hoc analysis revealing significantly increased total pain behaviours in the NS animals in the 
proestrus (p < 0.01) phase compared to NS animals in the metestrus/diestrus phase. There 
were no between-group differences observed in MS animals. 
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Figure 3.1. Early-life stress and oestrous cycle-dependent variations in visceral sensitivity. MS 
animals exhibit visceral hypersensitivity with a significantly lower threshold of visceral distension 
required for identifiable abdominal contraction [A] and increased total pain behaviours [B] compared 
to NS (**p < 0.01 non-sep vs mat-sep, ## p < 0.01, #### p < 0.0001 vs. met/die non-sep, n=9-10/group). 
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3.4.2 Early-life Stress and Oestrous Cycle-dependent Variations in Central EAAT 
Activity. 
3.4.2.1 Lumbosacral Spinal Cord 
 Two-way ANOVA analysis of EAAT function within the lumbosacral spinal cord revealed 
a significant effect of the oestrous cycle (F (2, 53) = 4.349, p < 0.05, Figure 3.2, n=10 per group) 
but no significant effect of stress or interaction effect. Post-hoc analysis revealed NS animals 
in the oestrus phase (p < 0.01) and the proestrus phase (p < 0.05) to have reduced EAAT 
function compared to NS animals in the metestrus/diestrus phase. 
 
Figure 3.2. Early-life stress and oestrous cycle-dependent variations in spinal EAAT function. Oestrous cycle 
plays a role in EAAT function in the lumbosacral spinal cord with both the oestrus and proestrus phases of the 
cycle inducing significant reductions in EAAT function (# p < 0.05, ## p < 0.01 vs. met/die non-sep, n=9-10/group). 
 
3.4.2.2 Anterior Cingulate Cortex 
 A significant interaction of stress x oestrous cycle was observed for EAAT function 
within the ACC (F (2, 51) = 27.00, p < 0.0001, Figure 3.3, n=10 per group) with post-hoc analysis 
revealing significant decreases in both the proestrus (p < 0.0001) and oestrus (p < 0.0001) 
phases in NS animals. However, cortical EAAT function in MS rats was inhibited in low-
oestrogen state, i.e., diestrus, rather than high-oestrogen states- an effect completely 
opposite to that seen in NS rats. Moreover, a student t-test direct comparison between both 
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groups showed that aspartate uptake was significantly low in MS diestrus rats compared to 
NS diestrus rats (p < 0.0001). 
 
Figure 3.3. Early-life stress and oestrous cycle-dependent variations in central EAAT function. Oestrous cycle 
and ELS play a role in EAAT function in the ACC with both the oestrus and proestrus phases of the cycle inducing 
significant reductions in EAAT function in NS rats (#### p < 0.0001 vs met/die non-sep, n=10/group) and oestrus 
and proestrus phases showing increased EAAT function in MS rats ($p < 0.05, $$p < 0.01 vs. met/die mat-sep, 
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3.5 Discussion 
 Here we show that ELS and the oestrous cycle play significant roles in visceral 
sensation. MS animals displayed similar visceral pain responses at all stages of the cycle while 
in NS controls, fluctuations in visceral sensitivity occurred across the cycle. We noted an early-
life stress-induced increase in visceral sensitivity in the combined metestrus and diestrus 
phases but not in the proestrus and oestrus phases. 
 Furthermore, excitatory amino acid transport, both within the lumbosacral spinal cord 
and the ACC, were also altered in response to stress and oestrous cycle, thus indicating that 
aberrant excitatory transport may in part lead to fluctuations in visceral sensitivity. 
 Functional gastrointestinal disorders, characterised by visceral pain have been more 
commonly reported in females, in particular, premenopausal women, with increasing focus 
on the effect of hormonal cycles on pain processing (Mayer et al., 2004). Female IBS patients 
report increased visceral pain during menses suggesting enhanced visceral sensitivity during 
the perimenstrual period (Heitkemper and Chang, 2009b). The hormonal cycle in the rodent 
is much shorter than that in humans with the cycle completed in just 4-5 days. Progressing 
through the stages may occur over the course of just a few hours, making it difficult to 
investigate the role of the oestrous cycle in nociceptive assays due to the inconsistent 
methodology. For this reason, many studies disregard the cycle (Kamp et al., 2003; Tammpere 
et al., 2005; Arvidsson et al., 2006), however, it is increasingly more appreciated that this is a 
significant confound and makes the interpretation of data difficult. Indeed, the oestrous stage 
has previously been shown to alter the responses in somatic nociceptive assays, in particular, 
the tail flick test (Martinez-Gomez et al., 1994; Kayser et al., 1996; Fillingim and Ness, 2000). 
This current study found significant changes in visceral sensitivity across the stages of the 
oestrous cycle in controls; with heightened visceral pain response in the proestrus and 
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oestrous phases. This is in agreement with previous reports (Sapsed-Byrne et al., 1996; Ji et 
al., 2008), however, it is pertinent to note that other studies have shown findings on the 
contrary, with evidence showing no changes in visceral pain throughout the cycle (Ji et al., 
2006). These discrepancies seen in animal models may be due in part to species and strain 
differences but also the impact of stress. Although not widely acknowledged in the literature, 
the methodology used to assess oestrous stage, i.e., vaginal lavage, can be stressful to animals 
and may result in changes in the cycle. Thus, it is important to acclimate animals to the vaginal 
smearing process itself as was performed in this study. 
 The most potent and prevalent endogenous oestrogen, oestradiol, is at its highest 
level during the proestrus phase, which also coincides with the highest level of visceral pain 
sensitivity, highlighting the potential role of the gonadal hormones in visceral pain. Moreover, 
its contribution to visceral hypersensitivity has been investigated in animal models through 
ovariectomy and hormone replacement studies (Ji et al., 2003; Myers et al., 2011). These 
studies reported reduced visceral sensitivity in ovariectomised females compared with intact 
females. Oestrogen replacement was reported to increase visceral sensitivity back to levels of 
that seen in the intact females (Ji et al., 2003). Furthermore, the implantation of micropellets 
containing oestradiol and progesterone into the amygdala increased visceral pain behaviours 
in ovariectomised rats, with no differences seen when placed in neighbouring brain regions 
(Myers et al., 2011). Interestingly no changes were observed in somatic pain thresholds. These 
findings suggest that female sex steroids do indeed play a significant role in visceral 
nociception. 
 Stress and altered HPA axis function are significant risk factors for the development of 
visceral pain. Thus, it is interesting to note that hormonal fluctuations have also been shown 
in stress responsivity and altered neurobiology of the HPA axis. Females have been found to 
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have higher corticotropin-releasing hormone, adrenocorticotropic hormone, and 
corticosterone levels during proestrus, the phase of the cycle in which oestradiol levels are 
higher than during other phases of the oestrous cycle (Buckingham et al., 1978; Bohler et al., 
1990; Atkinson and Waddell, 1997). Furthermore, plasma adrenocorticotrophic hormone and 
corticosterone levels in response to stress are higher during proestrus than during other 
phases of the cycle (Pollard et al., 1975; Viau and Meaney, 1991; Carey et al., 1995). Moreover, 
neurotransmitter systems implicated in the control of HPA function (Kaneko and Hiroshige, 
1978; Plotsky et al., 1989) show variations related to the oestrous cycle and are sensitive to 
gonadal steroid levels (Rance et al., 1981a; Rance et al., 1981b; Biegon and McEwen, 1982). 
Indeed, here we specifically focus on the glutamatergic system and the role of glial glutamate 
transport in visceral nociception. 
 Here we show that the activity of glutamate transporters in the lumbosacral spinal 
cord and ACC are significantly decreased during the phases of the oestrous cycle when visceral 
sensitivity is higher. The EAATs are responsible for removing excess glutamate from the 
synaptic cleft thereby reducing the availability of glutamate and preventing central 
sensitisation. Studies from our group have shown that expression of these transporters is 
reduced in animal models of heightened sensitivity to colorectal distension including the 
maternal separation model (Gosselin et al., 2010) as well the CBA/J strain of mouse (Moloney 
et al., 2015a). 
 Water avoidance stress has also been shown to alter expression levels of these 
transporters in the spinal cord which was positively correlated with pain behaviours (Bradesi 
et al., 2011; Lin et al., 2011). Taken together, it is plausible that glutamate uptake enhancers 
may prove to be a novel therapeutic strategy for the treatment of visceral hypersensitivity 
(Gosselin et al. 2010). Indeed, recent studies show downregulation of spinal EAAT transporters 
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in various models of chronic pain (Mao et al., 2002; Sung et al., 2003; Weng et al., 2005). 
Moreover, the importance of glial glutamate uptake is further highlighted by reports where 
EAAT overexpression reduces pain sensitivity (Lin et al., 2009a; Lin et al., 2011; Yang et al., 
2011). Previous studies have shown higher glutamate concentration in ACC in animals exposed 
to ELS (Mathew et al., 2003). 
 Overall, in MS rats, stress increased visceral sensitivity in metestrus/diestrus phases 
but had no effect in proestrus and oestrus compared to NS rats. The reason for this is not 
clear, but it is interesting to note that glutamate uptake in the spinal cord paralleled this. 
However, uptake in the ACC was opposite to the that of the NS controls. This may be 
compensatory as uptake was higher in the proestrus and oestrus in the MS animals, which 
may indicate that higher activity of these transporters is necessary to maintain behaviours at 
the same level. Moreover, it appears that visceral sensitivity in MS rats is linked to changes in 
EAAT function in the ACC, while both the spinal and ACC EAAT function was related to pain 
behaviours in the NS group. Both ACC and spinal cord EAAT function are reduced in the higher 
oestrogen state, i.e., proestrus and ensuing oestrus, paralleling that of the pain behaviours. 
Other studies have indicated that oestrogen can affect the expression of the EAATs as well as 
L-glutamate uptake activity in cultured midbrain astrocytes (Pawlak et al., 2005). Oestrogen 
exerts if effects through either membrane-bound or nuclear receptors and stimulation of PI3-
kinase coupled to nitric oxide production may be involved in the inhibitory regulation of 
glutamate transporter activity by oestrogen. The presence of nuclear oestrogen receptors in 
astrocytes has been demonstrated in-vitro and in-vivo (Garcia-Ovejero et al., 2002). 
Moreover, it should be appreciated that the expression of oestrogen receptors can change 
(Garcia-Ovejero et al., 2002) and hence influence the level of impact of oestrogen changes 
also. 
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 Our data further support an important role of glutamate transport at both the level of 
the spinal cord but also higher brain centres in the pathophysiology of visceral pain. 
3.6 Conclusion 
 The findings presented here highlight the important contribution of female sex 
hormones to the control, processing, and manifestation of visceral pain. Indeed, our studies 
suggest a complex link between steroid signalling, stress, and glutamatergic 
neurotransmission. Taken together these findings have added to the accumulating literature 
implicating the role of sex hormones and glutamate in visceral pain. 
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4.1 Abstract 
 
Background: Chronic stress, pain, and depression are interrelated. Oestrous cycle influences 
glutamatergic signalling in the central nervous system (CNS) through the involvement of 
hypothalamic-pituitary-adrenal (HPA) axis. Repeated stimulation of HPA axis in chronic stress 
may lead to important structural and functional changes in the CNS affecting 
neurotransmission leading to depressive characteristics. There is evolving evidence that 
microbiota-gut-brain axis is involved in the pathogenesis of certain CNS disorders and it may 
have a role in altered pain signalling in CNS. Here we further investigated changes in central 
glutamatergic system in Wistar-Kyoto (WKY) rats (an animal model of depression) with respect 
to oestrous cycle. We also evaluated if caecal microbiota had any correlation with changes in 
central glutamatergic system. 
Methods: We assessed the functional activity of the EAATs in the lumbosacral spinal cord and 
ACC in WKY rats. Additionally, the caecal microbiota composition of these animals was 
investigated. 
Results: EAAT function was similar in males compared to females in all phases of the oestrous 
cycle at the level of lumbosacral spinal cord. In the ACC, the glutamate transporter uptake was 
higher in diestrus females compared to males, proestrus and oestrus females. In males, 
aspartate uptake in the ACC was found to correlate positively with Bacteroides. Aspartate 
uptake in the spinal cord was found to correlate positively with relative abundances of 
the Lachnospiraceae NK4A136 in males. Further positive associations with aspartate 
uptake in the spinal cord were also observed for Alistipes and Bifidobacteruim during 
oestrus in females, as well as for the Eubacterium coprostanoligenes during proestrus. 
Clostridium sensu stricto1 was also found to be negatively associated with aspartate 
uptake in the ACC in males and diestrus females. 
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Discussion: This data suggests that EAAT function is not regulated by oestrogen in the 
lumbosacral spinal cord. In the ACC, glial transporter function changed across oestrous cycle, 
indicating that glutamate metabolism in areas of the brain processing affective components 
of pain is dependent on oestrous phase. Short-chain fatty acid (SCFA) producing gut bacteria 
seem to have positive correlation with aspartate uptake in males and oestrous state specific 
females. 
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4.2 Introduction 
 
Chronic stress has been linked with the aetiogenesis of a number of disorders including 
chronic pain syndromes, autoimmune disorders, hypertension and depression (O'Malley et 
al., 2011). In fact, the patients with chronic pain states such as irritable bowel syndrome have 
elevated baseline levels of norepinephrine in their blood indicating the relationship of stress 
and the pain disorders (Posserud et al., 2004). Chronic stress can lead to abnormal changes in 
the CNS, which may, in turn, dysregulate the body response to stress resulting in increased 
pain sensitivity. Activation of the HPA axis plays an important role in the stress responses 
through the secretion of cortisol from adrenal glands. Repeated stimulation of the HPA axis 
over an extended period of time has been shown to be implicated in the development of 
depression and IBS (Dinan et al., 2008; Thomson and Craighead, 2008). 
The rodent adult females have higher basal and stress-state levels of ACTH and 
corticosterone as compared to males (Lesniewska et al., 1990a). Moreover, there is a growing 
evidence toward the role of gonadal hormones in the regulation of HPA axis. For example, 
female rats have higher blood CRH, ACTH, and corticosterone levels during high-oestrogen 
state, i.e., proestrus compared to diestrus and oestrus (McCormick et al., 2002). Fluctuations 
in the circulating levels of oestrogen, during the menstrual cycle, can also lead to variation in 
the symptomatology of chronic pain syndromes through the activation of glutamatergic 
receptors (Heitkemper and Chang, 2009b; Mermelstein, 2009). Moreover, gonadal hormones 
have been shown to affect visceral sensitivity in animal models significantly; oestrogen being 
pronociceptive in rodents (Ji et al., 2003; Myers et al., 2011). 
The WKY rat strain demonstrates hyperresponsiveness to stress (Pare, 1993; De La 
Garza and Mahoney, 2004) and elevated basal and stress-state ACTH and corticosterone levels 
compared to other strains (Rittenhouse et al., 2002). Moreover, these animals showed a 
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decrease in expression of the astrocytic marker glial fibrillary acidic protein (GFAP)(Gosselin 
et al., 2009) and increased pain induced activation in the prefrontal cortex (infralimbic, 
prelimbic and ACC) when compared to Sprague-Dawley rats (Gibney et al., 2010). Changes in 
GFAP expression have been shown to modify glial glutamate metabolism through direct 
effects on EAAT's activity (Sullivan et al., 2007), which is also implicated in major depression 
(Choudary et al., 2005). Previously, WKY rats have been shown to be more sensitive to painful 
stimuli in tests such as colorectal distension and tactile allodynia, compared to Sprague-
Dawley (SD) rats in both male and female sexes (SM et al., 2013; Ackerman et al., 2015). 
However, there is no comparative study available in the literature comparing the pain 
responses in two sexes of WKY rats, as previously done on SD rats. In female WKY rats, the 
responses to painful stimuli across the oestrous cycle have currently not been demonstrated. 
Multiple studies now imply that the visceral pain can by influenced by the gut 
microbiota (Table 1.6). In rodent studies, probiotics have been shown to decrease stress-
induced or antibiotic-induced visceral pain (Verdu et al., 2006; Ait-Belgnaoui et al., 2009; 
McKernan et al., 2010). Some probiotics have been shown to alleviate abdominal pain in the 
humans (Curro et al., 2017). Interestingly, visceral hypersensitivity can be transferred via the 
microbiota of IBS patients to animals previously lacking microbes (Crouzet et al., 2013). 
However, the mechanisms underlying the effects of the microbiota on visceral pain perception 
remain to be explained. 
There is a paucity of data examining whether glutamate metabolism is altered in the 
key pain processing central nervous areas, in relation to the physiological alterations of 
circulating gonadal hormones; and if present how do these changes correlate with depression 
and gut microbiota. Thus, here we aim to investigate the changes in glial aspartate uptake in 
the spinal cord and ACC, in response to intrinsically alternating blood oestrogen levels during 
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various oestrous cycle stages in WKY rats, an animal model of depression. We also studied if 
there was a correlation between aspartate uptake and faecal microbiota. 
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4.3 Material and Methods 
4.3.1 Animals 
 
Adult WKY rats (weighing 125-150 g females and 150-175 g males) were housed in a 
local animal facility with food and water ad libitum, on a 12:12-hour dark–light cycle (lights on 
at 7:00 AM) with the temperature at 20°C ± 1°C. Animals were group housed by 4 to 5 per 
cage in plastic cages with sawdust bedding, shredded paper, and a cardboard roll. They were 
allowed to habituate in the new environment for a week before the commencement of 
experiments. Female rats underwent vaginal smearing on the day of each experiment to 
assess their oestrous cycle phase (Byers et al., 2012). One cohort of 10 males and 30 female 
rats was used for the aspartate uptake studies. All experiments were in full accordance with 
the European Community Council Directive (2010/63/EU) and approved by Animal 
Experimentation Ethics Committee of University College Cork. 
4.3.2 Vaginal Smears 
 
Females were vaginally lavaged with saline, and cells were viewed under a microscope. 
The stage of oestrous cycle was determined as previously described (Ji et al., 2008). Since 
metestrus only lasts for a short period (5-6 hours) and the plasma oestrogen concentration in 
metestrus do not differ from that in diestrus, data from these two groups of rats were pooled. 
Animals were lavaged immediately before euthanasia, to determine oestrous stage accurately 
for all tissue collected. 
4.3.3 Sample Preparation for Aspartate Transport Assay 
 
The animals were euthanised by decapitation immediately after vaginal smearing. 
Spinal cords were removed by hydraulic pressure into HBSS filled Petri dishes and 0.4 mm 
thick, slices were obtained from lumbosacral spinal cord using a McIIwain tissue chopper. 
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Brain tissue was removed from the skull and sectioned using a vibratome to obtain ACC 
sections. These slices were separated by fine dissection under a microscope and transferred 
to 24-well culture plates filled with both sodium-containing HBSS (labelled as Na+) and sodium-
free HBSS (labelled as Na-) separately. The Na+ plate was maintained at 35 °C and Na- plate 
was kept on ice. The slices from the Na+ plate were washed once with 1 mL of 35 °C HBSS and 
slices from Na- plate were washed with 1 mL of 4 °C sodium-free HBSS to assess sodium-
dependent and independent uptake, respectively. 
4.3.4 Aspartate Transport Assay 
 
Since EAATs show high-affinity to both glutamate and aspartate, we chose aspartate 
for uptake study as it is widely available. This protocol has been previously described in brain 
slices (Thomazi et al., 2004). We have optimised this technique to be used on spinal cord slices 
for the first time. Aspartic Acid, D-[2, 3-3H] (specific activity 12.9 Ci/mmol) was purchased from 
Perkin-Elmer, USA. RIPA buffer and Pierce BCA protein assay kit were purchased from Fisher 
Scientific Ireland. All other reagents were purchased from Sigma-Aldrich. HBSS was prepared 
containing (in mM): 137 NaCl; 0.63 Na2HPO4; 4.17 NaHCO3; 5.36 KCl; 0.44 KH2PO4; 1.26 CaCl2; 
0.41 MgSO4; 0.49 MgCl2 and 1.11 glucose, in pH 7.2. In sodium-free HBSS, NaCl was replaced 
by 137 mM N-methyl-D-glucamine. 
Spinal cord and ACC slices were pre-incubated at 35 °C and ice in Na+ and Na- HBSS 
respectively for 30 min. Following this, a solution containing 1µL 0.66 μCi/mL aspartic acid D- 
[2,3-3H], 15 µL of cold 100 μM D-Aspartate and 84 µL H2O was added. After 3 and 7 minutes 
of incubation of spinal cord and ACC respectively, the slices were washed twice with 1 ml of 
corresponding ice-cold HBSS. Tissue was transferred into 1.5 mL tubes containing RIPA buffer 
and was mechanically dissociated with pestles. This mixture was homogenised for 15 minutes 
at 4 °C, and the residue was removed. Radioactivity was measured in terms of scintillations 
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per minute (CPM) using a liquid scintillation counter and the results for Na- samples were 
subtracted from those of Na+ samples to achieve sodium-dependent uptake-hallmark of EAAT 
1 & 2 function. Uptake procedure was performed in triplicate. Protein was measured using 
Peirce BCA protein assay kit. Final scintillation result for each slice was divided by respective 
protein value to achieve aspartate uptake in terms of CPM/mg which is indicative of spinal 
and cortical EAAT’s function. 
4.3.5 Caecal Microbiota Analysis 
In order to acquire caecal microbiota data, caecal DNA was extracted, followed by 
Illumina MiSeq sequencing and bioinformatics analysis. 
 A 0.25 g aliquot of the faecal sample was added to 1 mL lysis buffer (500 mM NaCl, 50 
mM Tris-HCl, pH 8.0, 50 mM EDTA, and 4% sodium dodecyl sulfate) together with 0.4g of 
zirconia beads. The samples were homogenised for 3 minutes using the Biospec 
Minibeadbeater at maximum speed. The homogenised samples were then heated to 70°C for 
15 minutes and then centrifuged at 16,000 xg for 5 minutes. The supernatant was then 
removed, fresh lysis buffer added and the beadbeating, heating and centrifugation steps 
repeated. The nucleic acids were then precipitated using 10 M ammonium acetate, followed 
by addition of isopropanol. The nucleic acids were then pelleted, washed and resuspended in 
1X TE buffer. Subsequently, removal of RNA, protein, and purification of the DNA was 
completed using components of the QIAGEN QIAamp DNA Stool Mini kit along with the wash 
buffers and elution buffer, and DNA was stored at -20 °C.  
 The V3-V4 variable region of the 16S rRNA gene was amplified from the DNA extracts 
using the 16S metagenomic sequencing library protocol (Illumina). The DNA was amplified 
with primers specific to the V3-V4 region of the 16S rRNA gene which also incorporates the 
Illumina overhang adaptor (Forward primer 5’ 
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TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG; reverse primer 5’ 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC). Each PCR 
reaction contained DNA template, 5 µL forward primer (1 µM), 5 µL reverse primer (1 µM), 
12.5 µL 2X Kapa HiFi Hotstart ready mix (Anachem, Dublin, Ireland), PCR grade water to a final 
volume of 25 µL. PCR amplification was carried out as follows: heated lid 110°, 95 °C x 3 
minutes, 25 cycles of 95 °C x 30 s, 55 °C x 30 s, 72 °C x 30 s, then 72 °C x 5 mins and held at 4 
°C. PCR products were visualised using gel electrophoresis (1X TAE buffer, 1.5 % agarose, 100 
V). Successful PCR products were cleaned using AMPure XP magnetic bead based purification 
(Labplan, Dublin, Ireland). A second PCR reaction was completed on the purified DNA (5 µl) to 
index each of the samples, allowing samples to be pooled for sequencing on the one flow cell 
and subsequently demultiplexed for analysis. Two indexing primers (Illumina Nextera XT 
indexing primers, Illumina, Sweden) were used per sample. Each PCR reaction contained 5 µL 
index 1 primer (N7xx), 5 µL index 2 primer (S5xx), 25 µL 2x Kapa HiFi Hot Start Ready mix, 10 
µL PCR grade water. PCRs were completed as described above, but only 8 amplification cycles 
were completed instead of 25. PCR products were visualised using gel electrophoresis and 
subsequently cleaned (as described above). Samples were quantified using the Qubit™ 3.0 
Fluorometer (Biosciences, Dublin, Ireland) along with the high sensitivity DNA quantification 
assay kit. Samples were then pooled in an equimolar fashion. The sample pool was prepared 
following Illumina guidelines. Samples were sequenced on the MiSeq sequencing platform 
(Clinical Microbiomics, Denmark), using a 2 x 250 cycle kit, following standard Illumina 
sequencing protocols.    
 250 base pair paired-end reads were assembled using FLASH (FLASH: fast length 
adjustment of short reads to improve genome assemblies). Further processing of paired-end 
reads including quality filtering based on a quality score of > 25 and removal of mismatched 
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barcodes and sequences below length thresholds was completed using QIIME Version 1.9.0. 
Singleton removal (to ensure a minimum of 2 copies to be counted), denoising, chimera 
detection and clustering into operational taxonomic units (OTUs) (97% identity) were 
performed using USEARCH v7 (64-bit) (Edgar, 2010). OTUs were aligned using PyNAST 
(PyNAST: python nearest alignment space termination; a flexible tool for aligning sequences 
to a template alignment) and taxonomy was assigned using BLAST against the SILVA SSURef 
database release v123. Data were not rarefied/normalised for further analysis. The richness 
and α-diversity indices were generated in QIIME Version 1.9.0 (Caporaso et al., 2010). 
4.3.7 Statistical Analysis 
 
Aspartate assay data were normally distributed according to Gaussian distribution 
analysis. Data are expressed as mean ± SEM. One-way-ANOVA and Tukey post-hoc test were 
used in all cases. P < 0.05 was considered statistically significant. The sample size (n=10) was 
based on previous studies showing that it was sufficient to observe statistically significant 
results. Spearman rank correlation coefficients were calculated for determination of the 
existence of significant associations between aspartate uptake and microbial relative 
abundances in the gut. P-values were corrected for multiple comparisons as described by 
Benjamini and Hochberg (1995). Canonical Correspondence Analysis (CCA) was carried out 
using the vegan package in R (Oksanen et al., 2018). 
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4.4 Results 
4.4.1 Sex and Oestrous Cycle Have no Effect on the Spinal Glial Aspartate Uptake 
 
The aspartate uptake in the lumbosacral spinal cord of male WKY rats was similar to 
that of females. Moreover, there was no statistically significant change noticed in spinal 
aspartate uptake across the oestrous cycle stages (Figure 4.1). 
 
 
Figure 4.1. Aspartate uptake in lumbosacral spinal cord. Uptake was similar in males and females across all 
oestrous stages (n=9-10/group). 
4.4.2 Aspartate Uptake in ACC Relates to Oestrous Cycle 
Here we show that the oestrous cycle had a significant effect on the cortical aspartate 
uptake (p < 0.01, F (3,34) =6.4, Figure 4.2). Post-hoc analysis revealed that EAAT activity was 
considerably lower in the high-oestrogen state, i.e., proestrus and the following oestrus state 
as compared to diestrus female rats (p < 0.01 and p < 0.05 respectively). 
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Figure 4.2. Aspartate uptake at ACC. Aspartate uptake in females shows significant oestrogen-dependent 
changes in EAAT activity (one-way ANOVA, p < 0.01, F (3,34) =6.4, n=9-10/group). Uptake was higher in diestrus 
compared to proestrus females (**p < 0.01, Tukey’s post-hoc) and oestrus females (*p < 0.05, Tukey’s post-hoc). 
 
4.4.3 Associations between Bacterial Relative Abundances in the Gut and Aspartate 
Uptake in the ACC and Spinal Cord. 
 
Changes in relative abundances of the most prominent bacterial taxa are illustrated as 
a function of increasing levels of aspartate uptake in the ACC and spinal cord between samples 
at the genus level in females during different stages of the oestrous cycle as well as in males 
(Figure 4.3A). CCA revealed that the effect of aspartate uptake in the ACC on bacterial 
dispersion was orthogonal to the effect exerted by aspartate uptake in the spinal cord (Figure 
4.3B). However, neither aspartate uptake in the ACC (p = 0.912) nor that in the spinal cord (p 
= 0.586) were found to significantly influence the gradient of bacterial dispersion between 
samples with a clear majority of taxa observed to cluster together at the centre of the plot. 
Sample groups also failed to form distinct clusters indicating that differences in the 
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relationships between bacterial abundances of the gut microbiota and aspartate uptake in the 
ACC and spinal cord are not evident according to either gender or oestrous cycle stage. Despite 
this, significant associations were observed between aspartate uptake and the relative 
abundances of individual taxa at the genus level (Figure 4.3C). Aspartate uptake in the ACC 
was found to correlate positively with Bacteroides (q = 0.0003; Spearman’s rho 0.967) but 
negatively with Clostridium sensu stricto1 (q = 0.0215; Spearman’s rho -0.816) in males. 
Clostridium sensu stricto1 was also found to be negatively associated with aspartate uptake in 
the ACC (q = 0.0091; Spearman’s rho -0.905) during diestrus in females, as was Alloprevotella 
(q = 0.0145; Spearman’s rho -0.881). Aspartate uptake in the spinal cord was found to 
correlate positively with relative abundances of the Lachnospiraceae NK4A136 group (q = 
0.0427; Spearman’s rho 0.766) in males. Further positive associations with aspartate uptake 
in the spinal cord were also observed for Alistipes (q = 0.0344; Spearman’s rho 0.783) and 
Bifidobacteruim (q = 0.0427; Spearman’s rho 0.766) during oestrus in females, as well as for 




Figure 4.3. Associations between bacterial relative abundances and aspartate uptake in the ACC and Spinal 
Cord. A) The Influence of increasing aspartate uptake, in the ACC and spinal cord respectively, on sample relative 
abundances at the genus level, both in males and across the oestrous cycles in females. B) CCA of microbiota 
composition regressed on measures of aspartate uptake in both the ACC and spinal cord. Filled circles represent 
samples while red crosses represent bacterial taxa (genus level) with the top 5% of taxa which best fit the axes 
being indicated by name. The ACC and Spinal Cord vectors each point to the direction of taxa which exhibit the 
strongest association with the variable while their magnitude indicate the strength of the variable in explaining 
the bacterial dispersion observed. The Canonical variates explain 14.4% and 16.3% of the total explainable 
variance in the first and second axis respectively. C) Heat map of the 50 most abundant bacterial taxa (genus 
level) correlated against aspartate uptake in the ACC and spinal cord using Spearman's correlation (* q < 0.05; 
** q < 0.01; *** q < 0.001; q = False Discovery Rate adjusted p-value (q-value) after Benjamini-Hochberg multiple 
testing corrections). 
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4.5 Discussion 
 
Here we demonstrate that the circulating oestrogen regulates the function of sodium-
dependent glutamate transporters in female WKY rats. Cortical EAAT activity was upregulated 
in the diestrus stage of the oestrous cycle when compared with males, proestrus females and 
oestrus females. However, there was no such change in glutamate metabolism seen at the 
level of lumbosacral spinal cord. In males, aspartate uptake in the ACC and spinal cord was 
found to correlate positively with Bacteroides and Lachnospiraceae NK4A13,6, respectively. In 
females, positive associations with aspartate uptake in the spinal cord were observed for 
Alistipes and Bifidobacteruim during oestrus, as well as for the Eubacterium coprostanoligenes 
during proestrus. 
The lumbosacral spinal cord is an important part of the CNS in relation to processing 
of pain signals from most of the abdominal viscera. Afferents from the viscera play little role 
in the hormonal modulation of pain responses (Ji et al., 2012). A decreased expression of EAAT 
in the spinal cord of females WKY rats exposed to chronic stress has been shown to be 
associated with exaggerated pain responses (Ackerman et al., 2015). In our study, there was 
no change observed in the function of lumbosacral spinal EAATs, between the sexes and 
across oestrous cycle stages. This may suggest that in this animal strain, the hormonal state-
dependent function of EAATs may have more of a role in pain processing along the higher 
ascending pain pathways rather than lumbosacral cord. 
The ACC is an area of the brain that interconnects other key areas of the brain involved 
in cognition and behaviour such as frontal cortex, the thalamus, and the amygdala (Vogt, 
2005; Shackman et al., 2011). Clinical studies have demonstrated activation of ACC using 
imaging techniques in response to painful stimuli, suggesting its role in the pain processing 
(Fomberstein et al., 2013). The rostral part of ACC is particularly involved in the processing of 
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affective components of pain (Johansen et al., 2001) and increased expression of glutamate 
receptors in ACC has been observed in rats who are hypersensitive to visceral pain (Fan et al., 
2009b). As chronic pain and depression are closely related, various studies have investigated 
and elucidated the role of ACC in the development of depression (Pizzagalli, 2011). ACC 
volume reduction changes on MRI have been reported in depressed patients (Drevets et al., 
1998), and some studies have shown ablative procedures such as anterior cingulotomy to be 
effective in drug-resistant depressed patients (Shields et al., 2008). The reduction in the 
volume of ACC in depressed patients is believed to be caused by a decrease in glial density 
rather than neuronal tissue (Drevets et al., 1998; Rajkowska and Miguel-Hidalgo, 2007). Since 
glial cells participate in the uptake and recycling of glutamate, reduction in glial density seems 
to be accountable for the reported decreased glutamate levels in depressed patients (Taylor 
et al., 2009). In an animal model of depression, i.e., WKY rats, the glutamate receptors have 
been reported as either less functional or less in number (Lei et al., 2009). A decrease in 
functional connectivity of ACC has also been noted in other behavioural CNS disorders, such 
as autism (Zhou et al., 2016). Gut microbiota seems to influence the structure and functioning 
of ACC significantly. In germ-free (GF) mice, the volumes of ACC was seen to be reduced along 
with dendritic changes (Luczynski et al., 2017). Interestingly, feeding mice with Bacteroides 
Fragilis reversed the autism like behaviour in these mice (Li et al., 2017a). Our study showed 
that Bacteroides had a positive correlation with ACC glial aspartate uptake in males. 
Interestingly, this effect was sex-specific. Moreover, Lachnospiraceae had a positive 
correlation with lumbar spinal glial aspartate uptake in males. Lachnospiraceae and Alistipes 
abundance has been found to be reduced in animal models of major depressive disorder (Jiang 
et al., 2015; Li et al., 2017b). Intriguingly in our data, Bifidobacterium correlated positively 
with aspartate uptake in oestrus female rats. Probiotic Bifidobacterium longum has been 
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shown in animal models to reduce depression symptoms (Pinto-Sanchez et al., 2017). In 
summary, SCFA-producing bacteria, i.e. Bacteroides, Lachnospiraceae, and Bifidobacterium 
had a positive correlation on ACC and spinal cord in a sex-dependent manner. 
Oestrogen has a significant influence on the glutamate metabolism through the 
downregulation of EAATs via the nitric oxide pathway (Sato et al., 2003). The high-oestrogen 
state, i.e., proestrus showed a marked decreased activity of EAATs in ACC in our study, 
compared to diestrus and oestrus. SCFAs have been shown to enhance cellular oestrogen 
sensitivity through mitogen-activated protein kinase pathway (Jansen et al., 2004) and 
through this pathway, SCFAs-producing gut bacteria may have shown positive correlations 
with aspartate uptake in WKY rats that exhibit phenotypic features of depression with an 
altered ACC structure and function. 
Our data suggests that excitatory glial transport in the ACC is dependent on the 
oestrous cycle phase of the WKY female rats and gut microbiota may be an important 
modulating factor. As ACC is related to affective aspects of pain, our study suggests future 
preclinical and clinical trials evaluating pain associated behavioural traits in both sexes and 
across the oestrous/menstrual cycle in females, with an emphasis on gut microbiota analysis. 
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5.1 Abstract 
 Relative to men, women present with some chronic pain conditions more commonly. 
Consistent differences exist between healthy men and women in terms of pain perception. 
The underlying mechanisms of these differences are incompletely understood and could 
inform the development of effective treatments for pain. The gut microbiota can influence 
nervous system functioning, including sensory signalling. We hypothesised that the gut 
microbiota and components of the gut-brain axis may influence electrical pain thresholds. 
Further, we hypothesised that gender, menstrual cycle, and hormonal contraceptive use may 
account for inter-gender differences in pain perception. 
 Non-obese males (n=15) and females (n=16), of which nine were using hormonal 
contraceptives, were recruited. Male subjects were invited once, whereas females were 
invited three times across the menstrual cycle, based on self-reported early follicular (EF), late 
follicular (LF) and mid-luteal (ML) phase. On test days, electrical stimulation on the right ankle 
was performed. Cortisol levels were measured in morning saliva samples, levels of 
lipopolysaccharide-binding protein (LBP), soluble CD14 (sCD14) (only EF/ML), TNF-α, IL-8, and 
IFN-γ were measured in plasma and faecal microbiota-, and short-chain fatty acid (SCFA) 
composition was determined in the stools.   
 We observed that, in women but not in men, abundance of genus Anaerostipes (linked 
to butyrate formation) correlated positively with electrical pain sensation threshold (PST); a 
trend was also observed toward positive correlation between prevalence of genus 
Anaerostipes and pain tolerance threshold (PTT) (False discovery rate (FDR) <0.1), in women 
but not in men. Interestingly, PTT/PST was significantly lower in women than men, but not 
PST and PTT. Further, hormonal contraceptive use was associated with increased LBP levels 
(LF & ML phase), but not sCD14 and inflammation.  
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 Differential butyrate formation and absorption in healthy men and women may 
account for inter-gender differences in electrical pain perception. Further research is needed 
to investigate the potential of PTT/PST as a measure of inter-individual electrical pain 
tolerance differences, and to examine whether hormonal contraceptives increase LBP levels 
independently of gastrointestinal permeability. 
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5.2 Introduction  
 Chronic pain is a major healthcare challenge as it confers a substantial burden on 
individuals, employers, health care systems and society in general (Breivik et al., 2013). 
Understanding the mechanisms which regulate pain sensitivity is important for the 
development of new effective treatments. 
 Several chronic pain conditions are more prevalent among women than men. In 
general, laboratory tests demonstrate that women exhibit greater pain sensitivity compared 
with men (Mogil, 2012). Differences in pain perception (tolerance & threshold), between adult 
men and women, are greatest for electrical stimulation and pressure, whereas inter-gender 
differences in heat pain threshold are highly variable when assessing differences between 
men and women (Riley et al., 1998). Interestingly, in a meta-analysis including only healthy 
children, a greater number of studies demonstrated no significant inter-gender differences in 
pain perception; however, for those of age > 12 years, girls reported greater pain intensity in 
response to the cold pressor test compared to boys (Boerner et al., 2014). This suggests that 
the onset of puberty and the associated hormonal changes may contribute to pain gender bias 
in teenagers and possibly adults (Boerner et al., 2014). 
 Within each of our gastrointestinal tracts, a unique combination of different 
communities of organisms exists (O’Mahony, 2017). Microbes actively participate in shaping 
and maintaining our physiology-almost as an extra organ (Clarke et al., 2014). Furthermore, it 
is now accepted that important relationships exist between the gut microbiota, mood 
disorders, bowel disorders and neurodevelopmental disorders (e.g., autism) (Dinan and Cryan, 
2017b). Interactions between the gut microbiota and the brain are mediated through the 
immune system, the neuroendocrine system (e.g., tryptophan metabolism) and neural 
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pathways (vagus nerve) (Dinan and Cryan, 2017b). The nervous system is a master regulator 
of host function and, by signalling within this system, bacteria influence complex physiological 
processes. Gut bacteria are active producers of metabolites such as SCFAs, enabling the host 
nervous system to sample the chemical signature of gut bacterial communities. SCFAs such as 
acetate, propionate, and butyrate can act on intestinal epithelial cells through G protein-
coupled receptors 41, 43 and 109A, and also can directly or indirectly influence peripheral 
organs (Canfora et al., 2015; Morris et al., 2016). For example, at the intestinal level, dysbiosis 
and subsequent low levels of the important epithelial cell fuel, butyrate, can adversely affect 
intestinal barrier integrity and drive inflammatory diseases (Canfora et al., 2015; Morris et al., 
2016). 
 Microbial composition or activity of the gut can be modified by diet, antibiotics, host 
genetics, and stress (O'Mahony et al., 2017). Altered gut microbiota is also associated with 
changes to the intestinal permeability, low-grade inflammation and metabolic dysfunction 
(Cani et al., 2012). Microorganisms or components of microorganisms are able to activate 
macrophages and increase levels of pro-inflammatory cytokines, such as TNF-α. 
Administration of lipopolysaccharide (LPS), a cell wall component of Gram-negative bacteria 
increases several cytokines (TNF-α, interleukins (IL) 6, 8 and 10), cortisol and lowers pressure 
pain threshold (Wegner et al., 2014) and electrical pain threshold (de Goeij et al., 2013). 
Hence, increased systemic levels of bacterial components may initiate a reduction of pain 
thresholds and contribute to chronic pain through activation of inflammatory and stress 
pathways. 
 The microbiota and its manipulation have been associated with several types of pain 
including visceral pain (O'Mahony et al., 2014), inflammatory pain (Amaral et al., 2008), 
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migraine (van Hemert et al., 2014), interstitial cystitis (Braundmeier-Fleming et al., 2016), as 
well as autoimmune-related pain in rheumatoid arthritis (McLean et al., 2015). We have 
shown preclinically that manipulating the microbiota with antibiotics increases visceral pain 
(O'Mahony et al., 2014) and leads to changes in signalling pathways in the spinal cord 
(O'Mahony et al., 2014). Furthermore, we have shown that germ-free mice show a reduced 
pain tolerance to colorectal distension than conventionally colonised mice (Luczynski et al., 
2017). Sex differences are noted in the composition of the gut microbiota with clear effects of 
gonadectomy and hormone replacement on gut bacteria (Markle et al., 2013; Org et al., 2016). 
Whether the gut microbiota is involved in the aetiology of somatic pain disorders or gating 
somatic pain sensitivity and pain tolerance in healthy individuals is understudied. Sex-specific 
associations have been shown for pain symptoms in myalgic encephalomyelitis/chronic 
fatigue syndrome (ME/CFS) patients (Wallis et al., 2016). In male ME/CFS patients, 
Eubacterium was negatively correlated to pain symptoms, whereas Lactobacillus and 
Streptococcus were positively correlated to pain symptoms (Wallis et al., 2016). In contrast, 
Streptococcus was negatively correlated to pain symptoms in female ME/CFS patients (Wallis 
et al., 2016). 
 Whether specific microbiota taxa are related to pain thresholds at the visceral or 
somatic level in chronic pain patients, or pain disorder-free individuals remains to be 
investigated. Here, we examined gut microbiota abundance, cortisol awakening response, 
inflammatory factors and those associated with gut permeability in association with gender 
differences in electrical pain sensitivity in healthy adult volunteers. 
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5.3 Materials & methods  
 
5.3.1 Study Population  
 Students and employees of University College Cork were recruited and screened 
through a survey. The following inclusion criteria were used: 18 -35 years of age, regular 
menstrual cycle (28±4 days), no hormonal treatment during the past three months, and body 
mass index (BMI) <30 kg/m2. All subjects were screened through an online survey. Exclusion 
criteria were: current / recent (3 months) use of psychotropic drugs, beta-blockers or 
analgesic medication (24 h before measurements), neurological disease, diabetes mellitus and 
gastrointestinal disease (e.g., inflammatory bowel disease, inflammatory bowel syndrome). 
15 non-obese men and 16 non-obese women were included. Eight women used oral 
contraceptives, and one woman used a Nuova ring (etonogestrel / ethinyl oestradiol vaginal 
ring). Each was asked not to engage in strenuous physical activities, sleep regular hours and 
refrain from alcohol the day before the experiment. Smoking was not allowed for a period of 
2 h before the test session. This pilot study was approved by the local ethical committee of 
University College Cork (UCC) (CREC: ECM 3 granted on the 7th July 2015). 
 
 
Figure 5.1. Flowchart availability raw data and samples. stool, blood and saliva samples and neurophysiological 
assessments available for analysis. 
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 Of the recruited population, two females only visited twice (Figure 5.1). Raw 
data/samples of 59, 61, 50, 60 and 58 subjects were available for the analyses of 
neurophysiological assessments, faecal microbiota, faecal SCFAs, blood plasma markers, and 
salivary cortisol, respectively (Figure 5.1). Age, smoker’s status, native English language rate 
were evaluated through (online) questionnaires (Table 5.1). 
Table 5.1. Age, smoker’s status and native English language performance of the study population 
 
Data is presented as mean ± SEM. Abbreviations: HC = hormonal contraceptive users, nHC = non-hormonal 
contraceptive users  
 
5.3.2 Beck’s Depression Inventory  
 The Beck’s depression inventory (Beck et al., 1961) was completed by 21 subjects of 
whom 19 answered all questions. Only fully completed questionnaires were used for further 
analyses. 
5.3.3 Hospital Visits and Sample Collection 
 Male subjects were invited to attend at Cork University Hospital once, whereas 
females were invited to attend three times across a single menstrual cycle. A menstrual cycle 
diary was provided to record the menstruation onset of the current menstrual cycle. Self-
reported menstrual cycle days 2-7, 9-13, and 18-23 were defined as early follicular phase (EF), 
late follicular (LF) phase, and mid-luteal (ML) phase, respectively. During these visits, subjects 
brought saliva and stool samples, which were subsequently stored at -80 °C. Furthermore, an 
electrical stimulation test was performed, and blood samples were collected.   
Characteristic Male (n=15) Female HC (n=9) Female nHC (n=7) 
Age 23.5 ±1.1 22.8 ±1.3 26.1 ±1.8 
Smoker 3 (20%) 1 (11%) 1 (14%) 
Native English speaker 13 (87%) 6 (67%) 2 (29%) 
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5.3.4 Saliva Sample Collection  
 Subjects were asked to collect saliva samples upon awakening and 30, 45 and 60 
minutes after awakening in a salivette through chewing on a cotton swab for around 1.5 
minutes and transferring the bud from the mouth directly in the tube, without using 
hands/fingers. Next, they were instructed to place salivettes directly into a refrigerator, or into 
a plastic container with an ice pack prior to refrigerator placement. Additional notes included 
instructions not to brush teeth throughout the collection process, drink or eat anything prior 
to sample 1, between samples 2, 3 and 4, or 15 minutes prior to sample 2. 
5.3.5 Stool Sample Collection  
 Subjects were asked to collect stool samples as fresh as possible, ideally produced on 
the morning of the visit. If morning collection was not possible, they were asked to collect a 
sample from the evening/night before and store it in a cool place. Samples were collected in 
a plastic container with an anaerobic gas producing sachet (Thermo Fisher Scientific, 
Massachusetts, USA) Subjects were asked to store samples in a cool area prior to attendance 
at the Hospital.   
5.3.6 Neurophysiological Assessments  
 Quantitative sensory testing was performed by a trained clinician. The pain perception 
threshold to transcutaneous constant current electrical stimulation was assessed on subjects 
lying supine in a warm, quiet environment using Neuropack-S neuro-diagnostic stimulator 
with disposable surface electrodes (Natas Medical Instruments Inc, California, USA). Pain 
perception and pain tolerance thresholds were recorded during electrical stimulation; manual 
5 mA current increase (up to maximum 100 mA) using a standardised technique at the right 
ankle just below the medial malleolus. Stimuli were set at 1 Hz, duration 200 μs. If two 
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threshold values differed by > 10% between runs, testing was repeated until three consecutive 
thresholds were recorded, each within 10% of the others. Data for one subject could not be 
recovered, so data of 30 subjects instead of 31 were used for further analysis. 
5.3.7 Blood Sample Collection  
 Venous blood was collected in EDTA tubes by a single venepuncture from antecubital 
fossa after completion of the neurophysiology assessment. Blood samples were centrifuged, 
plasma was separated and stored at -80 °C.  
5.3.8 Faecal Microbiota Analysis  
 In order to acquire faecal microbiota data, faecal DNA was extracted, followed by 
Illumina MiSeq sequencing and bioinformatics analysis. 
 A 0.25 g aliquot of the faecal sample was added to 1 mL lysis buffer (500 mM NaCl, 50 
mM Tris-HCl, pH 8.0, 50 mM EDTA, and 4% sodium dodecyl sulfate) together with 0.4g of 
zirconia beads. The samples were homogenised for 3 minutes using the Biospec 
Minibeadbeater at maximum speed. The homogenised samples were then heated to 70°C for 
15 minutes and then centrifuged at 16,000 xg for 5 minutes. The supernatant was then 
removed, fresh lysis buffer added and the beadbeating, heating and centrifugation steps 
repeated. The nucleic acids were then precipitated using 10 M ammonium acetate, followed 
by addition of isopropanol. The nucleic acids were then pelleted, washed and resuspended in 
1X TE buffer. Subsequently, removal of RNA, protein, and purification of the DNA was 
completed using components of the QIAGEN QIAamp DNA Stool Mini kit along with the wash 
buffers and elution buffer, and DNA was stored at -20 °C.  
 The V3-V4 variable region of the 16S rRNA gene was amplified from the DNA extracts 
using the 16S metagenomic sequencing library protocol (Illumina). The DNA was amplified 
with primers specific to the V3-V4 region of the 16S rRNA gene which also incorporates the 
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Illumina overhang adaptor (Forward primer 5’ 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG; reverse primer 5’ 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC). Each PCR 
reaction contained DNA template, 5 µL forward primer (1 µM), 5 µL reverse primer (1 µM), 
12.5 µL 2X Kapa HiFi Hotstart ready mix (Anachem, Dublin, Ireland), PCR grade water to a final 
volume of 25 µl. PCR amplification was carried out as follows: heated lid 110°, 95 °C x 3 
minutes, 25 cycles of 95 °C x 30 s, 55 °C x 30 s, 72 °C x 30 s, then 72 °C x 5 mins and held at 4 
°C. PCR products were visualised using gel electrophoresis (1X TAE buffer, 1.5 % agarose, 100 
V). Successful PCR products were cleaned using AMPure XP magnetic bead based purification 
(Labplan, Dublin, Ireland). A second PCR reaction was completed on the purified DNA (5 µl) to 
index each of the samples, allowing samples to be pooled for sequencing on the one flow cell 
and subsequently demultiplexed for analysis. Two indexing primers (Illumina Nextera XT 
indexing primers, Illumina, Sweden) were used per sample. Each PCR reaction contained 5 µL 
index 1 primer (N7xx), 5 µL index 2 primer (S5xx), 25 µL 2x Kapa HiFi Hot Start Ready mix, 10 
µL PCR grade water. PCRs were completed as described above, but only 8 amplification cycles 
were completed instead of 25. PCR products were visualised using gel electrophoresis and 
subsequently cleaned (as described above). Samples were quantified using the Qubit™ 3.0 
Fluorometer (Biosciences, Dublin, Ireland) along with the high sensitivity DNA quantification 
assay kit. Samples were then pooled in an equimolar fashion. The sample pool was prepared 
following Illumina guidelines. Samples were sequenced on the MiSeq sequencing platform 
(Clinical Microbiomics, Denmark), using a 2 x 250 cycle kit, following standard Illumina 
sequencing protocols.    
 250 base pair paired-end reads were assembled using FLASH (FLASH: fast length 
adjustment of short reads to improve genome assemblies). Further processing of paired-end 
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reads including quality filtering based on a quality score of > 25 and removal of mismatched 
barcodes and sequences below length thresholds was completed using QIIME Version 1.9.0. 
Singleton removal (to ensure a minimum of 2 copies to be counted), denoising, chimera 
detection and clustering into OTUs (97% identity) were performed using USEARCH v7 (64-bit) 
(Edgar, 2010). OTUs were aligned using PyNAST (PyNAST: python nearest alignment space 
termination; a flexible tool for aligning sequences to a template alignment) and taxonomy was 
assigned using BLAST against the SILVA SSURef database release v123. Data were not 
rarefied/normalised for further analysis. Richness and α-diversity indices were generated in 
QIIME Version 1.9.0 (Caporaso et al., 2010).  
5.3.9 Faecal Short-chain Fatty Acid Analysis   
 Faecal supernatant and standards for SCFA analysis were prepared (protocol S1). In 
short, faecal samples were mixed with 5 mL milliQ/gram, acidified to pH ±2-3, spun and 
filtered (0.2 μm). The concentration of SCFA was determined by gas chromatography flame 
ionisation detection (GC-FID) using a Varian 3500 GC system, fitted with a ZB-FFAP column 
and a flame ionisation detector. Helium was supplied as the carrier gas at an initial flow rate 
of 1.3 mL/min. The initial oven temperature was 100 °C and was maintained for 0.5 min, and 
then raised to 180 °C at 8 °C/min and held for 1.0 min, before being increased to 200 °C at 20 
°C/min, and finally held at 200 °C for 5.0 min. The temperatures of the detector and the 
injection port were set at 250 °C and 240 °C, respectively. Samples were run in duplicate, and 
the injected sample volume was 0.5 μL. Blanks were measured in between different samples 
to ensure there was no potential carryover from previous samples. Peaks were integrated 
using Varian Star Chromatography Workstation version 6.0. Subsequently, peaks were 
quantified, and concentrations of acetate, propionate, isobutyrate, n-butyrate, isovalerate 
and valerate were calculated. Isobutyrate, isovalerate and valerate were excluded from 
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further analysis since some samples had concentrations < 0.1 mM (lowest standard) for these 
SCFA. Acetate concentrations greater than 10 mM (greatest standard) were not excluded. 
Duplicate samples with a %C.V. > 15% for acetate were repeated. One repeated duplicate had 
a %C.V. of 16% for acetate and was included. %C.V.s of all duplicates were < 15% and <1 0% 
for propionate and n-butyrate, respectively. A correction was made for the solution (milliQ 
and 5M HCl) that was added to the faeces and moles short-chain fatty acid/gram wet faeces 
were calculated. 
5.3.10 Biochemical Analyses of Proteins in Plasma 
 After thawing, plasma samples were used directly for analysis, or they were distributed 
in aliquots and frozen again. All plasma aliquots were spun at 1000 G for 10 min prior to 
analysis to remove excessive (gelatinous) masses. Duplicate oestradiol level measurements 
were performed in pretreated EDTA plasma samples (dilution factor, 1.6) using an oestradiol 
parameter assay kit (ELISA, R&D systems, Minneapolis, USA) according to manufacturer’s 
instructions. To determine oestradiol concentrations, a four-parameter logistic curve was 
generated from the standard dilution series (MyAssays Ltd). Values of one subject fell outside 
the standard curve and were excluded. Duplicates with calculated concentration intraplate 
coefficient variation (CV) > 15% were repeated.   
 Duplicate LBP and soluble cluster of differentiation 14 (sCD14) level measurements 
were performed in EDTA plasma samples (dilution factor 400, 300 respectively) using 
commercially available ELISAs for free human LBP (Enzo Life Sciences, New York, USA) and 
soluble CD14 (R&D systems, Minneapolis, USA). All procedures were carried out according to 
manufacturer’s instructions, except for the fact that a standard GEN5 pathlength correction 
(absorbance 977 nm, 900 nm) was included as an additional control (BioTek Synergy HT, 
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Vermont, USA). To determine LBP and sCD14 concentrations, a four-parameter logistic curve 
was generated from the standard dilution series (MyAssays Ltd). Duplicates of LBP with 
calculated concentration intraplate CV > 15% were repeated. Calculated concentration 
intraplate CV of duplicates of sCD14 were ≤10%. Plasma levels of pro-inflammatory cytokines 
interferon gamma (IFN-γ), IL-1β, IL-6, IL-8, and TNF-α were determined using a V-PLEX MULTI-
SPOT assay system (Mesoscale Discovery, Maryland, USA) according to manufacturer’s 
instructions. EDTA plasma samples (dilution factor, 1 or 2) were analysed in duplicate or 
triplicate. IL-1β and IL-6 data were excluded from further analysis since part of the sample 
concentrations were below standard curve range or detection range. Duplicates with 
calculated concentration intraplate CV > 10% for IFN-γ or TNF-α were repeated. Calculated 
concentration intraplate CV of included duplicates/triplicates were ≤ 10%, ≤ 10% and ≤ 15% 
for IFN-γ, IL-8, and TNF-α, respectively.  
5.3.11 Cortisol Awakening Response  
 Saliva samples were used directly for cortisol analysis after thawing. All samples were 
spun at 1000 G for 10 min prior to analysis to remove excessive (gelatinous) masses. Duplicate 
cortisol level measurements were performed in saliva samples (dilution factor, 2 or 3) using a 
cortisol ELISA kit (Enzo Life Sciences, New York, USA). All procedures were done according to 
manufacturer’s instructions, except for the fact that a standard GEN5 pathlength correction 
(absorbance 977 nm, 900 nm) was included as an additional control (BioTek Synergy HT, 
Vermont, USA) and a standard concentration of 0 pg/mL was included. A logistic curve was 
generated from the standard dilution series (GEN5), and concentrations were calculated. For 
validity testing purposes, the concentration of several samples was measured on three 
different plates. Values of the last plate were used for further analyses, except for 1 duplicate 
for which practical mistakes were noted. If sample values fell outside the standard curve 
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range, these were repeated in a lower or higher dilution (dilution factor, 1 or 5). If at least one 
value of an undiluted measurement was below the standard curve range, or a sample was not 
available, this resulted in exclusion of the total cortisol awakening response. If calculated 
intraplate CV for samples was higher than 20%, these were repeated. Area under the curve 
(AUC) of the cortisol awakening response was calculated by the following formula: 
 
 Since cortisol awakening response data appeared to be highly vulnerable for variation, 
Grubbs’ tests were performed for the seven groups (males, females using contraceptives (3 
phases) and normally menstruating females (3 phases)) to define outliers. If a Grubbs’ value 
was higher than the critical value (α=0.05, two-sided) for 1. cortisol concentration of one of 
the four timepoints, 2. cortisol %increase over the first 30 minutes or 3. AUC, this resulted in 
the exclusion of the total cortisol awakening response. For validity determination purposes, 
cortisol concentration of samples was determined on 3 different plates as described in the 
previous section. Samples with a calculated intraplate C.V. > 20% or sample analyses of which 
practical mistakes were noted were excluded from further analysis. Interplate C.V. was 
calculated for 33 samples.   
5.3.12 Statistical Analyses 
 Kruskal-Wallis and Friedman tests with Dunn’s post-hoc test were performed to 
determine differences between groups or within groups using GraphPad Prism 5. Comparisons 
with a p-value ≤ 0.05 were considered as statistically significant different. For statistical 
analysis of microbiota relative abundance, Kruskal-Wallis tests were performed using R-studio 
and Friedman tests were performed using SPSS version 21. FDR-adjusted p-values were 
calculated for all taxa (phylum, family, genus) that were observed for a certain comparison. 
AUC=30*([cort]t=0min+[cort]t=30min)/2+15*([cort]t=30min+[cort]t=45min)/2+15*([cort]t=45min+[cort]t=60min)/2 
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For FDR adjustments, only data of a specific group comparison was taken into account. For 
example, FDR adjustments were made for Kruskal-Wallis tests that were run for seven groups 
(1males, female contraceptive users (2EF, 3LF, 4ML), and normally menstruating females (5EF, 
6LF, 7ML), thereby not taking into account comparisons of another Kruskal-Wallis test run for 
four groups (1males, total females (2EF, 3LF, 4ML). An FDR-adjusted p-value < 0.1 was 
considered acceptable for Dunn’s post-hoc testing using GraphPad Prism 5. For the Dunn’s 
post-hoc test, comparisons with p-values ≤ 0.05 were considered as statistically significant 
different.   
 Spearman’s rank correlations of bacterial genera and other parameters (data of faecal 
SCFAs, intestinal integrity markers, inflammatory markers, oestradiol, and cortisol) were 
performed in R-Studio. Two fungal families were removed from the data set. FDR-adjusted p-
values were calculated for all correlations that yielded a correlation coefficient. Correlation 
coefficients and FDR-adjusted p-values were calculated separately for “males only” and 
“females only.”  
 Correlations between all parameters (except the microbiota) were performed in the 
same way as the genera correlations described above. 
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5.4 Results 
5.4.1 Age-matched, Non-obese Normally Menstruating Females Score Higher for 
Beck’s Perceived Stress Scale Than Men.  
 We demonstrated that Beck’s depression inventory score was significantly greater in 
normally menstruating females compared to males, whereas a “trend” toward a greater 
Beck’s score was observed for female contraceptive users compared to males (Supplementary 
Figure 1). However, it should be noted that for our study the mean score of female responders 
(8.9) can be linked to a relatively stable mood, since scores >20 indicate moderate+ depression 
and scores lower than 10 represent ‘normal’ mood fluctuations.   
5.4.2 Oestradiol Status 
 To confirm oestradiol differences between males and females and differences across 
the menstrual cycles, total oestradiol levels were measured in plasma. Contrary to 
expectations, no significant differences were observed between males and females 
(Supplementary Figure 2). R&D reports in their oestradiol manual a mean 31.7% difference 
between reference values of (apparently healthy) males and females (EDTA plasma samples). 
In this study, we observed a non-significant 26.7% difference between female and male 
samples. Further, we identified a considerable overlap in oestradiol plasma concentrations 
between males and females (consistent with the reference data provided by R&D). Our data 
did not demonstrate significant differences across the phases of the menstrual cycle 
(Supplementary Figure 2). Our specific interest was to include a phase with high levels of 
oestradiol levels. 
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5.4.3 Electrocutaneous Pain Assessment 
 Across the menstrual cycle, we did not observe significant PST and PTT differences in 
females using hormonal contraceptives and non-users (Figure 5.2). There was no significant 
difference in PST and PTT between males and females (Supplementary Figure 3). 
 
Figure 5.2. Pain tolerance thresholds & pain sensation thresholds did not vary significantly along menstrual 
cycle. There was no significant difference seen in PTT and PST along menstrual cycle stages in both hormonal 
and non-hormonal contraception female groups. Similarly, no differences were seen between males and females 
(data not shown).  
Abbreviations: EF = early follicular phase, LF = late follicular phase, ML = mid-luteal phase. 
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When we investigated the ratio of PTT/PST, we demonstrated significantly lower 
PTT/PST ratios in females in all phases of the menstrual cycle (EF, ML: p ≤ 0.01, LF: p ≤ 0.05) 
compared to males (Figure 5.3A). In categorising women as contraceptive users or non-users, 
significantly lesser PTT/PST ratios were demonstrated only for the EF phase of contraceptive 
users (p ≤ 0.05) and the ML phase of non-users (p≤0.05) (Figure 5.3B). 
 
Figure 5.3. The ratio electrocutaneous pain tolerance threshold/pain sensation threshold is lower in women 
than men. Ratio PTT/PST was determined in males, female contraceptive users and normally menstruating 
females. Kruskal-Wallis test and Friedman test with Dunn’s post-hoc test were performed to assess differences 
between selected groups, and differences across the menstrual cycle. **p ≤ 0.01, *p ≤ 0.05  
Abbreviations: EF = early follicular phase, LF = late follicular phase, ML = mid-luteal phase. 
5.4.4 Microbiota Composition 
 To evaluate whether gender, menstrual cycle or hormonal contraceptive use was 
associated with microbiota composition, richness/α-diversity indices and relative abundance 
of microbiota were determined. The number of reads and OTUs per sample were variable, 
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Table 5.2. Quality parameters microbiota data 
 Mean ± SEM Lowest value Highest value 
Number of reads 67,199 ± 3,424 15,734 146,997 
Joining efficiency 94.03 ± 0.25 86.40 97.35 
Number of merged paired-ends reads 49,675 ± 2,547 12,899 110,628 
Number of OTUs 43,718 ± 2,272 12,274 97,637 
Number of reads, joining efficiency, number of merged paired-ends reads and number of operational 
taxonomical units (n=61). 
5.4.4.1 Alpha diversity 
 We investigated potential differences in Chao1, number of observed species, 
Shannon’s diversity, Simpson’s diversity, and Phylogenetic diversity. No differences were 
observed for these α-diversity indices between men and women (contraceptive use y/n) and 
across the menstrual cycle (Table 5.3). 
Table 5.3. Gender, menstrual cycle phase, and hormonal contraceptive use did not influence microbiota 
richness and diversity indices 
 Males  Females HC Females nHC 




















































































Data is presented as a mean ± standard error of the mean (SEM). Kruskal-Wallis test and Friedman test with 
Dunn’s post-hoc test were performed to assess differences between selected groups, and differences across the 
menstrual cycle. Abbreviations: HC = hormonal contraceptive users, nHC = non-hormonal contraceptive users, 
BMI = body mass index, EF = early follicular phase, LF = late follicular phase, ML = mid-luteal phase.  
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5.4.4.2 Relative abundance of gut microbiota 
 When evaluating differences in relative abundance group distributions for phylum 
(Figure 5.4), family (Figure 5.5), and genus, significant differences were observed for five taxa 
when comparing males and females (3 phases) (Table 5.4). For relative abundance group 
distribution comparisons of males and females (contraceptive use y/n, 3 phases), significant 
differences were observed for another 14 taxa (Supplementary Table 1). Across the menstrual 
cycle of all females, significant differences were shown for 14 taxa (Supplementary Table 2). 
Across the menstrual cycle of contraceptive users and normally menstruating females, 
significant differences were demonstrated for 10 and 5 taxa, respectively (Supplementary 
Tables 3 & 4). However, only for genus Erysipelatoclostridium a FDR lower than 10% was 
demonstrated; hormonal contraceptive use was associated with an increased relative 
abundance of Erysipelatoclostridium, at least for the late follicular phase (Supplementary 
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Figure 5.4. Gender, menstrual cycle, and hormonal contraceptive use did not influence phylum relative 
abundance. Only phyla with a relative abundance ≥1% are visualised as independent taxa. Other phyla are listed 
under ‘other’. 
Abbreviations: HC= hormonal contraceptive users, nHC = non-hormonal contraceptive users, EF = early follicular 













   
   
Figure 5.5. Gender, menstrual cycle, and hormonal contraceptive use did not influence family relative 
abundance. Only families with a relative abundance ≥1% are visualised as independent taxa. Other families are 
listed under ‘other.’ 
Abbreviations: HC= hormonal contraceptive users, nHC = non-hormonal contraceptive users, EF = early follicular 
phase, LF = late follicular phase, ML = mid-luteal phase. 
 
































F HC LF F HC ML 
F nHC 
 
F nHC LF F nHC 
 
  136 
 
 
Figure 5.6. Hormonal contraceptive use is associated with an increased relative abundance of the 
Erysipelatoclostridium. Relative abundance of Erysipelatoclostridium in faecal contents of males, and females 
(using hormonal contraceptives y/n) across the menstrual cycle. Kruskal-Wallis test and Friedman test with 
Dunn’s post-hoc test were performed to assess differences between selected groups., p ≤ 0.1 & #: compared to 
hormonal contraceptive users (same phase). ##p ≤ 0.01. 
Abbreviations: EF = early follicular phase, LF = late follicular phase, ML = mid-luteal phase. 
5.4.5 Short-chain Fatty Acid Content 
 We observed no association of these factors with faecal acetate, propionate and n-
butyrate levels (Figure 5.7 & Table 5.5). This is in line with our finding that gender, menstrual 
cycle, and hormonal contraceptive use did not influence microbiota composition, except for 
the relative abundance of Erysipelatoclostridium that was associated with hormonal 
contraceptive use. 
 
Figure 5.7. Gender, menstrual cycle, and hormonal contraceptive use did not influence SCFA levels in faecal 
wet mass. SCFA content (sum of acetate, propionate and n-butyrate) in the faecal wet mass of males, and 
females across the menstrual cycle. Kruskal-Wallis test and Friedman test with Dunn’s post-hoc test were 
performed to assess differences between selected groups. 
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 Additionally, to our knowledge, no other studies have found differences in faecal SCFA 
levels between “healthy” males and females, across the menstrual cycle or differences 
associated with hormonal contraceptive use. 
Table 5.5. Gender, menstrual cycle, and hormonal contraceptive use did not influence acetate, propionate and 
n-butyrate levels in faecal wet mass 
 Males  Females HC Females nHC 































































Data is presented as mean ±SEM SCFA content in faeces (wet mass) of males, and females (using hormonal 
contraceptives y/n) across the menstrual cycle. Kruskal-Wallis test and Friedman test with Dunn’s post-hoc test 
were performed to assess differences between selected groups. Abbreviations: EF = early follicular phase, LF = 
late follicular phase, ML = mid-luteal phase.  
 
5.4.6 Hormonal Contraceptive Use Is Associated with Increased Levels of LBP, But 
Not Soluble CD14 and Inflammation  
 Levels of indirect intestinal integrity marker LBP were determined in plasma. LBP levels 
of females using hormonal contraceptives were greater compared to those of males (p≤0.01) 
and female non-users (LF: p ≤ 0.05, ML: p ≤ 0.01), except for the EF phase (Figure 5.8). Since it 
normally takes ±1-3 days to initiate a period after ingestion of the last pill of the contraceptive 
pill strip, and phases are based on self-reported menstrual cycle start date, we speculate that 
the two contraceptive pill users with high LBP levels during the EF already started ingesting 
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contraceptive pills of their new strip, which thereby may have caused the high LBP levels 
compared to the other five contraceptive pill users with relatively low LBP levels. 
Another indirect intestinal integrity marker, sCD14, were determined in the EF phase and ML 
phase of contraceptive users and non-users. For this marker, no differences were observed 
between the groups and phases (Figure 5.9). 
 
 
Figure 5.8. Hormonal contraceptive use is associated with increased systemic LBP levels. Plasma LBP 
concentrations of males, and females (using hormonal contraceptives y/n) across the menstrual cycle. Kruskal-
Wallis test and Friedman test with Dunn’s post-hoc test were performed to assess differences between selected 
groups. *compared to males, #compared to hormonal contraceptive users (same phase). *p ≤ 0.05, **p ≤ 0.01
  
Abbreviations: EF = early follicular phase, LF = late follicular phase, ML = mid-luteal phase, LBP = 
lipopolysaccharide-binding protein. 
 










Figure 5.9. Hormonal contraceptive use does not affect systemic sCD14 levels. No differences in sCD14 were 
observed between the early follicular phase and the mid-luteal phase, and between contraceptive users and 
normally menstruating females plasma sCD14 concentrations of females (using hormonal contraceptives y/n) in 
the EF and ML phase. Kruskal-Wallis test and Friedman test with Dunn’s post-hoc test were performed to assess 
differences between selected groups. Abbreviations: EF = early follicular phase, ML = mid-luteal phase, sCD14 = 
soluble cluster of differentiation 14. 
 
 To investigate whether gender, menstrual cycle or hormonal contraceptive use 
influenced the inflammatory state, plasma levels of TNF-α, IFN-γ and IL-8 were determined. In 
this study, we did not observe any differences in plasma TNF-α, IL-8 or IFN-γ between males 
and females, across the menstrual cycle or an association with hormonal contraceptive use 
(Figure 5.10A-C). However, in the EF phase of hormonal contraceptive users, we found a slight, 
but significant increase in IL-8 compared to the LF and ML phase, that may not be biologically 
relevant (Figure 5.10D). 




Figure 5.10. IL-8 levels were higher in the early follicular phase compared to the late follicular phase and mid-
luteal phase in hormonal contraceptive users. Plasma TNF-α (A), IFN-γ (B) and IL-8 (C & D) concentrations of 
males, and females (using hormonal contraceptives y/n) during the EF, LF, ML phase. Kruskal-Wallis test and 
Friedman test with Dunn’s post-hoc test were performed to assess differences between selected groups. 
*p≤0.05. 
Abbreviations: EF = early follicular phase, ML = mid-luteal phase, TNF-α = tumour necrosis factor α, IFN-γ = 
interferon γ, IL-8 = interleukin 8.  
 
5.4.7 Gender, Menstrual Cycle, and Hormonal Contraceptive Use Did Not Influence 
Cortisol Awakening Response 
 When looking at the CAR profile of all included subjects and timepoints (n=51), we 
observed a significant increase of salivary cortisol levels 30 minutes after awakening 
compared to levels at awakening (Figure 5.11). At 60 minutes after awakening, a significant 
decrease in cortisol levels was demonstrated compared to the peak (30 minutes) (Figure 5.11). 
This profile was not observed in the separate groups, except for the early follicular phase of 
females using hormonal contraceptives (Table 5.6). In addition, no significant differences were 
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2) cortisol increase during the first 30 minutes after awakening and 3) cortisol output during 
the first hour after awakening (AUC) (Table 5.6). Of special interest, for the late follicular phase 
of normally menstruating females, a mean negative cortisol awakening response was 
observed (Table 5.6). We also observed relatively high variation in mean cortisol levels at 
awakening and cortisol increase across the menstrual cycle (measurements on three different 




Figure 5.11. Mean cortisol levels during the awakening response of the study population. Salivary cortisol levels 
upon awakening (t=0 min) and 30, 45 and 60 minutes after awakening. 51 cortisol awakening responses were 
included. Friedman test with Dunn’s post-hoc test was performed to assess differences between selected 
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Table 5.6. Gender, menstrual cycle, and hormonal contraceptive use did not influence cortisol awakening 
response 
Cortisol level (pg/ml) Males  Females HC Females nHC 
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Negative response (%) 30 0 13 50 14 75 29 
Salivary cortisol levels upon awakening, 30, 45 and 60 minutes after awakening, %salivary cortisol increase during 
the first 30 minutes after awakening, cortisol awakening response AUC and %negative cortisol awakening 
responses. Friedman tests with Dunn’s post-hoc test were performed to assess differences between selected 
timepoints within a group. Kruskal-Wallis and Friedman tests with Dunn’s post-hoc test were performed to assess 
differences between selected groups *compared to t=0min, #compared to t=30min, *p≤0.05. Abbreviations-HC 
= hormonal contraceptive users, nHC = non-hormonal contraceptive users, EF = early follicular phase, LF = late 
follicular phase, ML = mid-luteal phase. 
 
 Another factor that we further investigated was the interplate variation of the cortisol 
assays used since cortisol analyses were determined over several different plates (only 96 
spots per plate available). Mean %CV was 12.8 for 33 included samples that were run on 3 
different plates. This is in line with the high %CV (13.4, 7.8) that the manufacturer reports for 
samples with cortisol levels of 451pg/ml and 969pg/ml, respectively. Strikingly, the 12.8% 
variation was an average, and observed interplate variation ranged from 3.9% to 33.0%. Taken 
together, relatively low sample size, high variability of the CAR, high variation of the cortisol 
assay, and potential non-compliance have a complicated demonstration of differences in HPA 
axis functioning between the groups.   
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5.4.8 Relative Abundance of Specific Genera Correlate Positively with Propionate, 
SCD14, TNF-α and Pain Sensation Threshold 
 Our secondary outcomes included investigating if associations existed between the gut 
microbiota, SCFA composition, indirect intestinal integrity markers, inflammation, HPA axis 
functioning and electrical pain thresholds in men and women.   
Here, we focused specifically on the relative abundance of genera that correlated with other 
parameters in men or women. We did not find any significant (FDR-corrected) correlations for 
men only (Supplementary Table 5 & Supplementary Figure 4). This is likely caused by the low 
sample size for men (n=15). For women (n=46 visits), we found several significant correlations 
between genus abundance and the other parameters (Supplementary Table 6 & 
Supplementary Figure 4). After filtering out low abundant/low prevalent genera (since these 
are probably not/less relevant), five remained (Figure 5.11). 
Figure 5.11. Overview of high prevalent/abundant genera that correlated with investigated parameters 
Spearman correlation coefficients expressed in colours, positive (red), negative (blue). *FDR-corrected p-value 
<0.05, **FDR-corrected p-value <0.01 FDR were calculated separately for men and women.   
Abbreviations: f=females, m=males, sCD14= soluble CD14, PST=pain sensation threshold, PTT=pain tolerance 
threshold 
 We did not find a significant correlation between Anaerostipes and faecal butyrate. 
Interestingly, we demonstrated a positive correlation between genus Anaerostipes and PST in 
females (correlation coefficient: 0.55, FDR-corrected p-value: 0.03). For PTT a trend for a 
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significant correlation with Anaerostipes was observed (correlation coefficient 0.49, FDR-
corrected p-value <0.1). In males, the correlation coefficients for correlations between 
Anaerostipes and PST and Anaerostipes and PTT were respectively, 0.35 and 0.02. Other 
genera that correlated with some of our parameters were Ruminiclostridium, Coprococcus 1, 
Rumminococcus Gauvreauii and Eubacterium hallii; the first two correlated positively to 
plasma sCD14, Rumminococcus Gauvreauii with TNF-α and Eubacterium hallii with propionate 
(Figure 5.11 & Supplementary Table 6). Next, we investigated potential associations between 
SCFAs data, cortisol awakening response data, oestradiol, LBP, sCD14 and inflammatory 
markers data, and pain data for males and females apart (Figure 5.12A, B & Supplementary 
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      Males   
Figure 5.12. Correlation plots of females (A) and males (B) Spearman correlation coefficients 
expressed in colors, positive (red), negative (blue). *FDR-corrected p-value <0.05, **FDR-corrected p-
value <0.01 FDR were calculated separately for men and women.   
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5.5 Discussion 
 In this study, we identified compositional alteration of the gut metagenome that may 
be related to altered pain sensitivity. Interestingly, we found a positive correlation between 
butyrate producing bacteria and pain sensitivity. We observed that in female participants only, 
an abundance of genus Anaerostipes correlated positively with PST. Although PTT and PST 
were not any different individually between the sexes, the ratio of PTT to PST was significantly 
low in women compared to men. Additionally, hormonal contraceptive use was associated 
with increased LBP levels. 
 Most of the pain models on humans measure either pain threshold or pain tolerance 
as a measure of experimental pain responses (Lund et al., 2005; Hegarty and Shorten, 2012; 
Nakashima et al., 2015). Although reliable, there is a presence of interpersonal variability 
within a group, mostly because the measurements are very subjective, purely relying on 
subject self-reporting. The neurophysiological pain stimulation has some advantages over the 
other forms such as thermal or mechanical pain. The electrical stimulations can be pre-
programmed, and measurement are not influenced by the observer’s bias. Moreover, if 
stimulations are applied over a motor nerve such as tibial nerve, the movement of 
corresponding muscle on stimulation may correlate directly with PST. A major shortcoming of 
electrical stimulations is that it bypasses the pain receptors and activates the nerve fibres 
directly and therefore, it does not cause a specific nociceptor activation (Reddy et al., 2012). 
In our study, there was no significant difference observed in PST or PTT between males and 
females. In addition, the menstrual cycle did not seem to have any effect on the pain 
responses. This can be partly due to a smaller number of participants in non-hormonal 
contraception group, or due to the fact that our method of menstrual cycle phase 
determination was based on self-reporting. However, one interesting observation was that 
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the ratio of PTT to PST was significantly low in women, which signifies decreased tolerance to 
repeated painful stimuli in women. The significance of this ratio has not been studied 
previously, therefore, leads to a future direction of further research work taking into account 
the PTT/PST ratio for pain assessments. 
In our experiments, women with a higher abundance of butyrate producing gut 
bacteria had high pain tolerance. The production of SCFAs, e.g. butyrate, propionate in the 
gut is dependent upon the diet, gut transit time and the composition of the colonic microbial 
flora. Butyrate beneficially affects inflammatory processes such as cytokine release and 
myeloperoxidase activity (Ogawa et al., 2003). It also supports mucosal barrier function, 
hence, decreases colonic epithelial permeability (Yan and Ajuwon, 2017). Despite all these 
benefits, the role of butyrate in visceral pain is controversial. Butyrate administration has been 
shown to induce colonic hypersensitivity in Sprague-Dawley rats (Bourdu et al., 2005). In 
contrast, an animal study on neuropathic pain found butyrate administration to be very 
beneficial (Kukkar et al., 2014). A human study observed intraluminal injections of butyrate 
into the bowel to decrease visceral pain perception in healthy subjects (Vanhoutvin et al., 
2009). The known mechanisms through which butyrate may modulate pain include 
serotonergic modulation, activation of transient receptor potential vanilloid 1 (TRPV1) 
receptor, and desensitisation of sensory neurons expressing TRPV1 receptors (Fukumoto et 
al., 2003; Kannampalli et al., 2011). SCFAs have the ability to inhibit histone deacetylases, 
which may be responsible for their behavioural effect (Mátis et al., 2013). Our somatic pain 
study showing a positive correlation between pain sensitivity and butyrate producing 
Anaerostipes abundance, supports the finding of this human visceral pain study mentioned. 
Interestingly, we observed relevant findings in women only. Since no microbiota intervention 
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was performed on our participants, an interaction between the neuroendocrine system and 
gut microbiota may be accountable for the findings we observed. 
Recent reviews suggest that gut microbiota may influence neuroendocrine function 
through direct production of neuroendocrine metabolites and indirectly as a modulator of 
inflammatory and immune responses (Cussotto et al., 2018). Gut microbiota have the ability 
to produce different neurotransmitters such as dopamine, noradrenaline, and GABA 
(Roshchina, 2016). LPS, a product of Gram-negative bacteria, has the ability to cross intestinal 
barrier and can activate TLR4 and HPA axis in CNS (Maes et al., 2008). The gut microbiota 
mediate the production of immune mediators such as TNF-α, IL-1β, and IL-6 which in turn, 
reach the brain and stimulate the HPA axis (Schirmer et al., 2016). Moreover, the gut 
microbiota is able to directly influence the production of glucocorticoid hormones (Mukherji 
et al., 2013). Sudo et al., have shown that germ-free (GF) mice exhibit altered HPA axis 
function, with elevated levels of plasma ACTH and corticosterone when compared to specific-
pathogen free (SPF) mice. GF mice also had reduced BDNF expression levels in the cortex and 
hippocampus when compared to SPF mice (Sudo et al., 2004). Several other studies have 
confirmed that GF animals have high levels of ACTH and corticosterone following a stressful 
stimulus (Clarke et al., 2013; Crumeyrolle-Arias et al., 2014). SCFA-producing gut microbiota 
can directly influence oestrogen function by modulating its cellular sensitivity through 
mitogen-activated protein kinase pathway (Jansen et al., 2004). 
Since HPA axis is closely related to sex hormones, these studies suggest a plausible 
relationship between HPA, sex hormones, and gut microbiota leading to differential pain 
responses in men and women. Further research on a larger scale is, however, required to 
completely understand these mechanisms and to develop therapeutic interventions. 
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6.1 Overview and Summary 
 The goal of the thesis is to explore the factors responsible for sex differences in 
pain. The particular focus was to see the effect of endogenous cyclical changes in 
oestrogen levels, stress and gut microbiota on EAAT functioning and pain sensation. To 
achieve this goal, we optimised an aspartate assay utilising radiolabelling on spinal cord 
and ACC. This assay has previously been used on brain slices but was optimised to be used 
in the spinal cord of rats for the first time. The validity of aspartate assay was confirmed 
with the use of an EAAT function enhancer and a blocker. To ascertain the effect of stress, 
well established animal models of early-life stress (maternally separated rats) and 
depression (Wistar-Kyoto rats) were utilised. In an attempt to translate the results of 
animal experiments onto humans, a multifactorial experimental pain study was 
performed on healthy men and women during different menstrual cycles phases. In the 
human study, our particular focus was to see if the difference in gut microbiota can 
influence the pain sensation. 
 Our first aim was to determine whether the EAAT function in the lumbosacral spinal 
cord changed in different stages of the oestrous cycle, where a particular oestrous phase 
would indicate a specific sex hormonal status. We carried out ex-vivo studies on rat spinal 
cord to achieve our goals (Chapter 2). We were able to demonstrate that the function of EAAT 
was dependent upon the oestrous phase. Hight oestrogen states, i.e., proestrus and oestrus 
were associated with downregulated EAAT function. Exogenous oestrogen showed a similar 
effect on male rat spinal cord glutamate metabolism. 
 Furthermore, with the utilisation of the PCR, we were able to demonstrate that there 
was a higher expression of oestrogen receptor ER-α during high-oestrogen states, and so was 
the expression of glutamate receptors subunit NR1. These findings suggest a positive 
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modulatory effect of oestrogen on glutamatergic signalling such that the endogenous 
oestrogen would enhance glutamate receptors expression and decrease glutamate uptake; 
thus, promoting a higher synaptic glutamate concentration and activity. These results denote 
an association of glutamate uptake and oestrogen levels, which in the context of pain 
sensitivity would suggest that in high-oestrogen states, the rats would be more sensitive to 
pain. 
 Based on our first aim and its results, our second aim was to look at the synaptic 
glutamatergic uptake in different oestrogen states and correlate it directly with the pain 
sensitivity in stress states (Chapter 2 & 3). We achieved this by performing colorectal 
distension (an established method to assess visceral pain) on maternally separated rats (an 
established model of earl life stress (ELS)). On a second cohort of the same rat model of ELS, 
we performed aspartate uptake assay and made a direct correlation between stress, 
hormones and the neurotransmission in pain states. Since anterior cingulate cortex (ACC) 
plays an important role in affective pain responses, we performed aspartate assay in both 
spinal cord and ACC. We were able to show that the visceral pain sensitivity corresponded 
with the EAAT function, as pain responses were considerably high in proestrus and oestrus 
phases. Furthermore, excitatory amino acid transport, both within the lumbosacral spinal cord 
and the ACC, were also altered in response to stress and oestrous cycle, thus indicating that 
aberrant excitatory transport may in part lead to fluctuations in visceral sensitivity. 
 After determining the effects of ELS on glutamatergic metabolism and visceral 
sensitivity, our goal was to see the if a similar effect can be confirmed on another animal stress 
model. We achieved this goal by utilising Wistar-Kyoto (WKY) rats which are an accepted 
model of depression and visceral hypersensitivity. We determined that the circulating 
oestrogen regulates the function of sodium-dependent glutamate transporters in female WKY 
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rats. Cortical EAAT activity was upregulated in the diestrus stage of the oestrous cycle as 
compared to males and females in proestrus and oestrus. However, there was no such change 
observed in glutamate metabolism seen at the level of the lumbosacral spinal cord. The 
aspartate uptake correlated positively with SCFA-producing gut bacteria in sex and hormonal 
state-dependent manner. These results highlight how chronic stress and early-life stress can 
lead to increased pain sensitivity and change the glutamatergic signalling in varying oestrogen 
environment. As chronic stress leads to dysfunction of normal HPA axis, the interaction of 
stress in these animals with oestrogen and gut microbiota may be accountable for these 
altered pain responses and glutamate metabolism through the altered HPA axis. 
 Finally, we performed neurophysiological electrical stimulation at the ankle in healthy 
humans to evaluate pain responses. We aimed to explore the sex differences in pain sensitivity 
in humans and various factors influencing it (Chapter 5). As microbiota-gut-brain axis has been 
shown to influence a number of CNS disorders, and there is emerging evidence of its role in 
pain processing in preclinical studies, we particularly focused on gut microbiota and its 
associated mechanisms influencing pain sensitivity. We achieved this goal by recruiting 
healthy non-obese young adults of both sexes. We utilised electrical stimulation along the 
tibial nerve and assessed pain sensory thresholds (PST) and pain tolerance thresholds (PTT) in 
men and women across their menstrual cycle. We could not see any significant difference in 
either PST or PTT between men and women, and among women in their different phases of 
the menstrual cycle. However, the PTT/PST ratio, indicating decrease tolerance to repeated 
painful stimuli, was significantly low in women in comparison to men. Interestingly, we noted 
a positive correlation between Anaerostipes and pain sensitivity in women. Use of hormonal 
contraception seemed to be associated with higher lipopolysaccharide-binding protein (LBP), 
a marker of gut mucosal wall integrity. 
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6.2 Can Preclinical Experimental Findings of Hormonal Modulation of Pain be 
Translated to Humans? 
 
 It is very important to determine the translatability of findings of animal studies to 
humans. In the context of oestrogen, the distribution patterns of ER mRNA are similar in the 
brains of most of the mammals (Heldring et al., 2007; Vanderhorst et al., 2009). Furthermore, 
ER-α distribution patterns in the brain stem and spinal cord of primates are identical to that 
of rodents. There is also molecular similarity seen in the ERs between species (Vanderhorst et 
al., 2009). 
 On the other hand, the physiological outcome of ER activation varies, probably 
because the binding characteristics of transcription factors may vary considerably (Odom et 
al., 2007). Direct comparison between rodent oestrous cycle and the human menstrual cycle 
is also not straightforward. The human hormonal cycle is a lot more complex process 
comprising of distinct ovarian and uterine cycles correlating with each other. The length of the 
human menstrual cycle is very variable among different individuals and can be affected by a 
number of modifiable factors (Liu et al., 2004). Similarly, the experiment setup on rodents can 
easily dysregulate the oestrous cycle. Although the ovariectomy can significantly reduce the 
oestrogen levels in rodents, the extragonadal production of oestrogen and release from 
storage in fatty areas continue to occur and may affect the pain-related sensory 
neurotransmission (Alagwu and Nneli, 2005). Ovariectomy affects the interactions of 
oestrogen with the HPA axis, and an altered HPA axis may further confound the experimental 
results. Notably, the absence of the direct cortical interoceptive representation and the direct 
medial motivational pathway in subprimates implies that they cannot experience feelings 
from the body in the same way that primates do, particularly pain (Craig, 2003). 
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 Although the experimental animal data may not translate entirely to humans, various 
animal models used today are providing vital information in the understanding of the 
pathogenesis of a number of diseases. Since rodents’ genome is very similar to the human 
genome, genetically engineered mice/rats for a particular disease provide a valid resource for 
research on pathogenesis and therapy of that disease (Vandamme, 2014). The Royal College 
of Surgeons rat is the first known animal with inherited retinal degeneration (Adachi et al., 
2016). The Zucker rat was bred to be a genetic model for research on obesity and 
hypertension (Buckley and Rasmussen, 2012). Genetically engineered knockout rat disease 
models for Parkinson's disease (Dave et al., 2014), Alzheimer's disease (Do Carmo and Cuello, 
2013), hypertension (Moreno et al., 2011), and diabetes (Plum et al., 2005) are commercially 
available and are extensively being used in preclinical research. It is not possible to create such 
models in humans, and trials to treat patients with these diseases require rigorous ethical 
approval where the success of similar experiments on animals needs to be sought beforehand. 
 We utilised maternally separated Sprague-Dawley rats and WKY rats; although not 
genetically engineered, both are validated models of ELS and depression, respectively, based 
on their phenotypic characteristics. Both rat models are commonly used to study visceral 
hypersensitivity. To investigate visceral pain and hypersensitivity, we used colorectal 
distension, which is an established model of gut-related visceral pain. We were able to 
investigate the interplay of endogenous oestrogens, glutamatergic metabolism, and stress, 
which provides us with very important information regarding the pathogenesis of visceral 
hypersensitivity in stress. 
6.3 Are EAATs the Only Modulators of Glutamatergic Transmission? 
 The glutamatergic system can be regulated at a synapse at multiple levels including 
presynaptic glutamate release, glial glutamate uptake from the synapse, and through the 
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expression of glutamate receptors on the postsynaptic neurons. The modulation by glial 
uptake and glutamate receptor expression has been elaborated in earlier segments of the 
thesis (Chapter 1 and 2). The presynaptic glutamate release is regulated by voltage-gated K+ 
(Kv) channels. A subtype Kv3.4 is robustly expressed at DRG neurons (Ritter et al., 2015a), and 
its dysfunction has been shown to be implicated in the pathophysiology of neuropathic pain 
(Ritter et al., 2015b). These findings suggest that this ion channel might play a significant role 
as a regulator of nociceptive synaptic activity at the level of the first synapse in the pain 
pathway. However, until recently, it was unclear whether the modulation of these receptors 
affects the actual neurotransmission along the synapse. With the help of 
immunofluorescence, measurement of excitatory postsynaptic currents and application of 
Kv3.4 enhancers, it has been demonstrated that these channels significantly prolong the 
action potential, slow the maximum rate of repolarisation in small diameter DRG neurons, and 
potentiate monosynaptic excitatory postsynaptic currents in dorsal horn laminae I and II 
through a presynaptic mechanism (Muqeem et al., 2018). These results strongly suggest that 
presynaptic Kv3.4 channels are one of the major regulators of nociceptive synaptic 
transmission in the spinal cord. More pain-related research including hormonal modulation of 
these particular channels is needed to establish their role in preclinical and clinical pain 
modulation. 
6.4 Can EAATs Be a Therapeutic Target for Clinical Pain? 
 
 As we have detailed the importance of the role of EAATs in pain transmission (Chapter 
2,3, and 4), it is important to see what evidence is available regarding the effectiveness of 
their enhancers as analgesics. Riluzole (used in the treatment of amyotrophic lateral sclerosis), 
ceftriaxone (a broad-spectrum antibiotic), and valproate (an antiepileptic) are known 
enhancers of the EAATs. 
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6.4.1 Riluzole As an Analgesic 
 
 Riluzole has been shown to be effective in alleviating neuropathic pain and improving 
functional recovery in cervical spondylotic myelopathy rodent model (Moon et al., 2014). 
Riluzole can reverse visceral hypersensitivity induced by ELS in rodents (Sung et al., 2003; 
Gosselin et al., 2010). In rodent studies of neuropathic pain involving spinal nerve avulsion, 
riluzole, when administered, was able to prevent the onset of evoked pain hypersensitivity 
but was unable to reverse the pre-established hypersensitivity (Chew et al., 2014). Some 
studies have shown its analgesic properties in rodent neuropathic models only when injected 
intraperitoneally compared to intrathecal injections, indicating a peripherally mediated 
antinociceptive mechanism (Hama and Sagen, 2011). However, central co-administration of 
riluzole and minocycline seems to reduce morphine induced drug tolerance in rats (Habibi-Asl 
et al., 2009). Although preclinical studies suggest a promising effect of riluzole as an analgesic, 
only a few human studies have attempted to examine its potential an effective clinical 
analgesic. Hammer et al., studied the effect of riluzole on a human model of inflammatory 
pain induced by thermal injury on healthy humans and found no benefit of riluzole on pain 
scoring (Hammer et al., 1999). Another group studied the effect of riluzole at different doses 
on humans with existing peripheral neuropathic pain. They were not able to see any efficacy 
of riluzole on neuropathic pain (Galer et al., 2000). In contrast, a group found riluzole to be 
effective as an add on to standard IBS treatment regimen, in relieving IBS related visceral pain 
(Mishra et al., 2014). 
6.4.2 Ceftriaxone as an Analgesic 
 
 Chronic treatment with ceftriaxone dampened visceral pain responses in mice in 
inflammatory colitis, colorectal and bladder distension models (Lin et al., 2009a; Yang et al., 
2011). Chronic administration of ceftriaxone in rodents also proved to be effective in the 
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prevention of morphine tolerance (Yan et al., 2009; Ramos et al., 2010). Ceftriaxone is also 
capable of both potentiating analgesic effect of nicotine and diminishing development of 
tolerance to nicotine analgesia (Schroeder et al., 2011). Ceftriaxone has been shown to reduce 
both thermal hyperalgesia and tactile allodynia (Yan et al., 2009; Hu et al., 2010; Ramos et al., 
2010) in a rodent model of neuropathic pain. In the cervical nerve root injury-based model of 
radicular pain, both thermal hyperalgesia and mechanical allodynia were attenuated by 
chronic treatment with ceftriaxone (Nicholson et al., 2014a). Another rodent pain study found 
ceftriaxone to exert its antinociceptive effect in both somatic and visceral pain (Stepanovic-
Petrovic et al., 2014). Similar to that of riluzole, the clinical data for the effectiveness of 
ceftriaxone as an analgesic in humans is scarce, although it is a widely used antibiotic. A single 
dose preoperative dose of ceftriaxone before ulnar and radial nerve decompression, 
significantly reduced postoperative pain scoring compared to normal saline and cefazoline 
(Macaluso et al., 2013). 
 Although preclinical studies show us the promising analgesic effects of these EAATs' 
modulators, the scarcity of relevant human data limits their clinical use. The lack of clinical 
data is partly due to ethical hurdles for clinical trials, research costs particularly for riluzole, 
and availability and usage of already licenced analgesics. Since we have described the role of 
EAAT and glutamate metabolism in the pathogenesis of a number of chronic pain disorder, it 
is paramount to establish human studies and trials utilising EAAT enhancers. The recruitment 
should include both healthy individuals and patients with existing chronic pain disorders, 
taking into consideration sex, menstrual cycle phases, use of contraceptives, normal births 
and deliveries through C-section, gut microbiota profiles and presence of stress conditions. 
6.5 Can Interventions Make Gut Microbiota a Potential Therapeutic Target in the 
Future? 
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 Recent research supporting a role for the microbiota in maintaining healthy brain 
function suggests targeting gut microbiota as a therapeutic potential in CNS disorders 
(Forsythe et al., 2012). There is growing evidence to support the use of antibiotics, prebiotics, 
and probiotics as a treatment option in IBS (Didari et al., 2015; Quigley, 2015). The use of 
probiotics has shown symptomatic pain relief in IBS patients (Brenner et al., 2009; Whorwell, 
2009; Moayyedi et al., 2010). Other possible microbiota interventions include dietary 
modification and faecal microbiota transplant (FMT) from healthy individuals to patients 
(Gupta et al., 2016). 
 B. infantis treatment, a probiotic for example, was shown to reverse behavioural 
deficits, restore basal noradrenaline concentrations in the brainstem of adult rats subjected 
to the early-life stress of maternal separation, an animal model of brain-gut axis dysfunction 
(Desbonnet et al., 2010; O'Mahony et al., 2011). A preclinical study using the same probiotic 
found that CRD-induced visceral pain behaviours were significantly reduced in the viscerally 
hypersensitive Wistar-Kyoto rat strain (McKernan et al., 2010). L. paracasei administration has 
also shown efficacy in reducing visceral hypersensitivity in a mouse model of IBS (Verdu et al., 
2006). Table 1.6 in Chapter 1 outlines similar studies in the context of pain modulation. 
 Understanding the role of gut microbiota in the bidirectional interaction between the 
gut and the brain is a novel and appealing research field. Microbiota-gut-brain-axis is being 
studied in relation to a number of CNS related disorders such as autism (Strati et al., 2017), 
Parkinsonism (Perez-Pardo et al., 2017), and Alzheimer’s disease (Jiang et al., 2017) to name 
a few. Currently, microbiota involvement and the mechanism of action involved in pain 
modulation are not yet clearly established. To be able to target the gut microbiota to alleviate 
painful symptoms requires a lot more preclinical and clinical research focusing on the 
interactions between gut microbiota, sex, pre-existing stress in both health individuals and 
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patients with existing pain disorders. Our experimental model (Chapter 5), although involved 
a small number of subjects, showed exciting results of correlation of Firmicutes with pain 
sensitivity. These results set a future direction toward human/clinical studies at a larger scale 
that should include interventions targeting gut microbiota with dietary modifications, 
prebiotics, probiotics, antibiotics, and FMT. 
6.6 Future Directions 
 
 My thesis investigated the modulation of EAAT function and pain sensitivity by 
oestrous cycle and demonstrated the effects of stress and gut microbiota on the modulation 
of pain. Our results add significant information to existing knowledge of nociceptive 
processes; however, more research is required to understand the pathogenesis of visceral 
pain disorders fully. We suggest following future research themes bases on our results. 
We are able to demonstrate EAAT function alterations in different phases of the oestrous 
cycle, and riluzole reversed the oestrus phases induced inhibition of EAAT function. Although 
visceral pain responses correlated to EAAT function, it is not known whether alteration in 
visceral pain responses was due to altered synaptic glutamate transmission under the 
influence of EAATs or the effect of endogenous oestrogen on other mechanisms responsible 
for pain modulation described earlier. We, therefore, suggest ex-vivo electrophysiological 
studies on male and female rodent spinal cord and brain slices and investigate whether the 
synaptic evoked potential change and correspond to the EAAT function. The resultant 
correlation between oestrous cycle, EAAT function, and synaptic action potential may confirm 
EAATs as therapeutic targets. The effect of EAAT enhancers on neurotransmission may also 
be investigated by pre-treating the CNS slices with these drugs. 
We suggest that all animal experiments examining nociception in males and females must 
consider the oestrous phase of the female rodent being assessed. We performed colorectal 
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distension on maternally separated rats across their oestrous cycle. There is room to perform 
this nociceptive test on WKY rats in males and females to reproduce the results. Likewise, pain 
models for neuropathic pain can be studied in the similar settings. Moreover, microbiota 
analysis can be performed and correlated with pain model results. Interventions such as the 
use of prebiotics, probiotics, and antibiotics can be performed to see their effect. We were 
able to see a positive correlation of SCFAs-producing gut bacteria on EAAT functioning in WKY 
rats, further correlation with pain responses may be beneficial to further understanding of 
microbiota-gut-brain axis in pain modulation. 
 Our human study showed exciting results as the relative abundance of Anaerostipes 
correlated positively with pain sensitivity. We were not able to see any significant effect of 
menstrual cycle status on experimental pain sensitivity; however, some trends were noted. 
Our sample size was relatively small. We suggest our human study experimental setup to be 
performed on a larger scale. This setup can also be performed on patients with existing pain 
disorders and by having a larger number of participants, a better understanding of the 
interaction between nociception, sex, stress, and microbiota-gut-axis can be elucidated. 
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Figure S1. Beck’s depression inventory score was higher in normally menstruating females 
than males. Scores of the Beck’s depression inventory that was filled in by the study participants. 
Kruskal-Wallis test with Dunn’s post-hoc test was performed to assess differences between 
selected groups. *p≤0.05  
Abbreviations: M = males, F HC = females using hormonal contraceptives, F nHC = females not 




Figure S2. Gender, menstrual cycle and hormonal contraceptive use did not influence 
plasma oestradiol levels. Plasma oestradiol concentrations of males, and females (using 
hormonal contraceptives y/n) across the menstrual cycle. Kruskal-Wallis test and Friedman test 
with Dunn’s post-hoc test were performed to assess differences between selected groups.   
Abbreviations: EF = early follicular phase, LF = late follicular phase, ML = mid-luteal phase 
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Figure S3. Pain tolerance thresholds & pain sensation thresholds did not vary significantly along menstrual 
cycle and between both sexes. There was no significant difference seen in PTT and PST along menstrual cycle 
stages in both hormonal and non-hormonal contraception female groups combined. Similarly, no differences 
were seen between males and females  
Abbreviations: EF = early follicular phase, LF = late follicular phase, ML = mid-luteal phase. 
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Table S1. Kruskal-Wallis tests for all phyla, families and genera comparing males, females 
using contraceptives (three phases), and normally menstruating females (three phases) 
 
Taxa p-value FDR-adjusted 
p-value 
Bacteria_Firmicutes_Erysipelotrichia_Erysipelotrichales_Erysipelotrichaceae_Erysipelatoclostridium 0.000184811 0.055073793 
Bacteria_Actinobacteria_Coriobacteriia_Coriobacteriales_Coriobacteriaceae_Slackia 0.002042006 0.304258923 
Bacteria_Tenericutes_Mollicutes_Mollicutes.RF9_uncultured.bacterium 0.011961159 1.188141827 
Bacteria_Tenericutes_Mollicutes_Mollicutes.RF9_uncultured.bacterium 0.011961159 0.89110637 
Bacteria_Firmicutes_Clostridia_Clostridiales_Lachnospiraceae_Lachnospiraceae.UCG.001 0.01461519 0.871065329 
Bacteria_Firmicutes_Clostridia_Clostridiales_Ruminococcaceae_Candidatus.Soleaferrea 0.0157854 0.784008217 
Bacteria_Firmicutes_Clostridia_Clostridiales_Family.XI_Peptoniphilus 0.016332206 0.695285339 
Bacteria_Firmicutes_Erysipelotrichia_Erysipelotrichales_Erysipelotrichaceae_Dielma 0.018019838 0.671238954 
Bacteria_Firmicutes_Bacilli_Lactobacillales_Lactobacillaceae_Pediococcus 0.020295746 0.67201469 
Bacteria_Proteobacteria 0.025986384 0.774394228 
Bacteria_Firmicutes_Clostridia_Clostridiales_Eubacteriaceae 0.031915405 0.864617348 
Bacteria_Firmicutes_Clostridia_Clostridiales_Lachnospiraceae_Lachnospiraceae.NK4A136.group 0.043469868 1.079501722 
Bacteria_Actinobacteria_Coriobacteriia_Coriobacteriales_Coriobacteriaceae_Eggerthella 0.044918523 1.02967076 
Bacteria_Firmicutes_Clostridia_Clostridiales_Lachnospiraceae_Lachnospiraceae.UCG.004 0.045605592 0.97074761 
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Table S2. Friedman tests to compare potential phylum, family and genera differences 
across the menstrual cycle in all females 
Taxa p-value FDR-adjusted p-value 
Bacteria_Firmicutes_Clostridia_Clostridiales_Lachnospiraceae_Coprococcus 3 0.010 2.92 
Bacteria_Firmicutes_Clostridia_Clostridiales_Lachnospiraceae 0.011 1.606 
Bacteria_Firmicutes_Clostridia_Clostridiales_Ruminococcaceae_Ruminococcaceae UCG-005 0.012 1.168 
Bacteria_Firmicutes_Bacilli_Lactobacillales_Streptococcaceae_Streptococcus 0.017 1.241 
Bacteria_Firmicutes_Clostridia_Clostridiales_Ruminococcaceae_Ruminococcus 2 0.020 1.168 
Bacteria_Bacteroidetes_Bacteroidia_Bacteroidales_Bacteroidales S24-7 group_uncultured bacterium 0.027 1.314 
Bacteria_Firmicutes_Clostridia_Clostridiales_Lachnospiraceae_[Eubacterium] oxidoreducens group 0.030 1.251429 
Bacteria_Firmicutes_Clostridia_Clostridiales_Ruminococcaceae_Faecalibacterium 0.030 1.095 
Bacteria_Firmicutes_Clostridia_Clostridiales_Ruminococcaceae_Ruminococcaceae UCG-011 0.036 1.168 
Bacteria_Actinobacteria_Coriobacteriia_Coriobacteriales_Coriobacteriaceae_Enterorhabdus 0.038 1.1096 
Bacteria_Firmicutes_Clostridia_Clostridiales_Family XIII_Family XIII UCG-001 0.041 1.088364 
Bacteria_Firmicutes_Clostridia_Clostridiales_Lachnospiraceae_uncultured 0.046 1.119333 
Bacteria_Firmicutes 0.046 1.033231 
Bacteria_Firmicutes_Clostridia_Clostridiales_Ruminococcaceae_Ruminococcaceae UCG-010 0.049 1.022 
 
Table S3. Friedman tests to compare potential phylum, family and genera differences 
across the menstrual cycle in female contraceptive users 
Taxa p-value FDR-adjusted p-value 
Bacteria_Firmicutes_Clostridia_Clostridiales_Lachnospiraceae_uncultured 0.002 0.542 
Bacteria_Firmicutes_Clostridia_Clostridiales_Peptococcaceae 0.006 0.813 
Bacteria_Firmicutes_Bacilli_Lactobacillales_Streptococcaceae 0.011 0.993667 
Bacteria_Firmicutes_Clostridia_Clostridiales_Peptococcaceae_uncultured 0.015 1.01625 
Bacteria_Firmicutes_Clostridia_Clostridiales_Ruminococcaceae_Ruminiclostridium 5 0.021 1.1382 
Bacteria_Firmicutes_Clostridia_Clostridiales_Ruminococcaceae_Ruminococcaceae UCG-005 0.025 1.129167 
Bacteria_Firmicutes_Clostridia_Clostridiales_Lachnospiraceae_Dorea 0.034 1.316286 
Bacteria_Firmicutes 0.034 1.15175 
Bacteria_Firmicutes_Clostridia_Clostridiales_Ruminococcaceae_Ruminococcaceae UCG-011 0.038 1.144222 
Bacteria_Firmicutes_Bacilli_Lactobacillales_Streptococcaceae_Streptococcus 0.044 1.1924 
 
Table S4. Friedman tests to compare potential phylum, family and genera differences 
across the menstrual cycle in normally menstruating females 
Taxa p-value FDR-adjusted p-value 
Bacteria_Firmicutes_Clostridia_Clostridiales_Lachnospiraceae_[Ruminococcus] gauvreauii group 0.016 4.368 
Bacteria_Firmicutes_Clostridia_Clostridiales_Ruminococcaceae_Faecalibacterium 0.016 2.184 
Bacteria_Firmicutes_Clostridia_Clostridiales_Ruminococcaceae_Ruminococcus 2 0.018 1.638 
Archaea_Euryarchaeota_Methanobacteria_Methanobacteriales_Methanobacteriaceae 0.050 3.4125 
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Figure S4. Overview of genera that correlated significantly with investigated parameters for males 
and females apart. Spearman correlation coefficients expressed in colours, positive (red), negative (blue). 
*FDR-corrected p-value <0.05, **FDR-corrected p-value <0.01, ***FDR-corrected p-value <0.001, FDR were 
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Table S5. Spearman correlation coefficient overview of genera correlated to investigated 
parameters (males) 







Propionate 0.912946 0.000226 0.728491 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Lachnospiraceae.NK4A136.gro
up 
E2 0.807143 0.000435 0.701605 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Tyzzerella.4 E2 -0.78021 0.0006 0.645137 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Fusicatenibacter TNF.alpha 0.760714 0.00151 1.217414 
Firmicutes.Erysipelotrichia.Erysipelotrichales.Erysipelotrichaceae.Turicibacter TNF.alpha 0.757143 0.001635 1.054277 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Lachnospiraceae.NK4A136.gro
up 
Acetate 0.866667 0.002681 1.440814 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Ruminiclostridium.9 Total.SCFA 0.866667 0.002681 1.234983 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Ruminococcaceae.UCG.014 LBP -0.69534 0.004001 1.612534 
Proteobacteria.Deltaproteobacteria.Desulfovibrionales.Desulfovibrionaceae.Desul
fovibrio 
cortisol60min 0.812897 0.004249 1.522157 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Lachnospiraceae.NK4A136.gro
up 
Total.SCFA 0.842424 0.004459 1.437591 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Ruminiclostridium.9 Acetate 0.842424 0.004459 1.306901 
Fusobacteria.Fusobacteriia.Fusobacteriales.Fusobacteriaceae.Fusobacterium E2 -0.68417 0.004906 1.318054 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Lachnospiraceae.UCG.005 cortisol30min 0.830303 0.005557 1.378088 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Ruminiclostridium.6 E2 0.673816 0.005882 1.354608 
Firmicutes.Clostridia.Clostridiales.Family.XIII..Eubacterium..brachy.group Perc.cortisol.incr
ease 
0.795205 0.005961 1.281262 
Proteobacteria.Deltaproteobacteria.Desulfovibrionales.Desulfovibrionaceae.Desul
fovibrio 
Total.SCFA 0.795205 0.005961 1.201183 
Firmicutes.Negativicutes.Selenomonadales.Veillonellaceae.Veillonella PST 0.663611 0.006989 1.32536 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Acetanaerobacterium cortisol45min 0.785334 0.007105 1.272531 
Actinobacteria.Actinobacteria.Actinomycetales.Actinomycetaceae.Actinomyces E2 -0.66131 0.00726 1.231869 
Firmicutes.Negativicutes.Selenomonadales.Veillonellaceae.Veillonella PTT 0.656452 0.007858 1.266645 
Firmicutes.Clostridia.Clostridiales.Family.XIII..Eubacterium..brachy.group PTT -0.65506 0.008036 1.233778 
Proteobacteria.Gammaproteobacteria.Enterobacteriales.Enterobacteriaceae.Ente
robacter 
IFN.gamma -0.65487 0.00806 1.181166 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Lachnospiraceae.UCG.005 AUC.cortisol 0.806061 0.008236 1.154412 
Firmicutes.Erysipelotrichia.Erysipelotrichales.Erysipelotrichaceae.Holdemanella cortisol60min 0.769345 0.009274 1.245837 
Proteobacteria.Deltaproteobacteria.Desulfovibrionales.Desulfovibrionaceae.Desul
fovibrio 
Acetate 0.769345 0.009274 1.196004 
Firmicutes.Negativicutes.Selenomonadales.Acidaminococcaceae.Acidaminococcus Propionate 0.768037 0.00947 1.174298 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Candidatus.Soleaferrea IFN.gamma 0.657143 0.009527 1.137646 
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Firmicutes.Clostridia.Clostridiales.Clostridiales.vadinBB60.group.uncultured.organism Propionate -0.74957 2.61E-08 1.05E-04 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Ruminococcaceae.UCG.011 Propionate -0.71527 2.14E-07 4.32E-04 
Firmicutes.Clostridia.Clostridiales.Peptococcaceae.uncultured Propionate -0.67505 1.77E-06 2.38E-03 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Coprococcus.1 sCD14 0.756912 3.14E-06 3.17E-03 
Firmicutes.Clostridia.Thermoanaerobacterales.Thermoanaerobacteraceae.Gelria Propionate -0.65338 4.86E-06 3.93E-03 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae..Eubacterium..oxidoreducens.group Propionate -0.62659 1.52E-05 1.02E-02 
Firmicutes.Clostridia.Clostridiales.Family.XIII..Eubacterium..nodatum.group Propionate -0.62637 1.54E-05 8.89E-03 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Intestinimonas Propionate -0.62424 1.67E-05 8.44E-03 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Ruminococcaceae.UCG.011 n-Butyrate -0.60581 3.44E-05 1.54E-02 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Ruminiclostridium.1 Propionate -0.59324 5.48E-05 2.21E-02 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Ruminococcaceae.UCG.011 Total.SCFA -0.59039 6.07E-05 2.23E-02 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae..Ruminococcus..gauvreauii.group TNF.alpha 0.567852 6.41E-05 2.16E-02 
Proteobacteria.Gammaproteobacteria.Pasteurellales.Pasteurellaceae.Haemophilus n-Butyrate 0.583449 7.77E-05 2.42E-02 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae..Eubacterium..hallii.group Propionate 0.584053 0.00010
3 
2.97E-02 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Anaerostipes PST 0.551763 0.00010
3 
2.79E-02 
Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Ruminiclostridium sCD14 0.660189 0.00013
2 
3.33E-02 
Proteobacteria.Betaproteobacteria.Burkholderiales.Alcaligenaceae.Parasutterella Propionate -0.5503 0.00023
4 
5.57E-02 
Firmicutes.Clostridia.Clostridiales.Clostridiales.vadinBB60.group.uncultured.organism Total.SCFA -0.54884 0.00024
5 
5.51E-02 
Firmicutes.Clostridia.Clostridiales.Clostridiales.vadinBB60.group.uncultured.organism n-Butyrate -0.54342 0.00029 6.18E-02 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae..Eubacterium..oxidoreducens.group n-Butyrate -0.54157 0.00030
7 
6.21E-02 








Cyanobacteria.Melainabacteria.Gastranaerophilales.uncultured.bacterium. Propionate -0.532 0.00041
1 
7.22E-02 
Tenericutes.Mollicutes.Mollicutes.RF9.uncultured.bacterium. PTT -0.50923 0.00041
5 
6.99E-02 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae..Eubacterium..oxidoreducens.group Total.SCFA -0.52884 0.00045
1 
7.29E-02 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae..Eubacterium..ventriosum.group LBP -0.49433 0.00055
8 
8.67E-02 








Firmicutes.Clostridia.Thermoanaerobacterales.Thermoanaerobacteraceae.Gelria Total.SCFA -0.51539 0.00066
6 
9.28E-02 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Howardella PTT 0.490648 0.00072
1 
9.72E-02 
Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Anaerostipes PTT 0.489528 0.00074
5 
9.71E-02 
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Table S7. Spearman correlation coefficients of investigated parameters, excluding 
microbiota (males) 






Total.SCFA acetate 0.987879 9.31E-08 1.42E-05 
Total.SCFA n-butyrate 0.915152 0.000204 0.015642 
n-butyrate acetate 0.90303 0.000344 0.017524 
Total.SCFA PTT/PST -0.81099 0.004414 0.168843 
cort.AUC 30min.cortisol 0.806061 0.004862 0.148779 
acetate PTT/PST -0.7805 0.007717 0.196796 
PTT/PST PTT 0.648479 0.008923 0.195034 
cort.AUC 0min.cortisol 0.733333 0.015801 0.302186 
n-butyrate PTT/PST -0.73172 0.016152 0.274577 
perc.cort.increase TNF.alpha 0.721212 0.018573 0.284169 
propionate 30min.cortisol -0.88571 0.018845 0.262123 
60min.cortisol acetate 0.885714 0.018845 0.24028 
60min.cortisol Total.SCFA 0.885714 0.018845 0.221797 
PST PTT 0.587558 0.021265 0.232399 
PTT/PST 60min.cortisol -0.69513 0.025647 0.261595 
E2 n-butyrate 0.660606 0.037588 0.359439 
PTT IL.8 -0.53085 0.041745 0.375705 
PTT n-butyrate -0.65036 0.041749 0.354865 
E2 acetate 0.648485 0.04254 0.34256 
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Table S8. Spearman correlation coefficients of investigated parameters, excluding 
microbiota (females) 








0.92561 0 0 
Total.SCFA acetate 0.982176 0 0 
60min.cortisol 45min.cortiso
l 
0.909233 2.22E-16 1.27E-14 
Total.SCFA n-butyrate 0.90788 6.66E-16 2.85E-14 
cort.AUC 45min.cortiso
l 
0.890767 6.22E-15 2.13E-13 
cort.AUC 60min.cortiso
l 
0.870557 1.41E-13 4.02E-12 
n-butyrate acetate 0.872233 2.30E-13 5.62E-12 
PTT PST 0.840712 9.33E-13 1.99E-11 
Total.SCFA propionate 0.830019 3.54E-11 6.74E-10 
45min.cortisol 30min.cortiso
l 
0.771603 3.52E-09 6.02E-08 
60min.cortisol 30min.cortiso
l 
0.762544 6.88E-09 1.07E-07 
propionate acetate 0.749531 2.62E-08 3.73E-07 
n-butyrate propionate 0.726642 1.11E-07 1.45E-06 
cort.AUC 0min.cortisol 0.645296 5.24E-06 6.4E-05 
30min.cortisol 0min.cortisol 0.502787 0.000807 0.009205 
perc.cort.increas
e 
0min.cortisol -0.49791 0.000924 0.00988 
IL.8 PST 0.44003 0.0028 0.02816 





0.433972 0.004586 0.04127 
TNF.alpha IFN.gamma 0.405138 0.005767 0.049307 
60min.cortisol 0min.cortisol 0.405401 0.00855 0.069625 
45min.cortisol 0min.cortisol 0.39216 0.011216 0.087182 
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